Rak v Sloveniji Cancer in Slovenia 2020 letno porocilo annual report Rak v Sloveniji Cancer in Slovenia 2020 Naslov Title Rak v Sloveniji 2020 / Cancer in Slovenia 2020 Uredniški odbor Editorial Board Vesna Zadnik, glavna urednica / editor-in-chief Gorana Gašljevic, Marko Hocevar, Katja Jarm, Vera Pompe-Kirn, Primož Strojan, Sonja Tomšic, Branko Zakotnik in Tina Žagar Obdelava in analiza podatkov Data Processing and Analysis Nika Bric, Tina Žagar, Katarina Lokar, Miran Mlakar in Mojca Birk Oblikovanje in priprava za tisk Design and Typesetting Nika Bric Lektura Copy editing Jezikovna zadruga Soglasnik / Soglasnik Language Cooperative Tisk Printing TISK ŽNIDARIC d.o.o. Izdajatelj Published by Onkološki inštitut Ljubljana / Institute of Oncology Ljubljana, SloveniaEpidemiologija in register raka / Epidemiology and Cancer RegistryRegister raka Republike Slovenije / Slovenian Cancer Registry Naklada Published in 500 izvodov / 500 copies Nasvet za citiranje Recommended Reference Rak v Sloveniji 2020. Ljubljana: Onkološki inštitut Ljubljana, Epidemiologija in register raka, Register raka Republike Slovenije, 2023. Cancer in Slovenia 2020. Ljubljana: Institute of Oncology Ljubljana, Epidemiology and Cancer Registry, Slovenian Cancer Registry, 2023. Osebje Registra raka Republike Slovenije Staff of the Slovenian Cancer Registry Vesna Zadnik, vodja / head Agata Campa, Vesna Drolec, Maruška Ferjancic, Katja Hribar, Andrej Kirn, Katja Kolenc Mokotar, Andrej Krašovec, Martina Omerzo, Branka Pestotnik, Sabina Prvinšek, PolonaRus, Darja Strle, Laura Šeneker Zupanc, Franciška Škrlec, Polona Škulj, Urška Tomšic, Snežana Umicevic, Boštjan Zavratnik, Brigita Zore, Mojca Birk, Nika Bric, Ana Mihor, Miran Mlakar, Teja Oblak, Katarina Lokar, Sonja Tomšic, Katarina Torkar, Tina Žagar Naslov Correspondence to Register raka Republike Slovenije / Slovenian Cancer Registry Onkološki inštitut Ljubljana / Institute of Oncology LjubljanaZaloška c. 2, 1001 Ljubljana, p.p. 2217, SlovenijaTelefon / Phone: + 386 1 5879 450 E-pošta / E-mail: register@onko-i.si Spletna stran / Web site: http://www.onko-i.si/rrs/ http://www.slora.si/ http://www.onko-i.si/eng/crs/ http://www.slora.si/en/ Kazalo Contents Uvodnik 6 Editorial 7 Podatki 8 Viri podatkov 8 Obdelava podatkov 9 Kakovost podatkov 10 Data 12 Data Sources 12 Data Processing 13 Data Quality 14 Rak v Sloveniji 15 Osnovni podatki o raku v Sloveniji 2020 16 Starost bolnikov 16 Casovni trend 16 Najpogostejši raki 18 Trend najpogostejših rakov 21 Redki raki 22 Preživetje 23 Primerjava z Evropo 26 Cancer in Slovenia 28 Basic figures on cancer in Slovenia 2020 28 Age of patients 28 Time trends 29 Most frequent cancers 29 Time trends for most frequent cancers 29 Rare cancers 30 Survival 30 Comparisons with Europe 31 Incidenca 32 Tabela 1: Opazovana in ocenjena incidenca raka po spolu, Slovenija 2011-2020 in 2023. 32 Table 1: Observed and estimated cancer incidence by sex, Slovenia 2011-2020 and 2023. 32 Tabela 2: Incidenca, groba incidencna stopnja in po svetovni, evropski ter slovenski standardni populaciji standardizirane incidencne stopnje raka po spolu, Slovenija 2020. 33 Table 2: Incidence, crude incidence rate and according to World, European and Slovenian standard population standardized cancer incidence rates by sex, Slovenia 2020. 33 Tabela 3: Incidenca raka po starosti in spolu ter groba stopnja (GS) na 100.000 prebivalcev in kumulativna stopnja (KS), Slovenija 2020. 34 Table 3: Cancer incidence by age and by sex with crude rate (GS) per 100,000 population and cumulative rate (KS), Slovenia 2020. Tabela 4a: Table 4a: Tabela 4b: Table 4b: Tabela 4c: Table 4c: Tabela 5: Table 5: Prevalenca Tabela 6: Prevalenca bolnikov z rakom po spolu, Slovenija, 31. 12. 2020. 46 Table 6: Prevalence of cancer patients by sex, Slovenia, December 31, 2020. 46 Umrljivost 47 Tabela 7: Table 7: Preživetje Tabela 8: Table 8: Incidenca mikroskopsko (histološko ali citološko) potrjenih primerov raka po morfološki vrsti, Slovenija 2020. 38 Incidence of microscopicaly (histologically or cytologically) confirmed cancer cases by morphological type, Slovenia 2020. 38 Incidenca malignih neoplazem limfaticnega tkiva v skladu s klasifikacijo Svetovne zdravstvene organizacije iz leta 2017, Slovenija 2020. 42 Incidence of malignant neoplasms of lymphoid tissue according to 2017 version of Classification of Tumours of Haematopoietic and Lymphoid Tissues (published by World Health Organization), Slovenia 2020. 42 Incidenca ne-Hodgkinovih limfomov (NHL) po lokaciji, Slovenija 2020. 43 Incidence of non-Hodgkin’s lymphomas (NHL) by cancer site, Slovenia 2020. 43 Incidenca raka po stadiju, Slovenija 2020. Cancer incidence by stage, Slovenia 2020. 44 44 46 Umrljivost za rakom po starosti in spolu, Slovenija 2020. Vir: Nacionalni inštitut za javno zdravje 47 Cancer mortality by age and by sex, Slovenia 2020. Source: National Institute of Public Health 47 48 Eno- in pet-letno cisto preživetje (s 95 % intervalom zaupanja) bolnikov po spolu, zbolelih v letih 2016–2020. 48 One- and five-year net survival (with 95% confidence interval) of patients diagnosed in period 2016–2020 by sex. 48 Zdravljenje 49 Tabela 9a: Število in deleži bolnikov (brez primerov, registriranih samo iz zdravniških porocil o vzroku smrti), v Sloveniji zbolelih leta 2020, ki so bili v okviru prvega zdravljenja operirani, zdravljeni s sistemskim zdravljenjem ali obsevani (številka v oklepaju se nanaša na obsevane na Onkološkem inštitutu Ljubljana - OIL). 49 Table 9a: Number of patients (without cases registered from death certificates only) diagnosed in Slovenia in 2020, that were treated by surgery, systemic therapy or radiotherapy during their first treatment (in parenthesis the number of radiotherapies at Institute of Oncology Ljubljana - IOL is given). 49 Tabela 9b: Število bolnikov (brez primerov, registriranih samo iz zdravniških porocil o vzroku smrti) v Sloveniji, zbolelih leta 2020, ki so bili v okviru prvega zdravljenja operirani*, po ustanovi posega. 50 Table 9b: Number of patients (without cases registered from death certificates only) diagnosed in Slovenia in 2020, that were treated by surgery during their first treatment* by treatment institution. 50 Tabela 9c: Število bolnikov (brez primerov registriranih samo iz zdravniških porocil o vzroku smrti) v Sloveniji, zbolelih leta 2020, ki so v okviru prvega zdravljenja prejeli sistemsko zdravljenje*, po ustanovi zdravljenja. 51 Table 9c: Number of patients (without cases registered from death certificates only) diagnosed in Slovenia in 2020, that were treated by systemic therapy during their first treatment* by treatment institution. 51 Breme najpogostejših rakov 52 Vsi raki / All cancer sites (C00–C96) 52 Prostata / Prostate (C61) 53 Pljuca in sapnik / Lung and trachea (C33, C34) 54 Dojka / Breast (C50) 55 Debelo crevo in danka / Colon and rectum (C18–C20) 56 Koža, razen melanoma / Skin, non-melanoma (C44) 57 Kožni melanom / Malignant melanoma of skin (C43) 58 Glava in vrat / Head and neck (C00–C14, C30–C32) 59 Maternicno telo / Corpus uteri (C54) 60 Ne-Hodgkinov limfom / Non-Hodgkin’s lymphoma (C82–C85) 61 Pojmovnik 62 Glossary 63 Uvodnik Register raka Republike Slovenije je prepoznan kot eden od najstarejših in najkvalitetnejših populacijskih registrov raka v Evropi in svetu. Ustanovljen je bil leta 1950 in vse od zacetka deluje na Onkološkem inštitutu Ljubljana. Zacetki temeljijo na daljnovidnosti njegove ustanoviteljice in prve vodje, profesorice dr. Božene Ravnihar, ki se je že mnogo let pred tovrstnimi priporocili Svetovne zdravstvene organizacije zavedala, da je uspešnost in ucinkovitost prizadevanja služb zdravstvenega varstva in zdravstvene politike za obvladovanje raka mogoce objektivno ovrednotiti le z ustreznimi podatki o bremenu te bolezni in analizami njegovega spreminjanja v casu. Leta 2020 smo praznovali 70-letnico neprekinjenega delovanja slovenskega Registra raka. Castitljivo obletnico smo zaznamovali tudi s pripravo zgodovinskega pregleda delovanja Registra raka v vseh teh letih. Zainteresiranemu bralcu so zgodovinska dejstva in anekdote prikazani na naši spletni strani (www.onko-i.si/rrs) ter v posebej za to priložnost izdani brošuri. Podatki o novih primerih raka (incidenci), preživetju in prevalenci, ki se zbirajo v Registru raka, so skupaj s podatki o umrljivosti, ki jih zbira in obdeluje Nacionalni inštitut za javno zdravje, osnova za ocenjevanje bremena rakavih bolezni v državi. Pomembni so za nacrtovanje in ocenjevanje Državnega programa obvladovanja raka na podrocju primarne in sekundarne preventive, diagnostike, zdravljenja in rehabilitacije, za nacrtovanje zmogljivosti in sredstev, ki so potrebni za obvladovanje rakavih bolezni (osebje, medicinska oprema, bolnišnicne zmogljivosti). Dragoceni so za klinicne in epidemiološke raziskave v Sloveniji in v širših mednarodnih raziskavah ter za vrednotenje ucinkovitosti presejalnih programov. Z natancnimi podatki o diagnostiki in zdravljenju, ki jih v Registru raka beležimo v klinicnih registrih, pa lahko poleg zgoraj opisanega spremljamo tudi kakovost obravnave onkoloških bolnikov. Podatki Bolnišnicnega registra Onkološkega inštituta Ljubljana, ki že ves cas deluje v sklopu nacionalnega Registra raka ter ga oskrbuje z velikim delom podatkov, pa omogocajo podrobnejši pregled nad bolniki, zdravljenimi na inštitutu. Redna letna porocila nacionalnega Registra raka so namenjena neposrednemu seznanjanju strokovne javnosti in drugih zainteresiranih. Ker je potreben cas za izdajo letnega porocila nekoliko daljši, v porocilih zadnja leta objavljamo tudi pricakovano incidenco raka v letu, ko je porocilo izdano (v tokratnem porocilu za leto 2023). Od leta 2010 deluje tudi naš interaktivni spletni portal, ki smo ga po zacetnih crkah besed »Slovenija in rak« poimenovali SLORA. Dostopen je na elektronskem naslovu www.slora.si. Omogoca preprost in hiter dostop do vecine podatkov o raku v Sloveniji ter s hitrim dostopom do tujih baz omogoca primerjavo bremena raka v Sloveniji z drugimi državami v Evropi in po svetu. Vsem, ki ste kakorkoli prispevali k izdaji tega porocila, tako sodelavcem Registra raka kot tudi vsem zdravnikom in klinicnemu osebju po vsej državi, ki ste nam posredovali porocila o diagnozi in zdravljenju raka, se v imenu uredniškega odbora najlepše zahvaljujem. prof. dr. Vesna Zadnik, dr. med. Ljubljana, september 2023 vodja Registra raka Republike Slovenije Editorial The Slovenian Cancer Registry is recognized as one of the oldest and best-quality population-based cancer registries in Europe and the world. Founded in 1950, it has from the very beginning operated under the auspices of the Institute of Oncology Ljubljana. It was established thanks to the hard work and visionary ideas of its founder and first director, prof dr Božena Ravnihar. Many years before the World Health Organization endorsed such measures, she recognized that the effectiveness and efficiency of the efforts of health services and health policy to manage cancer can be objectively evaluated only with appropriate data on the burden of disease and monitoring of changes over time. In 2020, the Slovenian Cancer Registry celebrated its 70th anniversary of continuous operation. To mark this venerable anniversary, we have also prepared a historical overview of the work of the Cancer Registry over all these years. Readers interested in learning more can find historical facts and anecdotes on our website (www.onko-i.si/eng/crs) and in a brochure published specially for this occasion. Data on new cancer cases (incidence), survival and prevalence amassed in the Cancer Registry, together with mortality data collected and processed by the National Institute of Public Health, form the basis for assessing cancer burden in the country. The Registry’s data are important for planning and evaluation of the National Cancer Control Programme for the primary and secondary prevention of cancer, diagnostics, treatment and rehabilitation, as well as for planning for the facilities and resources needed for cancer management (staff, medical equipment, hospital facilities). They are also extremely useful for Slovenian and international clinical and epidemiological research and for evalua ting the effectiveness of screening programmes. In addition, precise data on diagnosis and treatment that the Cancer Registry manages in clinical registries can be used to monitor the quality of treatment received by oncology patients. The Hospital Registry of the Institute of Oncology Ljubljana, which has always been managed as part of the nationwide Cancer Registry and is in large part also supplied with Cancer Registry data, provides a more detailed overview of patients treated at the Institute. Regular annual reports of the Slovenian Cancer Registry aim to directly inform the professional community and other stakeholders. Given that it takes a fair amount of time to prepare and publish the annual report, the projected cancer incidence for the year when the report is issued (i.e. for 2023 in this report) has in recent years been included in the report. Since 2010, our SLORA interactive web portal – www.slora.si/en – has also been up and running; its name is based on the initial letters of the words Slovenija in rak (Slovenia and cancer). It provides quick and easy access to most cancer data in Slovenia and, with useful links to foreign databases, enables the comparison of cancer burden in Slovenia with other countries in Europe and in the world. On behalf of the Editorial Board, I would like to sincerely thank everyone who has contributed to the publication of this report, including the staff of the Cancer Registry along with all the physicians and clinical staff across the country who have provided us with reports on cancer diagnosis and treatment. prof. Vesna Zadnik, MD, PhD Ljubljana, September 2023 Director of the Slovenian Cancer Registry Podatki Viri podatkov Prijavljanje raka je v Republiki Sloveniji obvezno in zakonsko predpisano že od ustanovitve Registra raka (Ur. l. SRS št. 10/50, št. 29/50, št. 14/65, št. 1/80, št. 45/82, št. 42/85; Ur. l. RS št. 9/92, št. 65/00, št. 47/15 in 31/18). Popolnost zajema podatkov se v Registru raka zagotavlja z vkljucevanjem razlicnih vi- rov podatkov, kot je shematsko prikazano na spodnji sliki. Pri povezovanju razlicnih zbirk se uporablja enoten državni identifikator EMŠO. Državne zdravstvene podatkovne zbirke: - Register umrlihUpravni registri: - CRP- GURSPresejalni programi: - ZORA- Svit- DORAZdravstveni zavodi: - Pasivna ali aktivna prijavaBolnišnicni register: - OIL- GolnikKlinicne in populacijske raziskaveREGISTER RAKA RS Osnovni vir podatkov so slovenski javnozdravstveni zavodi, ki bolezen diagnosticirajo, bolnika zdravijo in spremljajo. Tradicionalno bolnišnice porocajo Registru raka na posebnem formularju Prijavni- ca rakave bolezni. Na Onkološkem inštitutu Ljubljana (OIL) in deloma na Univerzitetni kliniki Golnik zbirajo podatke za Prijavnico v lastnem bolnišnicnem registru ter jih od tam v Register raka posredujejo elektronsko; v preostalih bolnišnicah Prijavnice izpolnjujejo zdravniki, ki bolnika obravnavajo, ali pooblašceno osebje. Skladno s cilji Državnega programa obvladovanja raka 2017–2021 smo v letu 2019 zaceli uvajati tako imenovano aktivno registracijo, pri kateri bolnišnice v svojih informacijskih sis- temih pripravijo in Registru raka posredujejo seznam bolnikov, ustreznih za registracijo, vse podatke o bolezni in obravnavi za te bolnike pa usposobljeno osebje Registra raka zbira in beleži samo z neposrednim dostopom do elektronske dokumentacije pri izvajalcih. Pasivno porocanje s Prijavnicami tako postopoma ukinjamo. Za zbolele v letu 2020, ki so prikazani v tem porocilu, smo v Registru raka zbrali podatke z aktivno registracijo na Onkološkem inštitutu Ljubljana, Univerzitetnem klinicnem centru Maribor, Pediatricni kliniki ter Klinicnem oddelku za hematologijo Univerzitetnega klinicnega centra Ljubljana. Dopolnilni vir podatkov Registra raka so podatkovna zbirka o vzrokih smrti, ki jo upravlja Nacionalni inštitut za javno zdravje, ter podatki o diagnosticiranih rakih, ki jih zabeležijo v treh državnih presejalnih programih: ZORA za odkrivanje predrakavih in zgodnjih rakavih sprememb na maternicnem vratu, DORA za odkrivanje raka dojk in Svit za odkrivanje predrakavih sprememb in raka na debelem crevesu in danki. Za izracun prevalence in preživetja bolnikov potrebujemo podatek, ki se imenuje vitalno stanje (ali je oseba živa, mrtva ali izgubljena iz registra prebivalstva). Podatek dobimo dnevno prek 8 varnih spletnih povezav iz Centralnega registra pre-Prebivalci Slovenije po starosti in spolu na dan 1. 7. 2020. Population of Slovenia by age and sex on July 1st 2020. bivalstva (CRP). Podrobne analize prostorske razpo reditve raka nam omogocata tocno opredeljevanje naslovov bolnikov z rakom in redna povezava z Re- gistrom prostorskih enot (RPE) Geodetske uprave RS (GURS). Pri razporeditvi prebivalcev v geografske enote uporabljamo podatek o stalnem naslovu oseb ob ugotovitvi bolezni, ne pa tudi o zacasnem naslovu, kot je upoštevano v pripravi števila prebivalcev po klasicni »statisticni« definiciji. Pri izracunavanju in interpretiranju vecine kazalnikov bremena raka so poleg podatkov o bolnikih kljucni tudi nacionalni podatki o številu prebivalcev in njihovi starostni strukturi. Za Slovenijo sta tocno število in starostna struktura prebivalcev na voljo za popisna leta že ves cas registracije raka. Nacionalni popis prebivalstva je bil pripravljen približno na vsakih deset let. Podatkov za vmesna obdobja do leta 1985 ni, zato smo pri izracunu kazalnikov predpostavili, da je bila med dvema popisnima letoma struktura enaka. Od sredine osemdesetih let, odkar število prebivalstva v Sloveniji spremlja CRP, je mogoce dobiti ažuren podatek o številu in starostni strukturi prebivalcev. V letnih porocilih uporabljamo podatek o prebivalcih na datum 1. julija po sameznega leta, kot ga dobimo na podatkovnem portalu SI-STAT Statisticnega urada RS. Podatki o prebivalstvu po spolu in petletnih starostnih skupinah za celotno Slovenijo za leto 2020 so prikazani v tabeli. Starostna skupina Age group Skupaj All Moški Males Ženske Females 0-4 99.951 51.516 48.435 5-9 109.752 56.571 53.181 10-14 106.954 54.984 51.970 15-19 93.674 48.350 45.324 20-24 103.442 55.623 47.819 25-29 113.475 60.739 52.736 30-34 134.316 71.745 62.571 35-39 151.422 80.492 70.930 40-44 160.837 85.373 75.464 45-49 150.023 78.712 71.311 50-54 151.029 77.390 73.639 55-59 150.947 76.018 74.929 60-64 144.449 71.909 72.540 65-69 135.564 66.074 69.490 70-74 101.248 46.901 54.347 75-79 77.562 33.021 44.541 80-84 60.447 23.332 37.115 85+ 55.034 15.733 39.301 Skupaj / Total 2.100.126 1.054.483 1.045.643 Vir: Statisticni urad RS / Source: Statistical Offfice of the Republic of Slovenia Obdelava podatkov Podatke, prispele v Register raka, posebej usposobljene medicinske sestre v procesu registracije kodirajo v skladu z mednarodnimi, nacionalnimi in internimi pravili. Lokacija tumorja Za razvršcanje neoplazem po primarni lokaciji je od leta 1997 v veljavi deseta revizija Mednarodne klasifikacije bolezni in sorodnih zdravstvenih problemov za statisticne namene (MKB-10), pred tem pa smo uporabljali osmo. Od leta 1993 je obvezno prijavljanje sprememb maternicnega vratu, oznacenih kot CIN III (šifra 219 po 8. reviziji MKB), dotlej pa so se registrirale le spremembe, oznacene s šifro 234.0 (karcinom in situ). Primerjava s podatki za obdobje 1961–1992 tako ni možna. Po 10. reviziji MKB so vse intraepitelijske spremembe maternicnega vratu uvršcene v šifro D06. Od leta 1987 registriramo tudi prijavljene intraepitelijske karcinome dojke (šifra D05), od leta 1995 pa intraepitelijske karcinome mehurja (šifra D09.0) in kožne melanome Clark I (šifra D03). Morfologija tumorja Pri uvršcanju med maligne bolezni uporabljamo morfološki del Mednarodne klasifikacije bolezni za onkologijo. Od leta 2012 uporabljamo njeno tretjo izdajo z dopolnitvami iz leta 2011, z letom 2020 pa njeno novo razlicico ICD-O-3.2. Zadnja razlicica je prinesla posodobitve izrazoslovja, spremembe morfoloških kod in spremembe malignosti tumorjev. Po tej razlicici so maligni vsi gastrointestinalni stromalni tumorji (GIST) ter skoraj vsi nevroendokrini tumorji in timomi. Pri nevroloških neoplazmah so dodane nove kode. Pomembne spremembe so predvsem pri hematoloških neoplazmah, kjer so nekatere kode za limfome brisane in prestavljene h kodam za levkemije ali obratno. Zadnja razlicica ne prinaša sprememb v razvršcanju v MKB-10. Z razvojem molekularne in genske tehnologije je mogoce natancneje opredeliti vrsto celicnih sprememb, ki nastanejo pri neoplazmah krvotvornega in limfaticnega tkiva, in jih zato bolj usmerjeno zdraviti. S tem se veca število razlicnih vrst bolezni, njihovo razvršcanje pa se vedno bolj izpopolnjuje. Svetovna zdravstvena organizacija je leta 2001 objavila klasifikacijo, ki opredeljuje malignome krvotvornega in limfaticnega tkiva glede na imunofenotip, genske spremembe in klinicno sliko. Leta 2017 je bila posodobljena in pri klinicnem delu zamenjuje številne dodatne klasifikacije malignomov krvotvornega in limfaticnega tkiva. Povzema jo tudi Mednarodna klasifikacija bolezni za onkologijo. Stadij bolezni Za prikaz porazdelitve bolezni po stadiju ob diagnozi v letnih porocilih pri solidnih tumorjih uporabljamo poenostavljeno razvršcanje v eno od treh skupin: omejena bolezen, regionalno razširjena bolezen in oddaljeno razširjena (razsejana) bolezen. Primer opredelimo na osnovi ugotovitev katere koli zapisane preiskave – od popisa operacije do obdukcije, ce bolnik predtem ni bil zdravljen. Poe- nostavljena opredelitev stadijev praviloma sledi klasifikaciji TNM. V omejen stadij je tako praviloma uvršcen primer bolezni, pri katerem je tumor oznacen s T1 ali T2. Pri dojki, kožnem melanomu in šcitnici so v omejen stadij vkljuceni tudi tumorji T3; pri maternicnem vratu, maternicnem telesu in sarkomih ter pri jajcniku, jajcevodu in trofoblastnih tumorjih se v omejen stadij uvršcajo le tumorji T1. Pri omejeni bolezni seveda niso prizadete podrocne bezgavke in ni zasevkov v oddaljenih organih (N0, M0). V stadiju regionalne razširitve je tumor opredeljen kot T3 in T4 (razen v omenjenih izjemah) in/ali so prizadete tudi podrocne bezgavke (N1), zasevkov v oddaljenih bezgavkah in organih pa ni (M0). V skupino oddaljeno razširjene bolezni pa uvršcamo primere, pri katerih je zapisano, da so bili zasevki že prisotni v oddaljenih bezgavkah ali organih (M1). V bazi Registra raka hranimo tudi podatek o stadiju bolezni po klasifikaciji TNM ali drugih klasifikacijah, ce je bil tako opredeljen na prijavnici oz. je bilo na njej vsaj dovolj podatkov za njegovo naknadno opredelitev. Dodatno ginekološke tumorje opredeljujemo po klasifikaciji FIGO, pri kožnem melanomu beležimo velikost po Clarku in Breslowu, maligni limfomi pa so opredeljeni po klasifikaciji Ann-Arbor. Kakovost podatkov V Registru raka spremljamo kakovost podatkov z dvema tradicionalnima mednarodno primerljivima posrednima kazalnikoma: odstotni delež mikroskopsko (histološko ali citološko) potrjenih primerov in odstotni delež primerov, registriranih samo iz zdravniških porocil o vzroku smrti. Vrednosti teh kazalnikov so prikazane v tabeli. Incidenca raka glede na nacin postavitve diagnoze po izbrani primarni lokaciji, Slovenija 2020. Cancer incidence according to basis of diagnosis, Slovenia 2020. Šifra MKB ICD code Primarna lokacija Primary site Število novih primerov Number of new cases Mikroskopsko potrjeni primeri Microscopically confirmed cases Ugotovljeni z drugimi preiskavami Confirmed by other investigations Registrirani samo iz zdravniških porocil o vzroku smrti Registered from death certificates only Število Number % Število Number % Število Number % C00-C96 Moški in ženske / Males and females Vse lokacije Moški / Males All sites Ženske / Females 15096 8062 7034 14223 7582 6641 94,2 94,0 94,4 839 466 373 5,6 5,8 5,3 34 14 20 0,2 0,2 0,3 C00-C14 Usta in žrelo / Mouth and pharynx 326 325 99,7 1 0,3 0 0,0 C15 Požiralnik / Oesophagus 94 91 96,8 3 3,2 0 0,0 C16 Želodec / Stomach 424 416 98,1 7 1,7 1 0,2 C18 Debelo crevo / Colon 825 795 96,4 26 3,2 4 0,5 C19-C20 Rektum in rektosigmoidna zveza / Rectum and rectosigmoid junction 479 464 96,9 14 2,9 1 0,2 C22 Jetra in intrahepaticni vodi / Liver and intrahepatic bile ducts 234 135 57,7 99 42,3 0 0,0 C23-C24 Žolcnik in žolcevodi / Gallbladder and billiary tract 198 121 61,1 77 38,9 0 0,0 C25 Trebušna slinavka / Pancreas 420 280 66,7 139 33,1 1 0,2 C32 Grlo / Larynx 91 90 98,9 1 1,1 0 0,0 C33-C34 Sapnik, sapnici in pljuca / Trachea, bronchus and lung 1554 1365 87,8 188 12,1 1 0,1 C43 Maligni melanom kože / Malignant melanoma of skin 639 639 100,0 0 0,0 0 0,0 C44 Druge maligne neoplazme kože / Skin, excl. melanoma 3010 2998 99,6 10 0,3 2 0,1 C48-C49 Vezivno in mehko tkivo / Connective and soft tissue 87 84 96,6 3 3,4 0 0,0 C50 Dojka / Breast 1459 1445 99,0 10 0,7 4 0,3 C53 Maternicni vrat / Cervix uteri 133 131 98,5 2 1,5 0 0,0 C54 Maternicno telo / Corpus uteri 373 370 99,2 3 0,8 0 0,0 C56 Jajcnik / Ovary 151 139 92,1 12 7,9 0 0,0 C61 Prostata / Prostate 1460 1407 96,4 45 3,1 8 0,5 C62 Modo / Testis 112 112 100,0 0 0,0 0 0,0 C64-C65 Ledvica z ledvicnim mehom / Kidney with renal pelvis 416 366 88,0 49 11,8 1 0,2 C67 Secni mehur / Bladder 387 371 95,9 13 3,4 3 0,8 C70-C72 Centralni in avtonomni živcni sistem / Central and autonomic nervous system 184 157 85,3 27 14,7 0 0,0 C73 Šcitnica / Thyroid gland 175 175 100,0 0 0,0 0 0,0 C81 Hodgkinov limfom / Hodgkin’s lymphoma 47 47 100,0 0 0,0 0 0,0 C82-C85 Ne-Hodgkinovi limfomi / Non-Hodgkin’s lymphoma 460 460 100,0 0 0,0 0 0,0 C90 Difuzni plazmocitom in maligne neoplazme plazmatk Multiple myeloma and malignant plasma cell neoplasms 155 155 100,0 0 0,0 0 0,0 C91-C95 Levkemije / Leukaemias 366 365 99,7 0 0,0 1 0,3 Data Data Sources Notification of cancer has been compulsory in Slovenia since the foundation of the Slovenian Cancer Registry and is prescribed by law (Official Gazette of SRS, No 10/50, 29/50, 14/65, 1/80, 45/82 and 42/85; Official Gazette of RS, No 9/92, 65/00, 47/15 and 31/18). Incorporation of data from different sources into the Cancer Registry, as schematically shown in the figure below, ensures data completeness. The unique national identification number (EMŠO) is used to facilitate linkage between different databases. National HealthDatabases: - Death RegistryAdministrative registries: - CPR- SMARSScreening programmes: - ZORA- Svit- DORAHealth Institutions: - Passsive or active registrationHospital- basedregistries: - IOL- GolnikClinical and demographic researchSLOVENIAN CANCER REGISTRY The main sources of data are Slovenian public healthcare institutions, where diagnostics, treatment and follow-up of patients are carried out. Traditionally, hospitals report cases to the Cancer Registry via the special Cancer Notification Form. At the Institute of Oncology Ljubljana (IOL) and in part also at the University Clinic Golnik, their own hospital registries collect data for the Notification Form and then send it electronically to the Cancer Registry; in other hospitals Notification Forms are filled in by the attending physicians or by the authorized staff. In accordance with the goals of the National Cancer Control Programme 2017–2021, in 2019 we began introducing data collection via so-called active registration, whereby hospital information systems are used to compile and provide the Cancer Registry with a list of patients eligible for registration, whose data on the disease and treatment are then collected and recorded directly from back-office information systems by the trained staff of the Slovenian Cancer Registry. Passive reporting using Notification Forms will gradually be phased out. For patients diagnosed in 2020, whose data are the subject of this report, active registration was employed by the Cancer Registry in collecting the data from the Institute of Oncology Ljubljana and the University Medical Centre Maribor, as well as the Division of Paediatrics and the Department of Haematology at the University Medical Centre Ljubljana. Complementary sources of information for the Cancer Registry are death certificates that we obtain from the National Institute of Public Health of the Republic of Slovenia and data on diagnosed can cers recorded in three national screening programmes: ZORA for detection of precancerous and early 12 cancerous cervical lesions, DORA for early detection of breast cancer, and Svit for detection of precancerous lesions and cancer of the colon and rectum. Calculation of cancer prevalence and survival requires information on the patient’s vital status (whether the person is alive, dead or lost to follow up). This data is updated daily through secure electronic linkage with the Central Population Registry (CPR). Detailed analyses of the spatial distribution of cancer are only possible if we have accurately defined addresses of cancer patients, which we obtain through regular linkage to the Register of Spatial Units of the Surveying and Mapping Authority of the Republic of Slovenia (SMARS). When allocating the population to geographical units, we take into account only the permanent residence of persons at the time of diagnosis and not the temporary one, contrary to the standard “statistical” definition of the population used for calculating the number of inhabitants. In addition to patient data, national population data, especially population size and age structure, are important for calculation and interpretation of most indicators of cancer burden. Census population data are available for the whole time period since the beginning of cancer registration in Slovenia. The census has been performed nearly every 10 years; however, until 1985 no data were available for intermediate years, so for this period it was assumed that the population structure between the two censuses was the same. Since the middle of the eighties, population data are available for any date at the Central Population Registry. In annual reports the population data on 1 July of the relevant year are used, obtained from the SISTAT Database of the Statistical Office of the Republic of Slovenia. In the table on page 9, the population size of Slovenia in 2020 is presented, stratified by age and sex. Data Processing At the Cancer Registry, specially trained nurses code the data retrieved from Cancer Notifications in accordance with international, national and internal guidelines for cancer registration. Tumour Location Since 1997, cancer sites have been coded according to the 10th revision of the International Statistical Classification of Diseases and Related Health Problems (ICD-10); previously, the 8th revision was used (ICD-8). In 1993, compulsory registration of all cervical intraepithelial dysplasia classified as CIN III was introduced (code 219 according to ICD-8). Until then, only carcinoma in situ (code 234.0) was registered. Thus, comparisons with data for the period 1961–1992 are not possible. According to ICD-10, all cervical intraepithelial neoplasms (in situ and CIN III) are coded as D06. Since 1987, the number of all reported intraepithelial carcinomas of breast (code D05) and since 1995, all reported intraepithelial carcinomas of the bladder (code D09.0) and all malignant melanomas of Clark level I (code D03) have been registered as well. Tumour Morphology When classifying tumours as malignant, the behaviour digit of the morphology code of the International Classification of Diseases for Oncology is used. Since 2012, the 3rd edition has been in use, including the 2011 updates, and since 2020 its newest revison ICD-O-3.2. The latest revision brought updates in terminology, changes in morphological codes and changes in tumour malignancy. According to this revision, all gastrointestinal stromal tumours (GIST) and nearly all neuroendocrine tumours and thy- momas are malignant. New codes have been added in the group of neurological neoplasms. Significant changes have been introduced to haematological neoplasms, where some codes for lymphomas have been deleted and moved to codes for leukaemias or vice versa. The latest revision does not bring any changes in the ICD-10 grouping. 13 Development of molecular and genetic technologies has enabled more detailed classification of the type of cellular changes found in malignant neoplasms of the lymphoid and haematopoietic tissues. Better and more detailed identification enables targeted treatment. This corresponds to a larger number of disease types with the classification system constantly updating. In 2001, the World Health Organization published a special classification of neoplasms of the lymphoid and haematopoietic tissue based on immunophenotype, genetic changes and clinical picture. The classification was updated in 2017 and it replaced several other classifications of neoplasms of the lymphoid and haematopoietic tissue in clinical use. Furthermore, the International Classification of Diseases for Oncology follows this classification. Cancer Staging For stage description, a simplified definition of stages at diagnosis is used for solid tumours, classifying them into localized, regional and distant stage of disease. The simplified definition is based on all investigation methods, including surgery. If the patient was not treated before death, the autopsy record is considered as well. The simplified stage definition generally follows the TNM classification. Localized stage includes all cancers where the tumour has been classified as T1 and T2. In breast cancer, skin melanoma and thyroid cancer, T3 tumour is also included in the localized stage. In cases of uterine cervix, corpus and sarcomas, ovarian cancer, Fallopian tube and trophoblastic tumours, only T1 tumour is included in the localized stage. In all these cases neither regional lymph node involve ment nor distant metastases are found (N0, M0). The regional stage includes tumours classified as T3 and T4 (with aforementioned exceptions) and/or with regional lymph node metastases (N1), without presence of metastases in distant lymph nodes or organs (M0). A disease with metastases in distant lymph nodes or organs is classified as a distant stage (M1). Stage according to TNM or any other appropriate classification, if available, is also stored in the Cancer Registry database. Additionally, FIGO classification is used for gynaecological tumours, Clark’s level and Breslow’s thickness in skin melanoma, and Ann-Arbor System for lymphomas. Data Quality The quality of information can be directly assessed by the following internationally harmonized stan dard parameters: the percentage of microscopically (histologically or cytologically) confirmed cases and the percentage of cancer cases registered on the basis of death certificates only. The values of these parameters are presented in the table on page 11. Rak v Sloveniji Povzetek Za dodatne podatke o bremenu raka v Sloveniji in svetu obišcite www.slora.si. . Med rojenimi leta 2020 bosta do svojega 75. leta starosti za rakom predvidoma zbolela eden od dveh moških in ena od treh žensk. . Za rakom zboli letno približno 16.000 Slovencev, vec kot 8.000 moških in vec kot 7.000 žensk, umre pa jih vec kot 6.000, približno 3.500 moških in nekaj manj kot 3.000 žensk; med nami živi že vec kot 120.000 ljudi, ki so kadarkoli zboleli zaradi ene od rakavih bolezni (prevalenca). . Leta 2020, v prvem letu epidemije Covid-19, je bilo diagnosticiranih 11 % manj rakov kot je bilo pricakovano. Najvecji manko diagnoz je bil pri nemelanomskem kožnem raku, rakih prostate, dojk in pljuc ter pri hematoloških rakih. . Ogroženost z rakom je najvecja pri starejših; med vsemi bolniki z rakom, zbolelimi leta 2020, je bilo 65 % starejših od 65 let. Ker se slovensko prebivalstvo stara, je samo zaradi vedno vecjega deleža starejših pricakovati, da se bo število novih primerov raka še vecalo. . Najpogostejši raki pri nas (kože, pljuc, dojke, prostate ter debelega crevesa in danke) so leta 2020 predstavljali 58 % vseh ugotovljenih rakov. Ti raki so povezani z nezdravim življenjskim slogom: kajenjem, cezmernim pitjem alkoholnih pijac, neustrezno prehrano, premalo gibanja in posledicno prekomerno težo ter cezmernim soncenjem. Ogroženost z njimi je treba zmanjšati z ukrepi primarne preventive. . Presejalni programi za rake, ki jih priporoca Svet Evropske unije in smo jih uvedli tudi v Sloveniji, so z zgodnjim odkrivanjem že zmanjšali umrljivost za rakom dojk, debelega crevesa in danke ter rakom maternicnega vratu; pri slednjih dveh so zmanjšali tudi incidenco. . Petletno cisto preživetje odraslih slovenskih bolnikov s katerokoli vrsto raka (brez nemelanomskega kožnega), ki so zboleli v obdobju 2016–2020, je bilo 58 %, bolnic pa 62 %. 0 20.000 40.000 60.000 80.000 100.000 120.000 7.034 6.4233.6022.821 124.83015.096 Incidenca 8.062 Incidence Umrljivost Mortality Prevalenca 57.593 Prevalence 67.237 Moški in ženske / Males and females Moški / Males Ženske / Females Slika 1. Breme raka, Slovenija 2020. Figure 1. Cancer burden, Slovenia 2020. Osnovni podatki o raku v Sloveniji 2020 . Leta 2020 je v Sloveniji za rakom zbolelo 15.096 ljudi (8.062 moških in 7.034 žensk). . Starostno standardizirana incidencna stopnja (evropsko prebivalstvo) je bila 465,5/100.000; 531,9 pri moških in 420,3 pri ženskah. Med rojenimi leta 2020 bosta do svojega 75. leta starosti za rakom predvidoma zbolela eden od dveh moških in ena od treh žensk. . Leta 2020 je za rakom umrlo 6.423 Slovencev, 3.602 moških in 2.821 žensk. Med nami je živelo 124.830 ljudi (57.593 moških in 67.237 žensk), ki so kadarkoli zboleli za eno od rakavih bolezni (prevalenca). . Med posameznimi slovenskimi regijami ne opažamo bistvenih razlik v bremenu raka. Starost bolnikov . Ceprav se ogroženost z rakom zmerno veca, je najvecja v poznejši starosti; med vsemi onkološkimibolniki je leta 2020 kar 67 % moških in 62 % žensk zbolelo po dopolnjeni starosti 65 let. Polovica odstotka vseh rakavih bolezni je bilo ugotovljenih pri otrocih in mladostnikih (do 20. leta). . Ker se slovensko prebivalstvo stara, je samo zaradi cedalje vecjega deleža starejših pricakovati, da se bo število novih primerov raka še vecalo. Ocenjujemo, da bomo leta 2023 zabeležili že 17.046novih bolnikov. 0–4 5–9 10–14 15–19 20–24 25–29 30–34 35–39 40–44 45–49 50–54 55–59 60–64 65–69 70–74 75–79 80–84 85+ 150.000 100.000 50.000 0 0 500 1000 1500 2000 2500 Število prebivalcev / Population Incidenca / Incidence Slika 2. Število novih primerov vseh rakov (desna stran) po starosti ter primerjava s številom prebivalcev (leva stran) v istih starostnih skupinah, Slovenija 2020. Figure 2. Number of new cancer cases (right side) by age and comparison with the population numbers (left side) in the same age groups, Slovenia 2020. Casovni trend . V splošnem se groba incidencna in umrljivostna stopnja raka vecata, vendar pa smo v letu 2020, prvem letu epidemije Covid-19, zabeležili 11 % padec v številu novih primerov raka. . Groba incidencna stopnja se je v zadnjih 20 letih skoraj podvojila, v zadnjem desetletju se veca za 1,6 % povprecno letno (1,0 % pri moških in 2,4 % pri ženskah). Groba umrljivostna stopnja se je pri moških v zadnjih 10 letih vecala povprecno za 0,8 % letno, pri ženskah pa za 1,2 %. . Vec kot polovico tega povecanja lahko pripišemo staranju prebivalstva, saj z daljšo življenjsko dobo lahko tudi vec ljudi docaka to bolezen. Starostno standardizirana kumulativna inciden- cna stopnja kaže, da se tveganje raka veca pocasneje, pri moških se trend celo obraca navzdol. Spodbudno je tudi, da se umrljivost zaradi raka (ce ne upoštevamo staranja prebivalstva) manjša, predvsem od sredine devetdesetih let, kar kaže na vecjo uspešnost zdravljenja. Leto / Year Incidenca moški Umrljivost moškiIncidenca ženske Umrljivost ženske Incidence males Mortality males Incidence females Mortality females * Povprecna letna sprememba je statisticno znacilna pri stopnji tveganja 0,05 / Average annual change is statistically significant at 0.05 significance level Slika 3. Groba letna incidencna in umrljivostna stopnja vseh rakov po spolu s povprecno letno spremembo za zadnjih 10 let, Slovenija 1950-2020. Figure 3. Crude annual incidence and mortality rates for all cancer sites by sex with average annual change in last 10 years, Slovenia 1950-2020. Leto / Year Incidenca moški Umrljivost moškiIncidenca ženske Umrljivost ženske Incidence males Mortality males Incidence females Mortality females * Povprecna letna sprememba je statisticno znacilna pri stopnji tveganja 0,05 / Average annual change is statistically significant at 0.05 significance level Slika 4. Kumulativna incidencna in umrljivostna stopnja vseh rakov po spolu s povprecno letno spremembo v zadnjih 10 letih, Slovenija 1950-2020. Figure 4. Cumulative annual incidence and mortality rates for all cancer sites by sex with average annual change in last 10 years, Slovenia 1950-2020. 1950 1955 1960 1965 1970 1975 1980 1985 1990 1995 2000 2005 2010 2015 2020 50 40 30 20 10 0 Kumulativna stopnja na 100.000Cumulative rate per 100,000 -1,2* % +1,4* % -1,9* % -0,6 % 1950 1955 1960 1965 1970 1975 1980 1985 1990 1995 2000 2005 2010 2015 2020 800 700 600 500 400 300 200 100 0 Groba stopnja na 100.000Crude rate per 100,000 +1,0 % +2,4* % +0,8* % +1,2* % Najpogostejši raki . Rak ni ena sama bolezen, temvec vec sto razlicnih. Te lahko vzniknejo v vseh tkivih in organih cloveškega organizma. Razlikujejo se po pogostosti, zdravljenju in izidu, imajo pa tudi razlicne bolj ali manj znane nevarnostne dejavnike. . Pet najpogostejših vrst raka pri nas – kožni (brez melanoma), pljuc, dojke, prostate ter raki debelega crevesa in danke – obsega 58 % vseh novih primerov rakavih bolezni. . Najpogostejši raki so povezani z nezdravim življenjskim slogom: kajenjem, cezmernim pitjem alkoholnih pijac, neustrezno prehrano, premalo gibanja in posledicno prekomerno težo ter cezmernim soncenjem. Ogroženost z njimi je treba zmanjšati z ukrepi primarne preventive. . Pri moških zavzemata nemelanomski kožni rak in rak prostate vsak približno petino vseh rakov, sledita pljucni rak ter rak debelega crevesa in danke. Pri ženskah je najpogostejši nemelanomski kožni rak, sledi rak dojke, ki predstavlja petino vseh rakov, nato pa še pljucni rak ter rak debelega crevesa in danke. . Najpogostejši raki se v razlicnih življenjskih obdobjih pojavljajo razlicno. Pri otrocih in mladostnikih do 20. leta starosti so najpogostejše levkemije, sledijo jim tumorji centralnega in avtonomnega živcnega sistema in limfomi. Mlajši odrasli (20–49 let) moški zbolevajo najvec za rakom mod in kože, pri ženskah v tej starosti pa je na prvem mestu rak dojke. Moški in ženske Males and females Koža, razen melanoma Skin, excl. melanoma Pljuca* Lung* Prostata Prostate Dojka Breast Debelo crevo in danka* Colorectum* Koža, melanom Skin, melanoma Ne-Hodgkinovi limfomi* Non-Hodgkin’s lymphoma* Glava in vrat* Head and neck* Želodec Stomach Trebušna slinavka Pancreas Ostalo Other 19,9 10,3 9,7 9,7 8,6 4,2 3,1 2,9 2,8 2,8 26,0 25 0 5 10 15 20 30 % *Pojasnilo: / Explanation: Glava in vrat / Head and neck (C00-C14, C30-C32) Debelo crevo in danka / Colorectum (C18-C20) Sapnik, sapnici in pljuca / Trachea, bronchus and lung (C33-C34) Ne-Hodgkinovi limfomi / Non-Hodgkin’s lymphoma (C82-C85) Slika 5a. Najpogostejše lokacije raka in njihov odstotni delež pri obeh spolih skupaj, Slovenija 2020. Figure 5a. The leading cancer sites with percentage distribution for both sexes combined, Slovenia 2020. Glava in vrat* Head and neck* 4,2 Pljuca* Lung* 11,6 9,7 3,5 3,4 18,1 19,6 4,1 19,6 2,1 8,8 20,4 7,4 5,3 3,2 20,6 4,4 22,6 Pljuca* Lung* LevkemijeLeukaemias DojkaBreast 3,0 Trebušna slinavka Pancreas 2,9 Ne-Hodgkinovi limfomi* Non-Hodkgin’s lymphoma* 3,5 2,1 JajcnikOvary Želodec Stomach Debelo crevo in danka* Colorectum* Debelo crevo in danka* Colorectum* Maternicno telo Corpus uteri Ledvica z ledvicnim mehom* Kidney with renal pelvis* Mehur Bladder Prostata Prostate Ne-Hodgkinovi limfomi* Non-Hodkgin’s lymphoma* Koža, melanom Skin, melanoma Koža, melanom Skin, melanoma ŽenskeFemalesMoškiMalesGlava in vrat* Head and neck* 4,2 Pljuca* Lung* 11,6 9,7 3,5 3,4 18,1 19,6 4,1 19,6 2,1 8,8 20,4 7,4 5,3 3,2 20,6 4,4 22,6 Pljuca* Lung* LevkemijeLeukaemias DojkaBreast 3,0 Trebušna slinavka Pancreas 2,9 Ne-Hodgkinovi limfomi* Non-Hodkgin’s lymphoma* 3,5 2,1 JajcnikOvary Želodec Stomach Debelo crevo in danka* Colorectum* Debelo crevo in danka* Colorectum* Maternicno telo Corpus uteri Ledvica z ledvicnim mehom* Kidney with renal pelvis* Mehur Bladder Prostata Prostate Ne-Hodgkinovi limfomi* Non-Hodkgin’s lymphoma* Koža, melanom Skin, melanoma Koža, melanom Skin, melanoma ŽenskeFemalesMoškiMales Koža, razen melanoma Skin, excl. melanoma Ostalo Other Koža, razen melanoma Skin, non-melanoma Ostalo Other 30 % 25 20 15 10 5 0 5 10 15 20 25 30 % *Pojasnilo / Explanation: Glava in vrat / Head and neck (C00-C14, C30-C32) Debelo crevo in danka / Colorectum (C18-C20) Sapnik, sapnici in pljuca / Trachea, bronchus and lung (C33-C34) Ledvica z ledvicnim mehom / Kidney with renal pelvis (C64-C65) Ne-Hodgkinovi limfomi / Non-Hodgkin’s lymphoma (C82-C85) Slika 5b. Najpogostejše lokacije raka in njihov odstotni delež po spolu, Slovenija 2020. Figure 5b. The leading cancer sites with percentage distribution by sex, Slovenia 2020. Starost /Age 0–19 20–49 50–74 75+ Vse starosti / All Ostalo 32,2 Ostalo 24,9 Ostalo 30,1 Ostalo 34,4 Ostalo 32,6 Kosti 4,4 Vezivno in mehko tkivo 7,2 Hodgkinov limfom 9,4 Šcitnica 9,9 Centralni in avtonomni živcni sistem Levkemije 12,7 23,8 Debelo crevo in danka Maternicni vrat 4,9 Šcitnica Koža, melanom 6,5 Koža, razen melanoma 4,9 9,1 17,3 Ženske Females Dojka Koža, razen melanoma Dojka Koža, razen melanoma Dojka Koža, razen melanoma Dojka Debelo crevo in danka Debelo crevo in danka 32,0 Debelo crevo in danka Pljuca Pljuca 10,8 8,1 Pljuca Maternicno telo Maternicno telo 6,3 5,0 7,6 Maternicno telo Koža, melanom Koža, melanom 3,6 3,7 Trebušna slinavka 7,3 19,3 22,8 4,0 6,3 9,1 12,7 29,6 4,0 20,1 22,7 Povprecna letna incidenca 36 874 3787 2660 7356 Starost /Age 0–19 20–49 50–74 75+ Vse starosti / All Ostalo 32,1 Ostalo 36,1 Ostalo 28,6 Ostalo 28,0 Ostalo 31,3 Kosti 7,4 Moški Males Ne-Hodgkinovi limfomi Hodgkinov limfom Centralni in avtonomni živcni sistem Levkemije Ne-Hodgkinovi limfomi Glava in vrat Debelo crevo in danka Koža, melanom Modo Modo Koža, razen melanoma Koža, razen melanoma Koža, razen melanoma 6,8 8,4 Prostata Prostata Prostata Koža, razen melanoma Debelo crevo in danka Pljuca 9,3 19,8 Debelo crevo in danka Debelo crevo in danka Pljuca Pljuca 9,4 Glava in vrat 4,3 Glava in vrat 5,4 Želodec 4,1 Ledvica z ledvic. mehom Koža, melanom 3,7 11,1 11,1 23,2 4,7 5,3 8,8 9,5 16,8 18,9 13,6 16,4 23,1 Secni mehur 4,0 10,7 16,9 26,7 3,8 9,7 11,5 19,6 Average annual incidence 38 559 5105 2713 8415 *Pojasnilo / Explanation: Debelo crevo in danka / Colorectum (C18-C20) Dojka / Breast (C50)Želodec / Stomach (C16) Trebušna slinavka / Pancreas (C25) Maternicni vrat / Cervix uteri (C53) Prostata / Prostate (C61) Pljuca / Lung (C33-C34) Maternicno telo / Corpus uteri (C54)Modo / Testis (C62) Kosti / Bone (C40-C41)Centralni in avtonomni živcni sistem / Central and Ledvica z ledvicnim mehom / Kidney with Koža, melanom / Skin, melanoma (C43) autonomic nervous system (C70-C72) renal pelvis (C64-C65) Koža, razen melanoma / Skin, excl. melanoma (C44) Šcitnica / Thyroid gland (C73) Secni mehur / Bladder (C67) Vezivno in mehko tkivo / Connective and soft tissue (C48-C49) Hodgkinov limfom / Hodgkin’s disease (C81) Ne-Hodgkinovi limfomi (NHL) / Non-Hodgkin’s Glava in vrat / Head and neck (C00-C14, C30-C32) Levkemije / Leukaemias (C91-C95) lymphoma (NHL) (C82-C85) Slika 6. Odstotni deleži najpogostejših rakov po starostnih skupinah in spolu, Slovenija 2015-2020. Figure 6: Percentage distribution of leading cancer sites by age group and sex, Slovenia 2015-2020. Trend najpogostejših rakov . V prvem letu epidemije Covid 2020 je bil najvecji manko diagnoz pri nemelanomskem kožnem raku, rakih prostate, dojk in pljuc ter pri hematoloških rakih. Nasprotno pa pri rakih debelega crevesa in danke ter pri kožnem melanomu manka ni bilo. . Med pogostejšimi rakavimi boleznimi pri moških se je incidencna stopnja pljucnega raka vecala vse do zacetka novega tisocletja, ko se je ustalila pri vrednosti okoli 90/100.000. . Pljucnega raka strmo prehitevata rak prostate (sprememba incidencne stopnje za povprecno -0,6% na leto) in nemelanomski kožni rak (povecanje za povprecno 4,1 % na leto). Izjemno povecanje incidence raka prostate v zadnjih dveh desetletjih ni posledica kakšnega novega nevarnostnega dejavnika, temvec predvsem vse širše rabe testa za dolocanje za prostato specificnega antigena(PSA) pri moških brez zdravstvenih težav in odkrivanja velikega števila primerov, ki bi sicer ostalivse življenje prikriti. Podatki za zadnja leta kažejo, da smo vrh incidence raka prostate že dosegli. . Tudi casovne spremembe v pojavljanju raka debelega crevesa in danke je treba ocenjevati ob upoštevanju sprememb v diagnostiki – leta 2009 smo namrec v Sloveniji uvedli Državni program presejanja in zgodnjega odkrivanja predrakavih sprememb in raka na debelem crevesu in danki (Svit). Groba incidencna stopnja raka debelega crevesa in danke pri moških od leta 2011 pada za 2,5 % letno, pred tem pa je v desetletnem obdobju 1999–2008 narašcala vsako leto za 3,6 %. Povprecne letne odstotne spremembe so prikazane ob krivuljah na Sliki 7a. . Med pogostejšimi rakavimi boleznimi pri ženskah so se vecale grobe incidencne stopnje rakadojk (za 2,6 % povprecno letno), nemelanomskega kožnega raka (povecanje za povprecno 4,5 % letno), pljucnega raka (za 6,3 %) in raka maternicnega telesa (za 2,1 %). . Incidencna stopnja raka maternicnega vratu od uvedbe Državnega programa zgodnjega odkrivanja predrakavih sprememb in raka maternicnega vratu (ZORA) pada (za povprecno 1,9 % na leto v zadnjih desetih letih). . Podobno kot pri moških se tudi pri ženskah zaradi uvedbe presejalnega programa Svit leta 2009spreminja casovni trend pojavljanja raka debelega crevesa in danke – od leta 2011 groba inciden- cna stopnja pada za 1,6 % letno, pred tem pa je med 1999 in 2008 narašcala vsako leto za 3,4 %. 180 160 140 -2,5* % -0,8 % -1,8* % +1,3 % +0,6 % +2,2* % MoškiMales +4,1* % -0,6 % Groba stopnja na 100.000 Crude rate per 100,000 120 100 80 60 40 20 0 195019551960196519701975198019851990199520002005201020152020 Pljuca / Lung (C33–C43) Prostata / Prostate (C61) Leto / Year Koža, razen melanoma / Skin, non-melanoma (C44) Glava in vrat / Head and neck (C00–C14, C30–C32) Debelo crevo in danka / Colorectum (C18–C20) Želodec / Stomach (C16) Mehur / Bladder (C67) Koža, melanom / Skin, melanoma (C43) * Povprecna letna sprememba je statisticno znacilna pri stopnji tveganja 0,05 / Average annual change is statistically significant at 0.05 significance level Slika 7a. Groba letna incidencna stopnja izbranih rakov s povprecno letno spremembo v zadnjih 10 letih pri moških, Slovenija 1950–2020. Figure 7a. Crude annual incidence rates of selected primary cancer sites with average annual change in last 10 years in males, Slovenia 1950-2020. Dojka / Breast (C50) Koža, razen melanoma / Skin, excl. melanoma (C44) Leto / Year Debelo crevo in danka / Colorectum (C18–C20) Pljuca / Lung (C43) Maternicno telo / Corpus uteri (C54) Koža, melanom / Skin, melanoma (C43) Maternicni vrat / Cervix uteri (C53) Želodec / Stomach (C16) * Povprecna letna sprememba je statisticno znacilna pri stopnji tveganja 0,05 / Average annual change is statistically significant at 0.05 significance level Slika 7b. Groba letna incidencna stopnja izbranih rakov s povprecno letno spremembo v zadnjih 10 letih pri ženskah, Slovenija 1950–2020. Figure 7b. Crude annual incidence rates of selected primary cancer sites with average annual change in last 10 years in females, Slovenia 1950-2020. Redki raki . Poseben izziv so redke rakave bolezni (opredeljene kot tiste, ki se jih letno diagnosticira manj kot 6 novih primerov na 100.000 prebivalcev). . Skupaj so redki raki v Sloveniji predstavljali približno petino vseh novo ugotovljenih primerov raka – letno je za njimi zbolelo približno 3.000 bolnikov. . Za redke rake je znacilno, da se v primerjavi s pogostejšimi veckrat pojavljajo pri otrocih in mladostnikih. . Kot pri vseh redkih boleznih se tudi pri redkih rakih spopadamo s podobnimi težavami: pozno intežko jih diagnosticiramo, njihov nastanek in možnosti zdravljenja so slabo raziskani ali pa najustreznejše zdravljenje ni široko dostopno. Da bi uspešno obvladovali redke rake, je pomembno, danjihovo breme natancno spremljamo ter da vse države sprejmejo smernice in dolocijo referencne centre za diagnostiko in zdravljenje teh bolnikov. Slika 8: Odstotni delež redkih, pogostih in nerazvršcenih rakov po starostnih skupinah, Slovenija 2004-2013. Figure 8: Percentage distribution of rare, common and unclassified cancers by age group, Slovenia 2004-2013. Nerazvršcen / Unclassified Pogosti / Common Redki / Rare 100 90 80 70 60 50 40 30 20 10 0 % 1950 1955 1960 1965 1970 1975 1980 1985 1990 1995 20002005201020152020 180 160 140 120 100 80 60 40 20 0 Groba stopnja na 100.000Crude rate per 100,000 +2,6* % -1,6* % +2,1* % -1,7 % +4,5* % +6,3* % -1,9 % +2,8* % ŽenskeFemales Age / Starost 0–45–9 10–1415–19 20–2425–29 30–34 35–3940–44 45–4950–54 55–5960–64 65–69 70–7475–79 80+ Vsi / All Preživetje . Petletno cisto preživetje moških bolnikov s katerokoli vrsto raka razen nemelanomskega kožnega, ki so zboleli v obdobju 2016–2020, je bilo že 58,0 %, pri ženskah pa 62,0 %. . Vec kot 80 % je bilo cisto petletno preživetje pri moških z rakom mod, prostate, šcitnice, kožnim melanomom in Hodgkinovim limfomom, pri ženskah pa pri bolnicah z rakom šcitnice, kožnim melanomom, rakom dojk in Hodgkinovim limfomom. . V letu 2020 je bil narejen pregled preživetij slovenskih onkoloških bolnikov, zbolelih med letoma 1997 in 2016. Rezultati analize so na voljo v publikaciji Preživetje bolnikov z rakom, zbolelih v letih 1997–2016 v Sloveniji (Zadnik et al., 2020), ki je v digitalni obliki dostopna na www.onko-i.si/rrs. Glavni zakljucki so: 1. Preživetje slovenskih bolnikov z rakom se s casom povecuje. V zadnjih 20 letih (1997–2001 in 2012–2016) se je petletno cisto preživetje povecalo za 11 odstotnih tock. Obcutno vecja je rast pri moških, kjer se je petletno cisto preživetje povecalo za 17 odstotnih tock (z 38 % na 55 %). Pri ženskah je petletno cisto preživetje zraslo za 6 odstotnih tock (s 54 % na 60 %). 2. Kljucni dejavniki za preživetje bolnikov z rakom so še vedno starost, stadij ob diagnozi in ustrezno zdravljenje. Petletno cisto preživetje je najmanjše pri starejših od 75 let, vendar se je tudi v skupini najstarejših bolnikov v zadnjih 20 letih petletno preživetje izboljšalo za 7 odstotnih tock. Petletno cisto preživetje bolnikov z omejenim stadijem se je v 20 letih povecalo za 10 odstotnih tock; preživetje pri bolnikih z razsejanim stadijem se ne izboljšuje. 3. Pri obeh spolih se je v zadnjih 20 letih znacilno povecalo preživetje pri treh pogostih rakih: raku na debelem crevesu in danki (za 14 odstotnih tock z 48 % na 62 %), kožnem melanomu (za 12 odstotnih tock z 79 % na 91 %) ter pri pljucnem raku (za 8 odstotnih tock z 10 % na 18 %). Rezultati kažejo zgodnejšo diagnostiko in napredek pri sistemskem zdravljenju. 4. Obcuten je tudi napredek pri obeh najpogostejših rakih, raku dojke pri ženskah in raku prostate pri moških: petletno cisto preživetje bolnic z rakom dojke se je v zadnjih 20 letih povecalo za 10 odstotnih tock, petletno cisto preživetje bolnikov z rakom prostate pa celo za vec kot 20 odstotnih tock. Velik napredek pri raku prostate je verjetno samo navidezen, saj smo ravno v obravnavnem obdobju v Sloveniji precej nekriticno uporabljali testiranje PSA, s katerim smo odkrivali rake prostate, ki bi po naravnem poteku še dolgo ostali klinicno nemi, ter tako z zgodnejšo diagnozo umetno podaljšali preživetje. 5. V skupino rakov, kjer napredka s casom ni opaziti ter pri katerih preživetje še vedno ostaja slabo, pa se uvršcajo rak trebušne slinavke, rak požiralnika, raki jeter, žolcnika in žolcevodov ter možganski tumorji. 6. V raziskavi CONCORD-3 smo primerjali petletna cista preživetja odraslih bolnikov, zbolelimi med letoma 2010 in 2014 v 26 evropskih državah, s 15 razlicnimi vrstami raka. Preživetje slovenskih bolnikov z rakom je v vecini primerov pod evropskim povprecjem, kar nam daje dobro osnovo za nadaljnje izboljšave. 7. Med bolniki z rakom je manj kot 1 % otrok in mladostnikov; zbolevajo predvsem za levkemijami, tumorji osrednjega živcevja in limfomi in imajo boljše petletno preživetje kot odrasli. V zadnjih 20 letih (1997–2001 in 2012–2016) se je petletno preživetje otrok in mladostnikov, zbolelih za rakom, povecalo za 7 odstotnih tock (z 79 % na 86 %). Moški Males Modo C62 Testis Prostata C61 Prostate Šcitnica C73 Thyroid gland Koža, melanom C43 Skin, melanoma Hodgkinov limfom C81 Hodgkin’s lymphoma Limfaticna levkemija C91 Lymphocytic leukaemia Ledvica z ledvicnim mehom C64–C65 Kidney with renal pelvis Kosti C40–C41 Bone Grlo C32 Larynx Ne-Hodgkinovi limfomi C82–C85 Non-Hodgkin’s lymphoma Rektum in rektosigmoidna zvezaRectum and rectosigmoid junction C19–C20 Debelo crevo C18 Colon Secni mehur C67 Bladder Vezivno in mehko tkivo C48–C49 Connective and soft tissue Usta Mouth C00–C09 Levkemije, drugoLeukaemias, other C92–C95 20 40 0 60 80 100 Preživetje je vec kot 50 % (61,6 % vseh ugotovljenih rakov v 2016–2020) Preživetje je 10–50 % (24,9 % vseh ugotovljenih rakov v 2016–2020) 97,1 97,6 94,0 92,3 87,6 89,1 87,3 89,3 85,0 83,0 80,2 70,6 70,8 65,6 70,6 63,7 66,5 63,6 65,1 65,8 63,4 63,3 63,0 62,1 55,0 56,6 54,9 59,0 52,8 53,7 40,0 35,9 31,1 29,1 29,3 30,2 20,4 14,5 12,1 9,8 11,1 10,5 9,3 5,6 58,0 56,6 Preživetje je manj kot 10 % (3,2 % vseh ugotovljenih rakov v 2016–2020) Žrelo Pharynx Želodec Stomach Sapnik, sapnici in pljuca Trachea, bronchus and lung Požiralnik Oesophagus Jetra in intrahepaticni vodi Liver and intrahepatic bile ducts Trebušna slinavka Pancreas Vsi raki, razen nemel. kožnega All cancer sites excl. skin C10–C14 C16 C33–C34 C15 C22 C25 C00–C96 brez C44 10 30 50 70 90% 2016–2020 2011–2015 Slika 9a. Petletno cisto preživetje (s 95-odstotnim intervalom zaupanja) pri moških, zbolelih za izbranimi raki v letih 2016–2020 in 2011–2015. Figure 9a. Five-year net survival (with 95% confidence interval) for males diagnosed with selected cancers in periods 2016–2020 and 2011–2015. Ženske Females Šcitnica C73 Thyroid gland Koža, melanom C43 Skin, melanoma Dojka C50 Breast Hodgkinov limfom C81 Hodgkin’s lymphoma Maternicno telo C54 Corpus uteri Maternicni vrat C53 Cervix uteri Limfaticna levkemija C91 Lymphocytic leukaemia Ne-Hodgkinovi limfomi C82–C85 Non-Hodgkin’s lymphoma Usta Mouth C00–C09 Debelo crevo C18 Colon Ledvica z ledvicnim mehom C64–C65 Kidney with renal pelvis Rektum in rektosigmoidna zveza C19–C20 Rectum and rectosigmoid junction Kosti C40–C41 Bone Vezivno in mehko tkivo C48–C49 Connective and soft tissue Secni mehur C67 Bladder Jajcnik C56 Ovary Žrelo C10-C14 Pharynx Levkemije, drugoLeukaemias, other C92–C95 Želodec C16 Stomach Sapnik, sapnici in pljuca C33–C34 Trachea, bronchus and lung Požiralnik C15 Oesophagus Jetra in intrahepaticni vodi C22 Liver and intrahepatic bile ducts Trebušna slinavka C25 Pancreas Vsi raki, razen kožnegaC00–C96 All cancer sites excl. skin brez C44 0 102030405060708090 100% More than 50% survival (62.6% of all cancers diagnosed in 2016–2020) 10–50% survival (21.1% of all cancers diagnosed in 2016–2020) 97,0 95,0 62,0 59,5 92,4 90,1 87,6 86,2 85,8 87,7 79,3 80,3 72,4 68,9 70,1 64,6 68,0 62,6 66,9 67,9 63,2 60,8 61,5 66,7 59,3 57,8 57,1 66,8 49,2 45,3 47,2 40,4 44,2 47,2 41,9 43,0 31,2 30,1 53,0 51,5 28,3 20,7 15,2 11,6 11,0 7,1 9,1 5,5 Less than 10% survival (3.6% of all cancers diagnosed in 2016–2020) 2016–2020 2011–2015 Slika 9b. Petletno cisto preživetje (s 95-odstotnim intervalom zaupanja) pri ženskah, zbolelih za izbranimi raki v letih 2016–2020 in 2011–2015. Figure 9b. Five-year net survival (with 95% confidence interval) for females diagnosed with selected cancers in periods 2016–2020 and 2011–2015. Primerjava z Evropo . Po ocenah Evropskega informacijskega sistema za raka (https://ecis.jrc.ec.europa.eu/) je bila Slovenija leta 2022 po incidencni stopnji (starostno standardizirani na evropsko prebivalstvo) vseh rakov razen kožnega (605/100.000) na osmem mestu med 27 evropskimi državami. Vecjo incidence so imele Danska, Irska, Nizozemska, Hrvaška, Madžarska, Belgija in Francija. . Po umrljivostni stopnji smo na petem mestu, vecjo umrljivost so imele Poljska, Madžarska, Hr- vaška in Slovaška. 422,4–483,6 483,6–544,8 544,8–606,1 606,1–667,3 667,3–728,5 Starostno standardizirana stopnja na 100.000Age standardized rate (European new) per 100.000 EU-27, vse lokacije brez nemelanomskega kožnega raka, vse starosti, oba spola 2022EU-27, all cancer sites excl. non-melanoma skin, all ages, both sexes, 2022 Ocena incidence po državahEstimated incidence by country Vir: ECIS - Evropski informacijski sistem za rakahttps://ecis.jcr.ec.europa.eu Source: ECIS - European Cancer Information System Slika 10a. Ocenjena starostno standardizirana (evropski standard) incidencna stopnja raka (brez nemelanomskega kožnega) v Evropi, 2022. Figure 10a. Estimated age-standardized (European standard) incidence rates of cancer (excluding non-melanoma skin) in Europe, 2022. 208,9–233,5 233,2–257,5 257,5–281,9 281,9–306,2 306,2–330,5 Starostno standardizirana stopnja na 100.000Age standardized rate (European new) per 100.000 Ocena umrljivosti po državahEstimated mortality by countryEU-27, vse lokacije brez nemelanomskega kožnega raka, vse starosti, oba spola 2022EU-27, all cancer sites excl. non-melanoma skin, all ages, both sexes, 2022 208,9–233,5 233,2–257,5 257,5–281,9 281,9–306,2 306,2–330,5 Starostno standardizirana stopnja na 100.000Age standardized rate (European new) per 100.000 Ocena umrljivosti po državahEstimated mortality by countryEU-27, vse lokacije brez nemelanomskega kožnega raka, vse starosti, oba spola 2022EU-27, all cancer sites excl. non-melanoma skin, all ages, both sexes, 2022 Vir: ECIS - Evropski informacijski sistem za rakahttps://ecis.jcr.ec.europa.eu Source: ECIS - European Cancer Information System Slika 10b. Ocenjena starostno standardizirana (evropski standard) umrljivostna stopnja raka (brez nemelanomskega kožnega) v Evropi, 2022. Figure 10b. Estimated age standardized (European standard) mortality rates of cancer (excluding non-melanoma skin) in Europe, 2022. Cancer in Slovenia For additional information on the burden of cancer in Slovenia and in the world, visit: www.slora.si/en. Figures are available on pages 15–27. Summary . Among those born in 2020, one in two men and one in three women are expected to develop cancer by the age of 75. . Every year around 16,000 Slovenians (more than 8,000 men and more than 7,000 women) are diagnosed with cancer and over 6,000 (about 3,500 men and just under 3,000 women) die of cancer. Currently, there are already over 120,000 people living in Slovenia who have at some point during their lifetime been diagnosed with cancer (prevalence). . In 2020, the first year of the Covid 19 epidemic, 11% fewer cancers were diagnosed than expected. The greatest shortage of diagnoses occurred in non-melanoma skin cancer, prostate, breast and lung cancers, as well as the hematological cancers. . The risk of developing cancer increases gradually with age and is highest among the elderly population; of all cancer patients diagnosed in 2020, 65% were over 65 years old. As the Slovenian population is ageing, the number of new cancer cases is expected to increase simply on account of the growing proportion of elderly people. . In 2020, the most frequent cancers in Slovenia (skin, lung, breast, prostate, and colorectal) accounted for 58% of all diagnosed cancers. These cancers are associated with unhealthy lifestyle: smoking, excessive alcohol consumption, unhealthy diet, lack of physical activity and consequential overweight and obesity, and excessive sun exposure – primary prevention measures shouldbe in place with the aim to reduce their burden. . Cancer screening programmes recommended by the Council of the European Union (EC) that have been introduced in Slovenia have already lowered mortality from breast, colorectal and cervical cancer through early detection; cancer incidence for colorectal and cervical cancers has also been reduced. . The five-year net survival of adult Slovenian patients with any type of cancer (excluding non-melanoma skin cancer) who were diagnosed in the 2016–2020 period was 58% in men and 62% in women. Basic figures on cancer in Slovenia 2020 . In 2020, 15,096 people (8,062 men and 7,034 women) were diagnosed with cancer in Slovenia. . The age-standardized incidence rate (European standard population) was 465.5/100,000; 531.9 in men and 420.3 in women. Among those born in 2020, one in two men and one in three women are expected to develop cancer by the age of 75. . In 2020, 6,423 Slovenians died of cancer, 3,602 men and 2,821 women. There were 124,830 people alive in Slovenia (57,593 men and 67,237 women) who had at some point during their lifetime been diagnosed with cancer (prevalence). . There are no significant differences in the burden of cancer between regions of Slovenia. Age of patients . Although the risk of cancer increases gradually with age, it is by far highest in older age; of all cancer patients in 2020, as many as 67% men and 62% women were diagnosed with cancer after the age of 65. Less than half a percent of all cancers were diagnosed in children and adolescents (up to 20 years of age). . As the Slovenian population is ageing, the number of new cancer cases is expected to increase simply on account of the growing proportion of elderly people. We estimate that in 2023, there will have been as many as 17,046 newly diagnosed cancer patients. Time trends . In general, the crude incidence and mortality rates of cancer are increasing. However, in 2020, the first year of the Covid 19 epidemic, we recorded an 11% decrease in the number of new cancer cases. . The crude incidence rate has almost doubled in the last twenty years, increasing by an average of 1.6% per year over the last decade (by 1.0% in men and 2.4% in women). The crude mortality ratehas increased on average by 0.8% per year in men over the last 10 years and by 1.2% in women. . More than half of this increase can be attributed to an ageing population, as longer life expectancy means more people are likely to be diagnosed with cancer. The age-standardized, cumulative incidence rate shows that the risk of cancer adjusted for ageing has been increasing more slowly, with the trend reversed for men. It is also encouraging that cancer mortality (if we adjust for ageing) has been declining, especially since the mid-1990s, pointing to greater successes of cancer treatment. Most frequent cancers . Cancer is not a single disease, but rather several hundred different diseases. These can occur in all tissues and organs of the human body. They vary in frequency, treatment and outcome, and are also associated with different, more or less established risk factors. . The five most frequent cancers in Slovenia – skin (excluding melanoma), lung, breast, prostate and colorectal – account for 58% of all new cancer cases. . The most frequent cancers are associated with an unhealthy lifestyle, excessive sun exposure, unhealthy diet, smoking and excessive alcohol consumption. Primary prevention measures should be in place with the aim to reduce their burden. . In men, prostate cancer and non-melanoma skin cancer account for around one-fifth of all cancers each, followed by lung and colorectal cancer. In women, non-melanoma skin cancer is the most frequent cancer, followed by breast cancer, which accounts for one-fifth of all cancer cases. The next most frequent cancers in women are colorectal and lung cancer. . The most frequent cancers differ according to age. In children and adolescents aged under 20 years leukaemias are the most frequent, followed by tumours of the central and autonomic nervous system and lymphomas. Young adult men are most often diagnosed with testicular cancer and skin cancer, while in young women breast cancer is ranked first. Time trends for most frequent cancers . In 2020, the first year of the Covid 19 epidemic, the greatest shortage of diagnoses occurred innon-melanoma skin cancer, prostate, breast and lung cancers, as well as the heamatological cancers. . Among the more frequent cancers in men, the incidence rate of lung cancer was increasing until the early 2000s, when it stabilized at around 90/100,000. . Lung cancer is outranked by the steep rising rates of prostate cancer (crude incidence rate changes at the rate of -0.6% per year on average) and non-melanoma skin cancer (an increase of 4.1% per year on average). The dramatic increase in the incidence of prostate cancer over the past two decades is not due to any newly identified risk factor, but rather to the increasing use of the prostate-specific antigen (PSA) test in healthy men and therefore detection of a large number of cancers that would have otherwise remained undetected for life. Data for recent years indicate that we have already reached the peak incidence of prostate cancer. . Time trends in the incidence of colorectal cancer must also be interpreted by taking into accountchanges in diagnostics – in 2009 Slovenia introduced the national screening and early detectionprogramme for colorectal cancer (Svit). The crude incidence rate of colorectal cancer in men decreased by 2.5% per year from 2011 on, but it was on the rise in 1999–2008 (3.6% on averageannually). Average annual percentage changes are shown next to the incidence curves in Figure 7. . Among the more frequent cancers in women, crude incidence rates have been increasing for breastcancer (by 2.6% on average per year), skin, excluding melanoma (by 4.5% on average per year), lung cancer (by 6.3% on average per year) and corpus uteri cancer (by 2.1% on average per year). . The incidence rate of cervical cancer has decreased significantly since the introduction of the national cervical cancer screening programme (ZORA) (by an average of 1.9% per year in the last ten years). . Similar to men, the introduction of the Svit screening programme in 2009 has had an impact on the time trend of colorectal cancer in women – the crude incidence rate of colorectal cancer in women decreased by 1.6% per year from 2011 on, but it was on the rise in the 1999–2008 period (3.4% on average annually). Rare cancers . A particular challenge is posed by rare cancers (defined as those with less than six new cases per 100,000 per year). . In total, rare cancers in Slovenia accounted for about a fifth of all newly diagnosed cancers – around 3,000 patients were diagnosed with rare cancers every year. . As opposed to frequent cancers, rare cancers are more likely to occur in children and adolescents. . Problems with rare cancers are similar to those characteristic of all rare diseases: they are difficult to diagnose and are often detected late, their aetiology and treatment options are poorly researched, or else the most appropriate treatment is hard to access. In order to successfully manage rare cancers, it is important that their burden is closely monitored, and that all countries adopt guidelines as well as establish reference centres for diagnostics and treatment of such patients. Survival . The five-year net survival of male patients with any type of cancer excluding non-melanoma skin cancer diagnosed between 2015 and 2020 was 58.0%, while in women it was 62.0%. . The five-year net survival was over 80% in men with testicular cancer, prostate cancer, thyroid cancer, skin melanoma and Hodgkin’s lymphoma, and in women with thyroid cancer, skin melanoma, breast cancer and Hodgkin's lymphoma. . In 2020, a survival analysis of Slovenian cancer patients diagnosed between 1997 and 2016 was performed. The results of the analysis are published in the publication Survival of Cancer Pa tients, Diagnosed in 1997–2016 in Slovenia (Zadnik et al., 2021) which is also available in digital format at www.onko-i.si/eng/crs. The main conclusions are on the next page. 1. Survival of Slovenian cancer patients is improving over time. During the 20 years observed (1997–2001 and 2012–2016), five-year net survival increased by 11 percentage points. The increase was significantly higher in men, for whom five-year net survival increased by 17 percentage points (from 38% to 55%). In women, five-year net survival increased by 6 percentage points (from 54% to 60%). 2. Age and stage at diagnosis are still key factors when it comes to survival of cancer patients. Five-year net survival is lowest in those aged 75–94, though even in this age group it has improved by 7 percentage points over the past 20 years. Five-year net survival of patients with localized disease increased by 10 percentage points over the observed 20 years and has reached 85% during the last period; survival of patients with distant disease has not improved. 3. For both sexes combined, survival has improved significantly over the last 20 years for the three most frequent cancers: colorectal cancer (by 14 percentage points, from 48% to 62%), skin melanoma (by 12 percentage points, from 79% to 91%), and lung cancer (by 8 percentage points, from 10% to 18%). This improvement is due to earlier diagnosis and advances in systemic treatment. 4. Progress has also been shown in the two most frequent cancers by sex: breast cancer in women and prostate cancer in men. The five-year net survival of breast cancer patients has increased for 10 percentage points in the last 20 years, while the five-year net survival of prostate cancer patients has increased for over 20 percentage points. The improvement in prostate cancer survival is probably not real, since in the period under review, PSA testing in Slovenia was performed rather uncritically and likely resulted in detection of prostate cancers that would have otherwise remained clinically silent for a long time, thus artificially prolonging survival on account of earlier diagnosis in the natural course of disease. 5. The group of cancers where no progress has been observed over time and where survival still remains low includes pancreatic cancer, oesophageal cancer, liver, gallbladder and bile duct cancers as well as brain tumours. 6. In the CONCORD-3 study, five-year net survival of adult patients with 15 different cancers diagnosed between 2010 and 2014 was compared among 26 European countries. In most cases survival rates of Slovenian cancer patients are below the European average, which highlights the need and serves as an incentive for future improvements. 7. Less than 1% of cancer patients are children and adolescents; they are mainly diagnosed with leukaemias, central nervous system tumours and lymphomas, and have a better five- year survival compared to adults. In the last 20 years (1997–2001 and 2012–2016), the five- year survival of children and adolescents with cancer has increased by 7 percentage points (from 79% to 86%). Comparisons with Europe . In 2022, according to the estimates of the European Cancer Information System (https://ecis. jrc.ec.europa.eu/) Slovenia ranked eighth among 27 European countries with respect to the incidence rate (age standardized, European population standard) of all cancers excluding skin cancer (605/100,000). Denmark, Ireland, the Netherlands, Croatia, Hungary, Belgium and France had a higher incidence. . We are in fifth place in terms of mortality, led by Poland, Hungary, Croatia and Slovakia. Incidenca Incidence Tabela 1: Opazovana in ocenjena incidenca raka po spolu, Slovenija 2011-2020 in 2023. Table 1: Observed and estimated cancer incidence by sex, Slovenia 2011-2020 and 2023. Šifra Primarna Spol Povprecne letne opazovane vrednosti 2011-2015 Povprecne letne opazovane vrednosti 2016-2020 Ocena za 2023 MKB lokacija Število Incidencna stopnja na 100.000 Število Incidencna stopnja na 100.000 Število s 95 % napovednim intervalom Incidencna stopnja na 100.000 s 95 % napovednim intervalom ICD Primary Sex Average annual observed values 2011-2015 Average annual observed values 2016-2020 Estimation for 2023 code site Number Incidence rate per 100,000 Number Incidence rate per 100,000 Number with 95% prediction interval Incidence rate per 100,000 with 95% prediction interval C00- C96 Vse lokacije All sites M+Ž M Ž 14209 7807 6402 690,2 765,8 616,0 15746 8400 7346 757,8 810,9 705,0 17046 16698-17393 8899 8652-9146 8147 7903-8392 805 789-822 837 814-860 773 750-796 C00- Usta in žrelo M 273 26,8 259 25,0 251 210-292 24 20-27 C14 Mouth and pharynx Ž 73 7,0 80 7,7 82 58-107 8 6-10 C15 Požiralnik Oesophagus M Ž 76 16 7,5 1,5 74 19 7,1 1,8 85 60-110 22 11-34 8 6-10 2 1-3 C16 Želodec Stomach M Ž 300 176 29,4 17,0 271 169 26,2 16,2 251 210-292 151 119-182 24 20-27 14 11-17 C18 Debelo crevo Colon M Ž 499 380 48,9 36,6 488 372 47,1 35,7 469 429-508 353 305-402 44 40-48 34 29-38 C19 Rektum in rektosigmoidna zveza M 383 37,6 326 31,5 259 219-300 24 21-28 -C20 Rectum and rectosigmoid junction Ž 215 20,7 189 18,1 159 124-194 15 12-18 C22 Jetra in intrahepaticni vodi Liver and intrahepatic bile ducts M Ž 154 51 15,1 4,9 174 71 16,8 6,8 200 162-239 91 67-115 19 15-22 9 6-11 C23 Žolcnik in žolcevodi M 78 7,7 100 9,6 122 91-152 11 9-14 -C24 Gallbladder and billiary tract Ž 106 10,2 99 9,5 92 67-117 9 6-11 C25 Trebušna slinavka Pancreas M Ž 193 182 18,9 17,5 218 205 21,1 19,7 248 205-290 224 185-264 23 19-27 21 18-25 C32 Grlo Larynx M Ž 88 12 8,7 1,2 92 13 8,8 1,3 88 63-112 12 3-21 8 6-11 1 0-2 C33 Sapnik, sapnici in pljuca M 897 88,0 968 93,5 1039 952-1127 98 89-106 -C34 Trachea, bronchus and lung Ž 424 40,8 595 57,1 752 683-821 71 65-78 C43 Maligni melanom kože Malignant melanoma of skin M Ž 280 250 27,5 24,1 316 294 30,5 28,3 355 304-406 327 281-373 33 29-38 31 27-35 C44 Druge maligne neoplazme kože Skin, excl. melanoma M Ž 1321 1281 129,6 123,3 1662 1664 160,4 159,7 1998 1879-2116 1957 1824-2090 188 177-199 186 173-198 C48 Vezivno in mehko tkivo M 31 3,1 38 3,6 48 28-67 4 3-6 -C49 Connective and soft tissue Ž 43 4,2 41 4,0 39 23-55 4 2-5 C50 Dojka Breast M Ž 13 1292 1,3 124,4 12 1481 1,2 142,2 12 3-21 1649 1543-1754 1 0-2 156 146-166 C53 Maternicni vrat Cervix uteri M Ž - 124 - 11,9 - 111 - 10,6 - - 99 74-123 - - 9 7-12 C54 Maternicno telo Corpus uteri M Ž - 333 - 32,0 - 367 - 35,2 - - 403 351-456 - - 38 33-43 C56 Jajcnik Ovary M Ž - 161 - 15,5 - 151 - 14,5 - - 150 118-181 - - 14 11-17 C61 Prostata Prostate M Ž 1620 - 158,9 - 1648 - 159,2 - 1578 1475-1682 - - 148 139-158 - - C62 Modo Testis M Ž 113 - 11,1 - 109 - 10,6 - 117 87-147 - - 11 8-14 - - C64 Ledvica z ledvicnim mehom M 251 24,6 284 27,5 310 263-357 29 25-34 -C65 Kidney with renal pelvis Ž 134 12,9 138 13,2 140 108-172 13 10-16 C67 Secni mehur Bladder M Ž 250 86 24,5 8,3 259 103 25,0 9,9 266 221-311 115 86-143 25 21-29 11 8-14 C70 Centralni in avtonomni živcni sistem M 87 8,6 103 10,0 122 91-152 11 9-14 -C72 Central and autonomic nervous system Ž 69 6,6 73 7,0 84 60-107 8 6-10 C73 Šcitnica Thyroid gland M Ž 46 126 4,5 12,1 49 150 4,8 14,4 57 37-76 175 141-209 5 4-7 17 13-20 C81 Hodgkinov limfom Hodgkin’s lymphoma M Ž 21 24 2,1 2,3 28 28 2,7 2,6 37 20-54 30 16-45 3 2-5 3 2-4 C82 Ne-Hodgkinovi limfomi M 201 19,8 231 22,3 266 219-313 25 21-29 -C85 Non-Hodgkin’s lymphoma Ž 200 19,2 223 21,4 253 212-295 24 20-28 C90 Difuzni plazmocitom in maligne neoplazme plazmatk Multiple myeloma and malignant plasma cell neoplasms M Ž 69 71 6,7 6,8 86 70 8,3 6,7 93 67-119 76 53-98 9 6-11 7 5-9 C91 Levkemije M 190 18,7 211 20,3 234 201-266 22 19-25 -C95 Leukaemias Ž 139 13,3 163 15,7 186 149-224 18 14-21 Tabela 2: Incidenca, groba incidencna stopnja in po svetovni, evropski ter slovenski standardni populaciji standardizirane incidencne stopnje raka po spolu, Slovenija 2020. Table 2: Incidence, crude incidence rate and according to World, European and Slovenian standard population standardized cancer incidence rates by sex, Slovenia 2020. Šifra MKB ICD code Primarna lokacija Primary site Spol Sex Število Number Groba incidencna stopnja na 100.000 Crude incidence rate per 100,000 SSS* - svetovni standard ASR* - World standard SSS* - evropski standard ASR* - European standard SSS* - slovenski standard ASR* - Slovenian standard C00-C96 Vse lokacije All sites M+Ž M Ž 15096 8062 7034 718,8 764,5 672,7 327,0 363,5 302,6 465,5 531,9 420,3 554,0 646,4 490,1 C00-C14 Usta in žrelo Mouth and pharynx M Ž 252 74 23,9 7,1 12,8 3,5 17,9 4,9 20,0 5,4 C15 Požiralnik Oesophagus M Ž 81 13 7,7 1,2 3,7 0,4 5,3 0,7 6,4 0,8 C16 Želodec Stomach M Ž 279 145 26,5 13,9 11,3 5,1 17,5 7,5 21,9 9,2 C18 Debelo crevo Colon M Ž 482 343 45,7 32,8 20,9 13,2 31,3 18,8 38,1 22,3 C19-C20 Rektum in rektosigmoidna zveza Rectum and rectosigmoid junction M Ž 300 179 28,4 17,1 13,8 7,0 20,1 10,1 23,8 11,8 C22 Jetra in intrahepaticni vodi Liver and intrahepatic bile ducts M Ž 169 65 16,0 6,2 7,3 2,0 10,9 3,0 13,4 3,9 C23-C24 Žolcnik in žolcevodi Gallbladder and billiary tract M Ž 108 90 10,2 8,6 4,5 2,5 6,8 4,0 8,6 5,1 C25 Trebušna slinavka Pancreas M Ž 210 210 19,9 20,1 8,9 6,7 13,5 10,3 16,7 12,7 C32 Grlo Larynx M Ž 81 10 7,7 1,0 3,9 0,5 5,5 0,7 6,4 0,7 C33-C34 Sapnik, sapnici in pljuca Trachea, bronchus and lung M Ž 935 619 88,7 59,2 41,0 24,7 60,4 35,5 73,7 42,3 C43 Maligni melanom kože Malignant melanoma of skin M Ž 330 309 31,3 29,6 16,7 16,0 23,4 21,2 27,4 24,3 C44 Druge maligne neoplazme kože Skin, excl. melanoma M Ž 1571 1439 149,0 137,6 64,4 52,9 99,6 77,4 125,2 93,4 C48-C49 Vezivno in mehko tkivo Connective and soft tissue M Ž 44 43 4,2 4,1 2,4 2,4 3,1 3,0 3,6 3,3 C50 Dojka Breast M Ž 11 1448 1,0 138,5 0,4 72,8 0,7 98,3 1,0 111,1 C53 Maternicni vrat Cervix uteri M Ž - 133 - 12,7 - 8,2 - 10,4 - 11,5 C54 Maternicno telo Corpus uteri M Ž - 373 - 35,7 - 16,7 - 23,5 - 26,6 C56 Jajcnik Ovary M Ž - 151 - 14,4 - 7,5 - 9,9 - 11,3 C61 Prostata Prostate M Ž 1460 - 138,5 - 62,2 - 93,4 - 116,0 - C62 Modo Testis M Ž 112 - 10,6 - 9,7 - 10,6 - 11,4 - C64-C65 Ledvica z ledvicnim mehom Kidney with renal pelvis M Ž 279 137 26,5 13,1 13,2 5,0 18,8 7,4 22,1 8,9 C67 Secni mehur Bladder M Ž 271 116 25,7 11,1 10,9 3,2 16,9 5,1 21,4 6,5 C70-C72 Centralni in avtonomni živcni sistem Central and autonomic nervous system M Ž 105 79 10,0 7,6 6,6 5,2 8,1 5,7 9,0 5,9 C73 Šcitnica Thyroid gland M Ž 52 123 4,9 11,8 3,3 7,9 4,1 9,6 4,6 10,7 C81 Hodgkinov limfom Hodgkin’s lymphoma M Ž 21 26 2,0 2,5 1,9 2,6 2,0 2,6 2,2 2,8 C82-C85 Ne-Hodgkinovi limfomi Non-Hodgkin’s lymphoma Difuzni plazmocitom in maligne M Ž 234 226 22,2 21,6 11,6 9,7 16,2 13,4 19,4 15,7 C90 neoplazme plazmatk Multiple myeloma and malignant plasma cell neoplasms M Ž 77 78 7,3 7,5 3,4 2,9 5,1 4,3 6,0 5,2 C91-C95 Levkemije Leukaemias M Ž 219 147 20,8 14,1 12,0 7,2 15,5 9,1 17,9 10,4 * SSS - starostno standardizirana incidencna stopnja na 100.000 ASR - age standardized incidence rate per 100,000 Tabela 3: Incidenca raka po starosti in spolu ter groba stopnja (GS) na 100.000 prebivalcev in kumulativna stopnja (KS), Slovenija 2020. Table 3: Cancer incidence by age and by sex with crude rate (GS) per 100,000 population and cumulative rate (KS), Slovenia 2020. Šifra MKB Primarna lokacija Spol Vse starosti Starost / Age GS KS 0-74 ICD code Primary site Sex All ages 0- 5- 10- 15- 20- 25- 30- 35- 40- 45- 50- 55- 60- 65- 70- 75- 80- 85+ C00 - C96 Vse lokacije All sites M+Ž M Ž 15096 8062 7034 24 14 10 18 8 10 14 6 8 25 12 13 34 20 14 67 30 37 131 61 70 248 89 159 394 144 250 564 224 340 884 401 483 1247 645 602 1686 976 710 2357 1417 940 2216 1348 868 2061 1199 862 1683 913 770 1443 555 888 718,8 764,5 672,7 37,8 42,8 33,6 C00 Ustnica Lip M Ž 16 11 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 1 0 0 0 0 0 0 4 2 2 1 3 2 4 3 2 2 1,5 1,1 0,1 0,0 C01 Baza jezika Base of tongue M Ž 21 4 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 2 1 0 2 0 4 0 4 0 5 1 1 1 2 0 0 0 1 0 2,0 0,4 0,1 0,0 C02 Jezik, drugi deli Tongue, other & unspecified parts M Ž 27 7 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 2 0 7 1 5 2 4 0 1 1 4 1 1 1 1 0 1 1 2,6 0,7 0,2 0,0 C03 Dlesen Gum M Ž 7 3 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 1 1 0 0 0 0 2 1 0 0 1 0 2 1 0 0 0,7 0,3 0,0 0,0 C04 Ustno dno Floor of mouth M Ž 18 6 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 1 1 2 2 3 0 4 2 1 0 2 1 2 0 1 0 1 0 1,7 0,6 0,1 0,0 C05 Nebo Palate M Ž 9 7 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 1 0 3 2 2 1 1 0 1 1 0 1 0 1 0 1 0,9 0,7 0,1 0,0 C06 Usta, drugi deli Mouth, other & unspecified parts M Ž 7 6 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 1 0 2 3 1 0 0 0 1 0 1 0 0 2 1 0 0,7 0,6 0,0 0,0 C07 Parotidna žleza Parotid gland M Ž 8 6 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 1 1 1 1 1 1 2 1 1 1 1 0 1 0 0 0 0 0 0,8 0,6 0,1 0,0 Druge in neopredeljene velike C08 žleze slinavke Other & unspecified major salivary M Ž 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 1 0 0 0 0 0 0 0 0 0 0 0,1 0,1 0,0 0,0 glands C09 Tonzila Tonsil M Ž 33 14 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 1 4 0 5 2 5 3 6 2 8 2 0 2 2 1 2 0 0 1 3,1 1,3 0,2 0,1 C10 Orofarinks Oropharynx M Ž 31 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 7 0 5 0 7 1 6 0 4 0 1 0 1 0 0 0 2,9 0,1 0,2 0,0 C11 Nazofarinks Nasopharynx M Ž 5 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 1 0 0 3 0 1 0 0 0 0 0 0 0 0 0 0 0 0,5 0,1 0,0 0,0 C12 Piriformni sinus Pyriform sinus M Ž 39 3 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 1 0 0 0 4 0 9 2 10 0 8 0 4 1 2 0 0 0 0 0 3,7 0,3 0,3 0,0 C13 Hipofarinks Hypopharynx M Ž 28 4 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 1 4 2 6 1 10 0 5 0 1 0 1 0 0 0 2,7 0,4 0,2 0,0 Druga in slabo opredeljena mesta na ustnici, v ustni votlini C14 in farinksu Other and ill-defined sites M Ž 2 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 1 0 0 0 0 0 0 0 0,2 0,0 0,0 0,0 in the lip, oral cavity and pharynx C15 Požiralnik Oesophagus M Ž 81 13 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 3 0 5 1 6 2 18 0 13 2 10 2 12 1 6 3 7 2 7,7 1,2 0,4 0,1 C16 Želodec Stomach M Ž 279 145 0 0 0 0 0 0 0 0 0 0 0 1 0 0 4 2 1 2 7 6 10 6 17 7 33 13 41 18 39 20 49 23 53 19 25 28 26,5 13,9 1,2 0,6 C17 Tanko crevo Small intestine M Ž 28 22 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 1 2 0 0 1 3 7 2 1 9 2 4 2 2 3 3 2 3 2 2,7 2,1 0,2 0,1 C18 Debelo crevo Colon M Ž 482 343 0 0 0 2 1 1 1 0 0 1 2 2 2 2 3 4 7 5 16 13 28 23 40 22 48 26 74 39 78 53 60 40 78 55 44 55 45,7 32,8 2,4 1,5 C19 Rektosigmoidna zveza Rectosigmoid junction M Ž 64 35 0 0 0 0 0 0 0 0 0 0 0 0 1 0 2 2 3 1 1 1 4 3 4 1 11 2 11 8 4 4 7 3 11 5 5 5 6,1 3,3 0,3 0,2 C20 Rektum Rectum M Ž 236 144 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 4 10 4 8 4 25 13 18 12 35 13 39 23 30 15 29 14 28 18 13 24 22,4 13,8 1,3 0,6 C21 Anus in analni kanal Anus and anal canal M Ž 10 14 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 1 0 0 0 6 2 1 2 1 3 1 1 1 1 0 0 3 0,9 1,3 0,1 0,1 C22 Jetra in intrahepaticni vodi Liver and intrahepatic bile ducts M Ž 169 65 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 2 1 1 2 18 3 23 3 44 9 38 13 27 10 12 18 3 6 16,0 6,2 1,0 0,2 C23 Žolcnik Gallbladder M Ž 24 33 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 1 0 1 0 2 1 0 2 4 4 2 6 4 7 5 6 4 7 2,3 3,2 0,1 0,1 Drugi in neopredeljeni deli C24 biliarnega trakta Billiary tract, other and unspec- M Ž 84 57 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 5 0 2 1 3 1 12 3 14 12 16 10 14 6 7 10 11 14 8,0 5,5 0,4 0,2 ified parts C25 Trebušna slinavka Pancreas M Ž 210 210 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 2 4 2 5 2 10 8 18 13 24 16 31 26 38 30 33 38 24 36 22 37 19,9 20,1 1,1 0,8 Nadaljevanje —> Continued —> Tabela 3: Nadaljevanje. Table 3: Continued. Šifra MKB Primarna lokacija Spol Vse starosti Starost / Age GS KS 0-74 ICD code Primary site Sex All ages 0- 5- 10- 15- 20- 25- 30- 35- 40- 45- 50- 55- 60- 65- 70- 75- 80- 85+ Druga in slabo opredeljena mesta C26 v prebavnih organih Other and ill-defined digestive organs M Ž 1 5 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 1 1 0 2 0 0 0 0 0 0 0 1 0,1 0,5 0,0 0,0 C30 Nosna votlina in srednje uho Nasal cavity and middle ear M Ž 8 6 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 1 1 1 1 1 1 0 2 1 0 0 2 0 0 0 0 2 0,8 0,6 0,0 0,0 C31 Obnosni sinusi Accessory sinuses M Ž 1 2 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 1 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0,1 0,2 0,0 0,0 C32 Grlo Larynx M Ž 81 10 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 3 0 7 0 9 5 15 1 23 4 12 0 5 0 5 0 1 0 7,7 1,0 0,5 0,1 C33 Sapnik Trachea M Ž 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0,1 0,1 0,0 0,0 C34 Sapnica in pljuca Bronchus and lung M Ž 934 618 0 1 0 0 0 0 0 0 0 0 0 0 0 1 0 1 6 8 14 9 31 22 83 57 145 95 230 132 179 116 130 84 75 53 41 39 88,6 59,1 5,5 3,3 C37 Timus Thymus M Ž 9 6 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 2 0 1 1 1 0 1 1 2 4 0 0 1 0 0 0 0,9 0,6 0,1 0,1 C38 Srce, mediastinum, plevra Heart, mediastinum, pleura Druga in slabo opredeljena mesta v dihalih in prsnih organih M Ž M 4 1 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 1 1 0 1 0 0 0 0 0 0,4 0,1 0,0 0,0 0,0 0,0 C39 Other and ill-defined sites in the respiratory system and intrathoracic organs Kosti, sklepni hrustanec Ž 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0,0 0,0 C40 udov Bone and articular cartilage of limbs Kosti, sklepni hrustanec, M Ž 3 6 0 0 0 0 1 1 1 0 0 2 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 1 0 1 0 1 0 0 0,3 0,6 0,0 0,0 C41 drugje Bone and articular cartilage of other and unspecified parts M Ž 3 2 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 2 0 0 1 0 0 0 1 0 0 0 0 0 0 0 0,3 0,2 0,0 0,0 C43 Maligni melanom kože Malignant melanoma of skin M Ž 330 309 0 0 0 0 0 0 2 2 1 2 3 4 7 10 7 14 16 21 20 28 31 34 39 25 32 15 35 32 52 27 39 40 30 24 16 31 31,3 29,6 1,9 1,6 C44 Druge maligne neoplazme kože Skin, excl. melanoma M Ž 1571 1439 0 0 0 0 0 0 1 1 2 1 3 4 6 8 16 27 29 31 48 49 54 78 95 92 136 133 213 152 251 205 297 218 253 185 167 255 149,0 137,6 6,9 5,9 C45 Mezoteliom Mesothelioma M Ž 25 8 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 1 7 1 3 1 3 0 6 0 3 2 0 1 2 2 2,4 0,8 0,2 0,0 C46 Kaposijev sarkom Kaposi’s sarcoma Periferni živci in avtonomno M Ž 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0,1 0,0 0,0 0,0 C47 živcevje Peripheral nerves and autonomic nervous system M Ž 2 2 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 1 0 1 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0,2 0,2 0,0 0,0 C48 Peritonej in retroperitonej Retroperitoneum and peritoneum M Ž 12 15 1 0 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 2 3 3 1 1 4 3 2 0 0 1 1 0 2 1,1 1,4 0,1 0,1 C49 Drugo vezivno in mehko tkivo Other connective and soft tissue M Ž 32 28 0 0 0 0 0 0 0 1 0 1 0 1 0 1 2 0 4 1 0 1 4 4 1 2 2 2 3 2 3 2 6 7 3 1 4 2 3,0 2,7 0,1 0,1 C50 Dojka Breast M Ž 11 1448 0 0 0 0 0 0 0 0 0 0 0 5 0 20 0 58 0 89 1 127 0 152 0 154 0 170 1 220 3 128 5 116 0 96 1 113 1,0 138,5 0,0 8,1 C51 Žensko zunanje spolovilo Vulva M Ž - 54 - 0 - 0 - 0 - 0 - 0 - 0 - 0 - 0 - 0 - 0 - 1 - 3 - 5 - 8 - 6 - 9 - 12 - 10 - 5,2 - 0,2 C52 Nožnica Vagina M Ž - 8 - 0 - 0 - 0 - 0 - 0 - 0 - 0 - 0 - 0 - 1 - 0 - 1 - 1 - 2 - 0 - 1 - 2 - 0 - 0,8 - 0,0 C53 Maternicni vrat Cervix uteri M Ž - 133 - 0 - 0 - 0 - 0 - 0 - 5 - 10 - 12 - 15 - 8 - 13 - 14 - 13 - 8 - 13 - 11 - 6 - 5 - 12,7 - 0,8 C54 Maternicno telo Corpus uteri M Ž - 373 - 0 - 0 - 0 - 0 - 0 - 0 - 1 - 4 - 11 - 13 - 36 - 56 - 56 - 59 - 47 - 32 - 31 - 27 - 35,7 - 2,1 C55 Maternica, neopredeljeno Uterus, unspecified M Ž - 15 - 0 - 0 - 0 - 0 - 0 - 0 - 0 - 0 - 0 - 1 - 2 - 1 - 1 - 3 - 2 - 3 - 1 - 1 - 1,4 - 0,1 C56 Jajcnik Ovary Drugi in neopredeljeni ženski M Ž - 151 - 0 - 1 - 1 - 1 - 0 - 0 - 2 - 7 - 8 - 14 - 11 - 14 - 14 - 17 - 17 - 13 - 15 - 16 - 14,4 - 0,8 C57 spolni organi Other and unspecified parts of female genital organs M Ž - 38 - 0 - 0 - 0 - 0 - 0 - 0 - 0 - 0 - 2 - 3 - 1 - 3 - 5 - 10 - 3 - 5 - 4 - 2 - 3,6 - 0,2 Nadaljevanje —> Continued —> 35 Tabela 3: Nadaljevanje. Table 3: Continued. Šifra MKB Primarna lokacija Spol Vse starosti Starost / Age GS KS 0-74 ICD code Primary site Sex All ages 0- 5- 10- 15- 20- 25- 30- 35- 40- 45- 50- 55- 60- 65- 70- 75- 80- 85+ C58 Posteljica Placenta M Ž - 0 - 0 - 0 - 0 - 0 - 0 - 0 - 0 - 0 - 0 - 0 - 0 - 0 - 0 - 0 - 0 - 0 - 0 - 0 - 0,0 - 0,0 C60 Penis Penis M Ž 16 - 0 - 0 - 0 - 0 - 0 - 0 - 0 - 0 - 2 - 0 - 0 - 2 - 1 - 1 - 2 - 5 - 2 - 1 - 1,5 - 0,1 - C61 Prostata Prostate M Ž 1460 - 0 - 0 - 0 - 0 - 0 - 0 - 0 - 0 - 2 - 10 - 44 - 115 - 213 - 318 - 331 - 233 - 122 - 72 - 138,5 - 8,5 - C62 Modo Testis Drugi in neopredeljeni moški M Ž 112 - 0 - 0 - 1 - 0 - 10 - 10 - 27 - 25 - 16 - 12 - 5 - 3 - 0 - 1 - 0 - 2 - 0 - 0 - 10,6 - 0,8 - C63 spolni organi Other and unspecified male genital organs M Ž 4 - 0 - 0 - 0 - 0 - 0 - 0 - 0 - 0 - 0 - 0 - 2 - 1 - 1 - 0 - 0 - 0 - 0 - 0 - 0,4 - 0,0 - C64 Ledvica razen meha Kidney, excl. renal pelvis M Ž 254 122 2 0 0 0 0 0 0 0 0 0 1 0 1 0 4 1 5 3 9 4 20 5 29 10 33 11 52 18 33 13 25 20 26 22 14 15 24,1 11,7 1,4 0,5 C65 Ledvicni meh Renal pelvis M Ž 25 15 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 1 1 1 1 0 1 0 1 3 1 4 2 5 2 3 4 7 0 1 1 2,4 1,4 0,1 0,1 C66 Secevod Ureter M Ž 14 7 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 4 0 1 0 3 0 0 2 2 1 3 2 1 0 0 2 1,3 0,7 0,1 0,0 C67 Secni mehur Bladder Drugi in neopredeljeni secni M Ž 271 116 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 2 2 3 1 13 0 7 3 32 6 46 19 49 16 49 18 46 13 23 38 25,7 11,1 1,3 0,4 C68 organi Other and unspecified urinary organs M Ž 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0,0 0,0 0,0 0,0 C69 Oko in ocesni adneksi Eye and adnexa M Ž 15 17 1 1 0 0 0 0 0 0 0 0 0 0 0 0 1 0 1 0 1 0 2 2 1 1 1 0 3 4 1 2 1 3 1 1 1 3 1,4 1,6 0,1 0,1 C70 Meninge Meninges M Ž 2 2 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 2 0 0 0 0 0 0 0 0 0 0,2 0,2 0,0 0,0 C71 Možgani Brain Hrbtni mozeg, možganski živci in M Ž 102 73 2 5 1 3 1 1 0 1 2 0 4 0 2 0 5 2 4 1 8 3 8 3 10 8 14 5 16 6 11 8 8 11 3 12 3 4 9,7 7,0 0,7 0,4 C72 drugi deli CŽS Spinal cord, cranial nerves and other parts of CNS M Ž 1 4 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 1 0 1 1 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0,1 0,4 0,0 0,0 C73 Šcitnica Thyroid gland M Ž 52 123 0 0 0 0 0 0 2 3 1 1 1 7 1 5 2 7 2 12 7 11 7 12 7 12 2 5 10 17 7 9 1 9 2 10 0 3 4,9 11,8 0,4 0,8 C74 Nadledvicna žleza Adrenal gland Druge endokrine žleze in sorodne M Ž 4 8 0 1 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 2 1 0 0 0 2 1 0 0 0 2 0 1 0 1 0 0 0 0 0,4 0,8 0,0 0,1 C75 strukture Other endocrine glands and related structures M Ž 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0,1 0,0 0,0 0,0 C76 Druga in slabo opredeljena mesta Other and ill-defined sites Metastaza in neopredeljena M Ž 1 12 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 1 1 0 0 0 1 0 2 0 1 0 6 0,1 1,1 0,0 0,0 C77 maligna neoplazma bezgavk Metastasis and unspecified malignant neoplasm of lymph nodes Metastaze dihal in M Ž 24 14 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 2 0 2 1 1 0 2 3 4 1 2 2 2 2 6 0 2 5 2,3 1,3 0,1 0,1 C78 prebavil Metastases of respiratory and digestive organs M Ž 22 37 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 2 0 0 0 1 1 3 2 2 2 1 3 4 2 1 3 8 9 15 2,1 3,5 0,1 0,1 C79 Metastaze, drugje Metastases of other sites Maligna neoplazma brez M Ž 13 10 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 1 1 1 0 2 1 5 0 1 3 2 5 1,2 1,0 0,0 0,0 C80 opredeljenega mesta Malignant neoplasm without specification of site M Ž 59 56 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 3 1 2 3 0 2 2 7 9 14 6 9 8 7 3 8 7 8 16 5,6 5,4 0,3 0,2 C81 Hodgkinov limfom Hodgkin’s lymphoma Folikularni ne-Hodgkinov M Ž 21 26 0 0 0 0 0 0 1 3 2 2 3 5 3 3 2 1 1 3 3 0 2 1 2 1 0 1 0 1 1 2 1 1 0 0 0 2 2,0 2,5 0,1 0,2 C82 limfom Follicular non-Hodgkin’s lymphoma M Ž 58 77 0 0 1 0 1 0 0 0 0 0 1 0 0 1 1 2 0 1 0 6 9 9 7 10 5 14 10 8 11 8 7 8 3 5 2 5 5,5 7,4 0,4 0,4 C83 Difuzni ne-Hodgkinov limfom Diffuse non-Hodgkin’s lymphoma M Ž 142 126 0 0 0 0 0 1 3 1 1 1 0 1 1 3 4 2 1 3 6 5 8 4 11 5 17 16 22 9 24 15 26 19 11 21 7 20 13,5 12,1 0,8 0,5 Nadaljevanje —> Continued —> Tabela 3: Nadaljevanje. Table 3: Continued. Šifra MKB Primarna lokacija Spol Vse starosti Starost / Age GS KS 0-74 ICD code Primary site Sex All ages 0- 5- 10- 15- 20- 25- 30- 35- 40- 45- 50- 55- 60- 65- 70- 75- 80- 85+ Limfomi celic T in kožni limfom C84 celic T Peripheral and cutaneous T-cell lymphomas Druge in neopredeljene vrste M Ž 22 13 0 0 0 0 0 0 0 0 0 0 0 0 1 1 0 0 2 1 1 0 1 1 1 0 2 0 7 2 5 1 2 7 0 0 0 0 2,1 1,2 0,2 0,0 C85 ne-Hodgkinovega limfoma Other and unspecified types of non-Hodgkin’s lymphoma Maligne imunoproliferativne M Ž 12 10 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 1 0 0 1 1 2 2 0 1 2 3 1 2 0 1 4 1,1 1,0 0,0 0,0 C88 bolezni Malignant immunoproliferative diseases Difuzni plazmocitom in maligne M Ž 4 2 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 2 0 1 0 1 1 0,4 0,2 0,0 0,0 C90 neoplazme plazmatk Multiple myeloma and malignant plasma cell neoplasms M Ž 77 78 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 1 1 2 3 5 7 12 4 10 10 15 10 7 7 11 15 9 8 5 12 7,3 7,5 0,4 0,3 C91.0 Limfoblastna levkemija Lymphoblastic leukaemia, acute M Ž 18 17 6 2 5 3 0 2 0 0 0 0 0 1 2 0 3 1 1 1 0 2 0 0 0 1 1 1 0 1 0 2 0 0 0 0 0 0 1,7 1,6 0,1 0,1 C91.1- Limfaticna levkemija, druga M 99 0 0 0 0 0 0 2 1 1 4 7 8 8 16 12 14 17 9 9,4 0,5 C91.9 Lymphoid leukaemia, other Ž 61 0 0 0 0 0 0 0 1 1 7 4 3 4 2 10 10 12 7 5,8 0,2 C92 Mieloicna levkemija Myeloid leukaemia M Ž 67 47 1 0 0 0 0 1 1 0 1 0 0 0 1 0 3 1 4 1 3 1 2 4 3 3 7 4 6 5 11 4 8 7 9 9 7 7 6,4 4,5 0,3 0,2 C93 Monocitna levkemija Monocytic leukaemia Druge opredeljene M Ž 4 4 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 1 3 3 0 0 0 0,4 0,4 0,0 0,0 C94 levkemije Other leukaemias of specified cells Levkemija z neopredeljenim M Ž 27 18 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 2 2 1 2 1 1 0 2 3 2 5 4 6 0 7 2 1 2 0 1 2,6 1,7 0,2 0,1 C95 celicnim tipom Leukaemia, unspecified cell type Druge in neopredeljene maligne neoplazme limfaticnega, krvot- M Ž 4 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 1 0 2 0 0,4 0,0 0,0 0,0 C96 vornega ali sorodnega tkiva Other and unspecified malignant neoplasms of lymphoid, haematopoietic and related tissue M Ž 107 106 0 0 0 0 0 0 0 0 0 2 0 0 0 0 0 1 2 1 1 1 4 2 4 7 9 8 18 11 13 10 28 19 18 24 10 20 10,1 10,1 0,4 0,3 Zgoraj nevkljuceni: Not included above: D03 Melanom, in situ Melanoma, in situ M Ž 182 153 0 0 0 0 0 0 0 2 1 4 2 2 5 5 7 11 6 11 6 15 18 15 11 16 14 13 27 12 32 13 31 19 10 9 12 6 17,3 14,6 1,0 0,9 D05 Dojka, in situ Breast, in situ M Ž 3 189 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 1 9 0 20 0 52 1 21 0 38 0 37 1 4 0 6 0 1 0 0 0,3 18,1 0,0 1,3 D06 Maternicni vrat, in situ (CIN III) Cervix uteri, in situ M Ž - 977 - 0 - 0 - 0 - 0 - 81 - 188 - 159 - 155 - 132 - 94 - 54 - 48 - 32 - 14 - 12 - 5 - 2 - 1 - 93,4 - 7,6 D09.0 Secni mehur, in situ Bladder, in situ Meninge, benigna neoplazma in neoplazma M Ž 196 74 0 0 0 0 0 0 0 0 0 0 0 0 1 0 1 1 3 1 4 1 8 6 13 5 24 13 48 9 41 14 23 13 15 7 15 4 18,6 7,1 1,2 0,4 D32.0, negotovega znacaja M 55 0 0 1 0 0 0 0 2 0 3 2 6 6 13 7 6 4 5 5,2 0,3 D42.0 Benign neoplasm and neoplasm of uncertain behaviour of meninges Ž 111 0 0 0 0 0 1 1 3 6 7 9 8 21 10 17 8 17 3 10,6 0,6 D33.0- Možgani, benigna neoplazma M 8 2 2 1 1 0 0 0 0 0 0 1 0 0 0 1 0 0 0 0,8 0,1 D33.2 Benign neoplasm of brain Jajcnik, neoplazma Ž 3 0 0 0 0 0 1 0 0 1 0 0 0 0 0 1 0 0 0 0,3 0,0 D39.1 negotovega znacaja Ovary, neoplasm of uncertain behavior M Ž - 63 - 0 - 0 - 0 - 1 - 2 - 6 - 7 - 4 - 2 - 6 - 6 - 7 - 12 - 4 - 3 - 3 - 0 - 0 - 6,0 - 0,5 D43.0- D43.2 Možgani, neopredeljeno Central nervous system (CNS), uncertain or unknown M Ž 8 4 0 0 0 0 1 0 1 0 0 0 0 0 0 1 1 0 0 2 1 0 2 1 1 0 0 0 0 0 0 0 1 0 0 0 0 0 0,8 0,4 0,1 0,0 Tabela 4a: Incidenca mikroskopsko (histološko ali citološko) potrjenih primerov raka po morfološki vrsti, Slovenija 2020. Table 4a: Incidence of microscopicaly (histologically or cytologically) confirmed cancer cases by morphological type, Slovenia 2020. Histološka vrsta Skupaj Primarna lokacija (šifra MKB) Histologic type All Sites Primary site (ICD code) C00-C80 C00 C01 C02 C03 C04 C05 C06 C07 C08 C09 C10 C11 C12 C13 C14 C15 C16 C17 C18 Vse vrste / All types 12977 27 24 34 10 24 16 13 14 2 47 32 6 42 32 2 91 416 47 795 Small cell carcinoma 215 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 1 0 0 Non-small cell carcinoma 66 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Squamous cell carcinoma 1567 27 24 34 10 24 12 6 1 0 47 32 5 41 30 2 62 2 0 1 Basal cell carcinoma 2380 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Transitional cell carcinoma 425 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Adenocarcinoma 6792 0 0 0 0 0 2 6 6 1 0 0 1 0 0 0 26 371 28 789 Other specified carcinomas 153 0 0 0 0 0 2 0 6 0 0 0 0 1 1 0 1 2 1 1 Carcinoma, unspecified 121 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 4 2 3 Malignant thymoma 13 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Malignant paraganglioma/pheochromocytoma 8 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Malignant melanoma 690 0 0 0 0 0 0 1 0 0 0 0 0 0 1 0 0 0 0 0 Fibrosarcoma 13 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Fibrohistiocytic sarcoma 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Liposarcoma 24 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Leiomyosarcoma 22 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Rhabdomyosarcoma 2 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Synovial sarcoma 5 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Angiosarcoma 5 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Kaposi sarcoma 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Osteosarcoma 7 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Chondrosarcoma 3 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Ewing sarcoma/PNET 3 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Other specified sarcomas 3 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Sarcoma, unspecified 29 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 Malignant complex mixed and stromal tumors 95 0 0 0 0 0 0 0 1 1 0 0 0 0 0 0 1 36 15 1 Malignant fibroepithelial tumors 5 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Malignant mesothelioma 33 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Malignant gonadal stromal tumors 6 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Dysgerminoma and seminoma 81 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Other malignant germ cell tumors 36 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Malignant trophoblastic tumors 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Malignant gliomas 154 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Malignant neuroepithelial tumors 6 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Malignant meningioma 2 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Malignant nerve sheath tumors 2 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Other specified malignant tumors 2 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Malignant tumor, unspecified 7 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Nadaljevanje —> Continued —> Tabela 4a: Nadaljevanje. Table 4a: Continued. Histološka vrsta Skupaj Primarna lokacija (šifra MKB) Histologic type All Sites Primary site (ICD code) C00-C80 C19 C20 C21 C22 C23 C24 C25 C26 C30 C31 C32 C33 C34 C37 C38 C39 C40 C41 C43 Vse vrste / All types 12977 93 371 23 135 37 84 280 4 13 3 90 2 1363 15 2 0 9 5 639 Small cell carcinoma 215 0 1 0 0 0 0 0 0 1 0 0 0 198 0 0 0 0 0 0 Non-small cell carcinoma 66 0 0 0 0 0 0 0 0 0 0 0 0 66 0 0 0 0 0 0 Squamous cell carcinoma 1567 0 3 13 0 1 0 0 0 5 1 90 1 310 2 0 0 0 0 0 Basal cell carcinoma 2380 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Transitional cell carcinoma 425 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Adenocarcinoma 6792 93 362 8 130 33 77 256 3 5 1 0 1 728 0 0 0 0 0 0 Other specified carcinomas 153 0 1 1 0 2 2 4 0 1 1 0 0 43 0 0 0 0 0 0 Carcinoma, unspecified 121 0 0 0 1 1 5 20 1 0 0 0 0 14 0 0 0 0 0 0 Malignant thymoma 13 0 0 0 0 0 0 0 0 0 0 0 0 0 13 0 0 0 0 0 Malignant paraganglioma/pheochromocytoma 8 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Malignant melanoma 690 0 1 1 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 639 Fibrosarcoma 13 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Fibrohistiocytic sarcoma 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Liposarcoma 24 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Leiomyosarcoma 22 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Rhabdomyosarcoma 2 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Synovial sarcoma 5 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Angiosarcoma 5 0 0 0 2 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 Kaposi sarcoma 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Osteosarcoma 7 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 7 0 0 Chondrosarcoma 3 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 1 0 Ewing sarcoma/PNET 3 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 Other specified sarcomas 3 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Sarcoma, unspecified 29 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 1 0 Malignant complex mixed and stromal tumors 95 0 3 0 0 0 0 0 0 0 0 0 0 2 0 0 0 0 0 0 Malignant fibroepithelial tumors 5 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Malignant mesothelioma 33 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Malignant gonadal stromal tumors 6 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Dysgerminoma and seminoma 81 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Other malignant germ cell tumors 36 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Malignant trophoblastic tumors 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Malignant gliomas 154 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Malignant neuroepithelial tumors 6 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 Malignant meningioma 2 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Malignant nerve sheath tumors 2 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Other specified malignant tumors 2 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 2 0 Malignant tumor, unspecified 7 0 0 0 1 0 0 0 0 0 0 0 0 1 0 0 0 1 0 0 Nadaljevanje —> Continued —> 39 Tabela 4a: Nadaljevanje. Table 4a: Continued. Histološka vrsta Skupaj Primarna lokacija (šifra MKB) Histologic type All Sites Primary site (ICD code) C00-C80 C44 C45 C46 C47 C48 C49 C50 C51 C52 C53 C54 C55 C56 C57 C58 C60 C61 C62 Vse vrste / All types 12977 2998 33 1 4 25 59 1445 53 8 131 370 12 139 37 0 16 1407 112 Small cell carcinoma 215 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 3 0 Non-small cell carcinoma 66 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Squamous cell carcinoma 1567 585 0 0 0 0 0 0 44 6 105 0 0 0 0 0 16 0 0 Basal cell carcinoma 2380 2375 0 0 0 0 0 0 3 0 1 0 0 0 0 0 0 0 0 Transitional cell carcinoma 425 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 7 0 Adenocarcinoma 6792 21 0 0 0 6 0 1391 4 0 19 301 0 114 34 0 0 1396 0 Other specified carcinomas 153 1 0 0 0 0 0 21 0 0 5 48 0 1 0 0 0 1 0 Carcinoma, unspecified 121 6 0 0 0 0 0 28 0 0 0 1 0 7 1 0 0 0 0 Malignant thymoma 13 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Malignant paraganglioma/pheochromocytoma 8 0 0 0 2 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Malignant melanoma 690 0 0 0 0 0 0 0 2 2 0 0 0 0 0 0 0 0 0 Fibrosarcoma 13 1 0 0 0 1 10 0 0 0 0 0 0 0 0 0 0 0 0 Fibrohistiocytic sarcoma 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Liposarcoma 24 0 0 0 0 10 11 0 0 0 0 0 0 0 0 0 0 0 0 Leiomyosarcoma 22 4 0 0 0 3 6 0 0 0 0 0 9 0 0 0 0 0 0 Rhabdomyosarcoma 2 0 0 0 0 0 2 0 0 0 0 0 0 0 0 0 0 0 0 Synovial sarcoma 5 0 0 0 0 0 5 0 0 0 0 0 0 0 0 0 0 0 0 Angiosarcoma 5 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 Kaposi sarcoma 1 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Osteosarcoma 7 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Chondrosarcoma 3 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 Ewing sarcoma/PNET 3 0 0 0 0 0 2 0 0 0 0 0 0 0 0 0 0 0 0 Other specified sarcomas 3 0 0 0 0 0 2 0 0 0 0 0 0 0 0 0 0 0 0 Sarcoma, unspecified 29 4 0 0 0 1 19 0 0 0 0 0 0 0 0 0 0 0 0 Malignant complex mixed and stromal tumors 95 0 0 0 0 1 0 0 0 0 1 20 3 7 2 0 0 0 0 Malignant fibroepithelial tumors 5 0 0 0 0 0 0 5 0 0 0 0 0 0 0 0 0 0 0 Malignant mesothelioma 33 0 33 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Malignant gonadal stromal tumors 6 0 0 0 0 0 0 0 0 0 0 0 0 6 0 0 0 0 0 Dysgerminoma and seminoma 81 0 0 0 0 1 0 0 0 0 0 0 0 3 0 0 0 0 76 Other malignant germ cell tumors 36 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 35 Malignant trophoblastic tumors 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 Malignant gliomas 154 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Malignant neuroepithelial tumors 6 0 0 0 0 2 0 0 0 0 0 0 0 0 0 0 0 0 0 Malignant meningioma 2 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Malignant nerve sheath tumors 2 0 0 0 2 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Other specified malignant tumors 2 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Malignant tumor, unspecified 7 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Nadaljevanje —> Continued —> Tabela 4a: Nadaljevanje. Table 4a: Continued. Histološka vrsta Skupaj Primarna lokacija (šifra MKB) Histologic type All Sites Primary site (ICD code) C00-C80 C63 C64 C65 C66 C67 C68 C69 C70 C71 C72 C73 C74 C75 C76 C77 C78 C79 C80 Vse vrste / All types 12977 4 326 40 19 371 0 23 4 149 4 175 12 1 8 36 32 9 72 Small cell carcinoma 215 0 0 0 0 4 0 0 0 0 0 0 0 0 0 3 0 0 3 Non-small cell carcinoma 66 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Squamous cell carcinoma 1567 0 0 1 0 1 0 1 0 0 0 0 0 0 0 17 0 1 4 Basal cell carcinoma 2380 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Transitional cell carcinoma 425 0 0 39 19 359 0 0 0 0 0 0 0 0 0 0 1 0 0 Adenocarcinoma 6792 0 320 0 0 3 0 0 0 0 0 171 5 0 5 8 21 1 45 Other specified carcinomas 153 0 0 0 0 1 0 0 0 0 0 2 0 0 0 3 0 0 0 Carcinoma, unspecified 121 0 4 0 0 3 0 0 0 0 0 1 0 0 1 2 7 1 8 Malignant thymoma 13 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Malignant paraganglioma/pheochromocytoma 8 0 0 0 0 0 0 0 0 0 0 0 6 0 0 0 0 0 0 Malignant melanoma 690 0 0 0 0 0 0 20 1 0 0 0 0 0 0 2 2 6 11 Fibrosarcoma 13 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 Fibrohistiocytic sarcoma 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Liposarcoma 24 3 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Leiomyosarcoma 22 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Rhabdomyosarcoma 2 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Synovial sarcoma 5 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Angiosarcoma 5 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 Kaposi sarcoma 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Osteosarcoma 7 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Chondrosarcoma 3 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Ewing sarcoma/PNET 3 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Other specified sarcomas 3 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Sarcoma, unspecified 29 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 Malignant complex mixed and stromal tumors 95 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Malignant fibroepithelial tumors 5 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Malignant mesothelioma 33 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Malignant gonadal stromal tumors 6 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Dysgerminoma and seminoma 81 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 Other malignant germ cell tumors 36 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Malignant trophoblastic tumors 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Malignant gliomas 154 0 0 0 0 0 0 0 0 149 4 0 0 1 0 0 0 0 0 Malignant neuroepithelial tumors 6 0 0 0 0 0 0 2 0 0 0 0 1 0 0 0 0 0 0 Malignant meningioma 2 0 0 0 0 0 0 0 2 0 0 0 0 0 0 0 0 0 0 Malignant nerve sheath tumors 2 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Other specified malignant tumors 2 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Malignant tumor, unspecified 7 0 0 0 0 0 0 0 0 0 0 0 0 0 2 0 0 0 1 Tabela 4b: Incidenca malignih neoplazem limfaticnega tkiva v skladu s klasifikacijo Svetovne zdravstvene organizacije iz leta 2017, Slovenija 2020. Table 4b: Incidence of malignant neoplasms of lymphoid tissue according to 2017 version of Classification of Tumours of Haematopoietic and Lymphoid Tissues (published by World Health Organization), Slovenia 2020. Šifra ICD-O-3 ICD-O-3 code Moški in ženske / Males and females 864 Burkittov limfom / levkemija Vse vrste 9687 7 Moški / Males 454 Burkitt lymphoma / leukaemia All types Ženske / Females 410 Primarni mediastinalni (timicni) velikocelicni limfom B 9679 8 Primary mediastinal (thymic) large B-cell lymphoma 9727, 9835, Neoplazme nezrelih celic B 27 Sestavljeni (kompozitni) Hodgkinov in non-Hodgkinov limfom 9811-9819 Precursor lymphoid neoplasms B 9596 2 Composite Hodgkin and non-Hodgkin lymphoma Limfoblastna levkemija B / limfom B, BDO 9835, 9811 18 Velikocelicni B-celicni limfom bogat z limfociti T in histiociti B lymphoblastic leukaemia / lymphoma, NOS 9688 1 T-cell/histiocyte rich large B-cell lymphoma Limfoblastna levkemija B / limfom B z rekurentnimi citogenetskimi 9812, 9814, anomalijami 9 Neoplazme zrelih celic T/NK 9815, 9816 B lymphoblastic leukaemia / lymphoma with recurrent genetic 39 Mature T- and NK-cell neoplasms abnormalities 9827, 9831, Levkemicne neoplazme zrelih celic T/NK 4 9834, 9948 Leukaemic mature T- and NK-cell neoplasms Neoplazme nezrelih celic T 9837 8 Precursor lymphoid neoplasms T Levkemija velikih granuliranih limfocitov T 9831 3 Limfoblastna levkemija T / limfom T T-cell large granular lymphocytic leukemia 9837 8 T Lymphoblastic leukaemia / lymphoma Prolimfocitna levkemija T 9834 1 T-cell prolymphocytic leukaemia 9833, 9940, 9766 Ekstranodalni limfom NK/T, nazalni 9719 1 Kronicna limfaticna levkemija B / drobnocelicni limfocitni limfom Extranodal NK/T-cell lymphoma, nasal type 9823 147 Chronic lymphocytic leukaemia / small lymphocytic lymphoma Podkožni panikulitisu podoben limfom T 9708 1 Splenicni limfom robne cone Subcutaneous panniculitis-like T-cell lymphoma 9689 22 Splenic marginal zone lymphoma Fungoidna mikoza 9700 7 Ne-Hodgkinovi limfomi, BDO; primarni vranicni limfom / levkemija, Mycosis fungoides unclassifiable; splenic diffuse red pulp small B-cell lymphoma; Primarne kožne CD30+ T-celicne limfoproliferativne bolezni 9718 2 hairy cell leukaemia-variant Primary cutaneous CD30+ T-cell lymphoproliferative disorder Dlakastocelicna levkemija 9702, 9705, Zrele (nodalne) neoplazme celic T/NK 9940 8 22 Hairy cell leukaemia 9714, 9715 Mature (nodal) T- and NK-cell neoplasms Limfoplazmacitni limfom 9671 7 Periferni limfom T, BDO Lymphoplasmacytic lymphoma 9702 10 Peripheral T-cell lymphoma, NOS Waldenströmova makroglobulinemija 9761 6 Angioimunoblastni limfom T Waldenström macroglobulinemia 9705 9 Angioimmunoblastic T-cell lymphoma Multipli mielom 9732 147 Anaplasticni velikocelicni limfom, ALK-pozitivni Plasma cell myeloma 9714 1 Anaplastic large cell lymphoma, ALK positive Solitarni kostni in zunajkostni plazmacitom 9731, 9734 8 Anaplasticni velikocelicni limfom, ALK-negativni Solitary plasmacytoma of bone and extraosseous 9715 2 Anaplastic large cell lymphoma, ALK negative B-celicni limfom robne cone, nodalni 9699, nodalni 45 Marginal zone B-cell lymphoma, nodal Hodgkinov limfom (HL) 9650–9667 47 9699, B-celicni limfom robne cone, ekstranodalni Hodgkin lymphoma (HL) 26 ekstranodalni Marginal zone B-cell lymphoma, extranodal HL z nodularno limfocitno predominanco 9659 5 Folikularni limfom, BDO Nodular lymphocyte predominant HL 9690 8 Follicular lymphoma, NOS Klasicni HL 9650 3 Folikularni limfom, gradus 1 in 2 Classical HL 9691, 9695 37 Follicular lymphoma, grade 1 and 2 Klasicni HL, tip nodularne skleroze Folikularni limfom, gradus 3 9663 24 9698 18 Nodular sclerosis classical HL Follicular lymphoma, grade 3 Z limfociti bogat klasicni HL Primarni kožni limfom folikularnih centrov 9651 3 9597 1 Lymphocyte-rich classical HL Primary cutaneous follicle centre lymphoma Mešanocelicni tip klasicnega HL Limfom plašcnih celic 9652 12 9673 29 Mixed cellularity classical HL Mantle cell lymphoma Plazmablastni limfom Neopredeljeni limfomi / levkemije 9735 2 9590, 9832 4 Plasmablastic lymphoma Unspecified lymphoma / leukemia Difuzni velikocelicni limfom B (DLBCL), BDO; primarni DLBCL CŽS;Maligni limfom, BDO 9590 4 primarni kožni DLBCL, nožni tip; EBV-pozitivni DLBCL starejših; DLBCLMalignant lymphoma, NOS povezan s kronicnim vnetjem; nerazvršceni B-celicni limfom, mejni primer med difuznim velikocelicnim limfomom B in Burkittovim limfomom Neoplazme histiocitov in dendriticnih celic 9680 Malignant lymphoma, large B-cell, diffuse (DLBCL), NOS; 192 9750–9759 2 Histiocytic and dendritic cell neoplasms BDO - brez drugih oznak / NOS - not otherwise specified,EBV - Epstein-Barr virus, Histološka vrsta Histology type Število Number Šifra ICD-O-3 ICD-O-3 code Histološka vrsta Histology type Število Number 9591-9597, 9671-9699, 9712, 9731-9738, 9760-9764, 9823, Periferni B-celicni limfom / neoplazme zrelih celic B Mature B-cell neoplasms 737 9700, 9701, 9708, 9709, 9716–9719 Neoplazme zrelih (ekstranodalnih) celic T/NK Mature (extranodal) T- and NK-cell neoplasms 13 9591 nerazvršceni; difuzni drobnocelicni limfom B rdece pulpe; posebna oblika dlakastocelicne levkemije Non-Hodgkin lymphoma, NOS; splenic B-cell lymphoma / leukaemia, 16 9701 Sézaryjev sindrom Sézary syndrome 2 primary DLBCL of the CNS; primary cutaneous DLBCL, leg type; EBV positive DLBCL of the elderly; DLBCL associated with chronic inflammation; B-cell lymphoma, unclassifiable, with features intermediate between diffuse large B-cell lymphoma and Burkitt lymphoma 9755 Histiocitni sarkom Histiocytic sarcoma 2 CŽS - centralni živcni sistem / CNS - central nervous system, NK - natural killer cells, ALCL - anaplasticni velikocelicni limfom / anaplastic large cell lymphoma Tabela 4c: Incidenca ne-Hodgkinovih limfomov (NHL) po lokaciji, Slovenija 2020. Table 4c: Incidence of non-Hodgkin’s lymphomas (NHL) by cancer site, Slovenia 2020. Šifra MKB-8 Primarna lokacija Vse starosti ICD-8 code Primary site All ages Vsi NHL All NHL 460 141 Jezik Tongue 1 142 Slinavke Salivary glands 2 143 Dlesni Gum 1 145 Usta, drugo Mouth, other parts 2 146 Orofarinks Oropharynx 8 151 Želodec Stomach 18 152 Tanko crevo Small intestine 3 153 Debelo crevo Colon 2 160 Nos, obnosne votline, drugo Nos, obnosne votline, drugo 4 162 Sapnik, sapnica, pljuca Trachea, bronchus, lung 5 163 Plevra, mediastinum, drugo Pleura, mediastinum, etc. 1 170 Kosti Bone 3 171 Mehka tkiva Soft tissues 1 173 Koža, drugi malignomi Skin, other malignancies 22 174 Dojka Breast 3 186 Modo Testis 3 190 Oko Eye 7 191 Možgani Brain 10 192 Živcevje, drugo Nervous system, other 1 193 Šcitnica Thyroid 4 194 Endokrine žleze, druge Endocrine glands, other 3 202 Bezgavke Lymph nodes 356 Tabela 5: Incidenca raka po stadiju, Slovenija 2020. Table 5: Cancer incidence by stage, Slovenia 2020. Šifra MKB ICD code Primarna lokacija Primary site Število novih primerov Number of new cases Stadij / Stage Omejen Localized Razširjen Regional Razsejan Distant Neznan Unknown ** Število Number %* Število Number %* Število Number %* Število Number %* C00-C80 Moški in ženske / Males and females Vse lokacije / All sites Moški / Males Ženske / Females 13849 7400 6449 7539 3889 3650 54,6 52,7 56,8 3466 1955 1511 25,1 26,5 23,5 2705 1475 1230 19,6 20,0 19,1 139 81 58 0,8 0,9 0,6 C00 Ustnica / Lip 27 24 88,9 3 11,1 0 0,0 0 0,0 C01 Baza jezika / Base of tongue 25 3 12,0 21 84,0 1 4,0 0 0,0 C02 Jezik, drugi deli / Tongue, other & unspecified parts 34 11 32,4 23 67,6 0 0,0 0 0,0 C03 Dlesen / Gum 10 1 - 9 - 0 - 0 - C04 Ustno dno / Floor of mouth 24 7 29,2 16 66,7 1 4,2 0 0,0 C05 Nebo / Palate 16 8 50,0 6 37,5 2 12,5 0 0,0 C06 Usta, drugi deli / Mouth, other & unspecified parts 13 5 - 8 - 0 - 0 - C07 Parotidna žleza / Parotid gland 14 9 - 5 - 0 - 0 - C08 Druge in neopredeljene velike žleze slinavke Other & unspecified major salivary glands 2 1 - 0 - 1 - 0 - C09 Tonzila / Tonsil 47 6 12,8 39 83,0 2 4,3 0 0,0 C10 Orofarinks / Oropharynx 32 4 12,5 26 81,3 2 6,3 0 0,0 C11 Nazofarinks / Nasopharynx 6 1 - 5 - 0 - 0 - C12 Piriformni sinus / Pyriform sinus 42 2 4,8 35 83,3 5 11,9 0 0,0 C13 Hipofarinks / Hypopharynx 32 0 0,0 28 87,5 4 12,5 0 0,0 C14 Druga in slabo opredeljena mesta na ustnici, v ustni votlini in farinksu Other and ill-defined sites in the lip, oral cavity and pharynx 2 0 - 2 - 0 - 0 - C15 Požiralnik / Oesophagus 94 8 8,5 49 52,1 34 36,2 3 3,2 C16 Želodec / Stomach 424 77 18,2 163 38,4 174 41,0 10 2,4 C17 Tanko crevo / Small intestine 50 9 18,0 15 30,0 25 50,0 1 2,0 C18 Debelo crevo / Colon 825 162 19,6 467 56,6 189 22,9 7 0,8 C19 Rektosigmoidna zveza / Rectosigmoid junction 99 10 10,1 54 54,5 34 34,3 1 1,0 C20 Rektum / Rectum 380 96 25,3 191 50,3 86 22,6 7 1,8 C21 Anus in analni kanal / Anus and anal canal 24 9 37,5 13 54,2 2 8,3 0 0,0 C22 Jetra in intrahepaticni vodi / Liver and intrahepatic bile ducts 234 75 32,1 65 27,8 93 39,7 1 0,4 C23 Žolcnik / Gallbladder 57 11 19,3 16 28,1 28 49,1 2 3,5 C24 Drugi in neopredeljeni deli biliarnega trakta Billiary tract, other and unspecified parts 141 29 20,6 57 40,4 54 38,3 1 0,7 C25 Trebušna slinavka / Pancreas 420 70 16,7 129 30,7 217 51,7 4 1,0 C26 Druga in slabo opredeljena mesta v prebavnih organih Other and ill-defined digestive organs 6 0 - 1 - 3 - 2 - C30 Nosna votlina in srednje uho / Nasal cavity and middle ear 14 3 - 11 - 0 - 0 - C31 Obnosni sinusi / Accessory sinuses 3 1 - 1 - 0 - 1 - C32 Grlo / Larynx 91 42 46,2 44 48,4 5 5,5 0 0,0 C33 Sapnik / Trachea 2 1 - 1 - 0 - 0 - C34 Sapnica in pljuca / Bronchus and lung 1552 355 22,9 375 24,2 820 52,8 2 0,1 C37 Timus / Thymus 15 12 80,0 0 0,0 3 20,0 0 0,0 C38 Srce, mediastinum, plevra / Heart, mediastinum, pleura Druga in slabo opredeljena mesta v dihalih in prsnih organih 5 0 - 2 - 2 - 1 - C39 Other and ill-defined sites in the respiratory system and intrathoracic organs 0 0 - 0 - 0 - 0 - C40 Kosti, sklepni hrustanec udov / Bone and articular cartilage of limbs 9 3 - 4 - 2 - 0 - C41 Kosti, sklepni hrustanec, drugje Bone and articular cartilage of other and unspecified parts 5 2 - 2 - 1 - 0 - C43 Maligni melanom kože / Malignant melanoma of skin 639 487 76,2 138 21,6 12 1,9 2 0,3 C44 Druge maligne neoplazme kože / Skin, excl. melanoma 3010 2889 96,0 116 3,9 2 0,1 3 0,1 C45 Mezoteliom / Mesothelioma 33 8 24,2 18 54,5 7 21,2 0 0,0 C46 Kaposijev sarkom / Kaposi’s sarcoma 1 1 - 0 - 0 - 0 - C47 Periferni živci in avtonomno živcevje Peripheral nerves and autonomic nervous system 4 2 - 1 - 1 - 0 - C48 Peritonej in retroperitonej / Retroperitoneum and peritoneum 27 1 3,7 15 55,6 11 40,7 0 0,0 C49 Drugo vezivno in mehko tkivo / Other connective and soft tissue 60 18 30,0 31 51,7 11 18,3 0 0,0 C50 Dojka / Breast 1459 882 60,5 457 31,3 115 7,9 5 0,3 Nadaljevanje —> Continued —> 44 Tabela 5: Nadaljevanje. Table 5: Continued. Šifra MKB ICD code Primarna lokacija Primary site Število novih primerov Number of new cases Stadij / Stage Omejen Localized Razširjen Regional Razsejan Distant Neznan Unknown ** Število Number %* Število Number %* Število Number %* Število Number %* C51 Žensko zunanje spolovilo / Vulva 54 27 50,0 22 40,7 3 5,6 2 3,7 C52 Nožnica / Vagina 8 4 - 4 - 0 - 0 - C53 Maternicni vrat / Cervix uteri 133 61 45,9 49 36,8 23 17,3 0 0,0 C54 Maternicno telo / Corpus uteri 373 254 68,1 75 20,1 36 9,7 8 2,1 C55 Maternica, neopredeljeno / Uterus, unspecified 15 8 53,3 2 13,3 3 20,0 2 13,3 C56 Jajcnik / Ovary 151 25 16,6 19 12,6 107 70,9 0 0,0 C57 Drugi in neopredeljeni ženski spolni organi Other and unspecified parts of female genital organs 38 2 5,3 3 7,9 33 86,8 0 0,0 C58 Posteljica / Placenta 0 0 - 0 - 0 - 0 - C60 Penis / Penis 16 11 68,8 4 25,0 1 6,3 0 0,0 C61 Prostata / Prostate 1460 864 59,2 395 27,1 171 11,7 30 2,1 C62 Modo / Testis 112 89 79,5 12 10,7 10 8,9 1 0,9 C63 Drugi in neopredeljeni moški spolni organi Other and unspecified male genital organs 4 3 - 1 - 0 - 0 - C64 Ledvica razen meha / Kidney, excl. renal pelvis 376 223 59,3 64 17,0 87 23,1 2 0,5 C65 Ledvicni meh / Renal pelvis 40 9 22,5 19 47,5 12 30,0 0 0,0 C66 Secevod / Ureter 21 8 38,1 9 42,9 4 19,0 0 0,0 C67 Secni mehur / Bladder 387 258 66,7 76 19,6 48 12,4 5 1,3 C68 Drugi in neopredeljeni secni organi Other and unspecified urinary organs 0 0 - 0 - 0 - 0 - C69 Oko in ocesni adneksi / Eye and adnexa 32 29 90,6 2 6,3 1 3,1 0 0,0 C70 Meninge / Meninges 4 4 - 0 - 0 - 0 - C71 Možgani / Brain Hrbtni mozeg, možganski živci in drugi deli 175 173 98,9 1 0,6 1 0,6 0 0,0 C72 centralnega živcnega sistema (CŽS) Spinal cord, cranial nerves and other parts of central nervous system (CNS) 5 5 - 0 - 0 - 0 - C73 Šcitnica / Thyroid gland 175 128 73,1 41 23,4 6 3,4 0 0,0 C74 Nadledvicna žleza / Adrenal gland 12 8 - 1 - 3 - 0 - C75 Druge endokrine žleze in sorodne strukture Other endocrine glands and related structures 1 1 - 0 - 0 - 0 - C76 Druga in slabo opredeljena mesta / Other and ill-defined sites 13 0 - 5 - 7 - 1 - C77 Metastaza in neopredeljena maligna neoplazma bezgavk Metastasis and unspecified malignant neoplasm of lymph nodes 38 0 0,0 0 0,0 3 7,9 35 92,1 C78 Metastaze dihal in prebavil Metastases of respiratory and digestive organs 59 0 0,0 0 0,0 59 100,0 0 0,0 C79 Metastaze, drugje / Metastases of other sites 23 0 0,0 0 0,0 23 100,0 0 0,0 C80 Maligna neoplazma brez opredeljenega mesta Malignant neoplasm without specification of site 115 0 0,0 0 0,0 115 100,0 0 0,0 Šifra MKB ICD code Primarna lokacija Primary site Število novih primerov Number of new cases Stadij / Stage I II III + IV Neznan / Unknown Število Number %* Število Number %* Število Number %* Število Number %* C81 Hodgkinov limfom / Hodgkin’s lymphoma 47 1 2,1 18 38,3 27 57,4 1 2,1 C82 Folikularni ne-Hodgkinov limfom / Follicular non-Hodgkin’s lymphoma 135 37 27,4 14 10,4 79 58,5 5 3,7 C83 Difuzni ne-Hodgkinov limfom / Diffuse non-Hodgkin’s lymphoma 268 52 19,4 32 11,9 167 62,3 17 6,3 C84 Limfomi celic T in kožni limfom celic T Peripheral and cutaneous T-cell lymphomas 35 9 25,7 3 8,6 21 60,0 2 5,7 C85 Druge in neopredeljene vrste ne-Hodgkinovega limfoma Other and unspecified types of non-Hodgkin’s lymphoma 22 2 9,1 2 9,1 16 72,7 2 9,1 * Odstotki niso racunani, ce je število novih primerov manjše od 15 Percentages are not calculated when number of new cases is less than 15 ** Vkljuceni tudi primeri, ki so registrirani samo iz zdravniških porocil o vzroku smrti, razen pri C78-C80, kjer so prišteti k razsejanemu stadiju Cases registered from death certificates only are included, except for C78-C80, where they are added to the distant stage Prevalenca Prevalence Tabela 6: Prevalenca bolnikov z rakom po spolu, Slovenija, 31. 12. 2020. Table 6: Prevalence of cancer patients by sex, Slovenia, December 31, 2020. Šifra MKB ICD code Primarna lokacija* Primary site* Spol Sex Leta po diagnozi Years after diagnosis Celotna prevalenca Lifetime prevalence <1 1-4 5-9 10+ Vsi / All C00-C96 Vse lokacije All sites M+Ž M Ž 12223 6386 5837 39787 20078 19709 33100 16780 16320 49222 19521 29701 124830 57593 67237 C00-C14 Usta in žrelo Mouth and pharynx M Ž 204 68 540 209 434 174 556 302 1734 753 C15 Požiralnik Oesophagus M Ž 39 10 53 12 29 7 22 14 143 43 C16 Želodec Stomach M Ž 179 94 346 229 291 190 415 383 1231 896 C18 Debelo crevo Colon M Ž 394 283 1158 936 1064 854 1314 1316 3930 3389 C19-C20 Rektum in rektosigmoidna zveza Rectum and rectosigmoid junction M Ž 250 148 842 459 836 465 1103 913 3031 1985 C22 Jetra in intrahepaticni vodi Liver and intrahepatic bile ducts M Ž 83 28 125 48 40 12 26 14 274 102 C23-C24 Žolcnik in žolcevodi Gallbladder and billiary tract M Ž 54 40 68 60 38 43 42 47 202 190 C25 Trebušna slinavka Pancreas M Ž 117 94 120 102 35 41 30 40 302 277 C32 Grlo Larynx M Ž 71 10 255 42 198 26 356 58 880 136 C33-C34 Sapnik, sapnici in pljuca Trachea, bronchus and lung M Ž 572 423 1008 819 433 313 428 250 2441 1805 C43 Maligni melanom kože Malignant melanoma of skin M Ž 318 299 1024 1029 972 958 1220 1944 3534 4230 C44 Druge maligne neoplazme kože Skin, excl. melanoma M Ž 1521 1401 5806 6141 4522 4651 5008 6193 16857 18386 C48-C49 Vezivno in mehko tkivo Connective and soft tissue M Ž 39 37 86 92 69 87 214 220 408 436 C50 Dojka Breast M Ž 11 1384 40 5157 38 4577 36 8715 125 19833 C53 Maternicni vrat Cervix uteri M Ž - 120 - 303 - 381 - 2631 - 3435 C54 Maternicno telo Corpus uteri M Ž - 346 - 1142 - 1129 - 2432 - 5049 C56 Jajcnik Ovary M Ž - 122 - 343 - 259 - 934 - 1658 C61 Prostata Prostate M Ž 1358 - 5692 - 5374 - 4183 - 16607 - C62 Modo Testis M Ž 112 - 419 - 529 - 1709 - 2769 - C64-C65 Ledvica z ledvicnim mehom Kidney with renal pelvis M Ž 233 107 745 340 582 329 827 547 2387 1323 C67 Secni mehur Bladder M Ž 227 86 554 193 438 132 471 171 1690 582 C70-C72 Centralni in avtonomni živcni sistem Central and autonomic nervous system M Ž 69 48 110 62 66 45 195 159 440 314 C73 Šcitnica Thyroid gland M Ž 51 118 168 589 174 560 304 1306 697 2573 C81 Hodgkinov limfom Hodgkin’s lymphoma M Ž 19 24 98 96 79 98 390 369 586 587 C82-C85 Ne-Hodgkinovi limfomi Non-Hodgkin’s lymphoma M Ž 186 184 581 598 473 498 648 667 1888 1947 C90 Difuzni plazmocitom in maligne neoplazme plazmatk Multiple myeloma and malignant plasma cell neoplasms M Ž 71 63 201 153 92 90 72 78 436 384 C91-C95 Levkemije Leukaemias M Ž 189 111 480 392 379 291 556 472 1604 1266 * Pri posameznih lokacijah je pri prikazu prevalence oseba z vec raki vkljucena pri vsaki lokaciji, pri vseh lokacijah skupaj pa se v prevalenci tudi oseba z vec raki šteje le enkrat Person diagnosed with more than one cancer is included as a prevalent case in each cancer site, but for all sites together (C00-C96) each person is counted once only Umrljivost Mortality Tabela 7: Umrljivost za rakom po starosti in spolu, Slovenija 2020. Vir: Nacionalni inštitut za javno zdravje Table 7: Cancer mortality by age and by sex, Slovenia 2020. Source: National Institute of Public Health Šifra MKB ICD code Primarna lokacija Primary site Spol Sex Vse starosti All ages Starost / Age 0-19 20-49 50-74 75+ C00-C97 Vse lokacije All sites M+Ž M Ž 6423 3602 2821 8 5 3 200 83 117 2834 1794 1040 3381 1720 1661 C00-C14 Usta in žrelo Mouth and pharynx M Ž 139 20 0 0 7 1 111 8 21 11 C15 Požiralnik Oesophagus M Ž 97 19 0 0 5 0 65 6 27 13 C16 Želodec Stomach M Ž 194 119 0 0 6 5 80 39 108 75 C18 Debelo crevo Colon M Ž 234 179 0 0 6 11 89 50 139 118 C19-C20 Rektum in rektosigmoidna zveza Rectum and rectosigmoid junction M Ž 170 98 0 0 2 6 92 27 76 65 C22 Jetra in intrahepaticni vodi Liver and intrahepatic bile ducts M Ž 212 90 0 0 1 3 142 32 69 55 C23-C24 Žolcnik in žolcevodi Gallbladder and billiary tract M Ž 54 59 0 0 0 0 29 19 25 40 C25 Trebušna slinavka Pancreas M Ž 209 209 0 0 7 9 108 80 94 120 C32 Grlo Larynx M Ž 49 4 0 0 1 0 29 2 19 2 C33-C34 Sapnik, sapnici in pljuca Trachea, bronchus and lung M Ž 742 451 0 0 15 9 488 251 239 191 C43 Maligni melanom kože Malignant melanoma of skin M Ž 74 67 0 0 3 9 36 26 35 32 C44 Druge maligne neoplazme kože Skin, excl. melanoma M Ž 26 34 0 0 1 0 6 3 19 31 C48-C49 Vezivno in mehko tkivo Connective and soft tissue M Ž 15 19 0 0 2 2 7 4 6 13 C50 Dojka Breast M Ž 3 472 0 0 0 33 1 175 2 264 C53 Maternicni vrat Cervix uteri M Ž - 38 - 0 - 4 - 16 - 18 C54 Maternicno telo Corpus uteri M Ž - 77 - 0 - 0 - 31 - 46 C56 Jajcnik Ovary M Ž - 107 - 0 - 4 - 55 - 48 C61 Prostata Prostate M Ž 460 - 0 - 1 - 128 - 331 - C62 Modo Testis M Ž 5 - 0 - 3 - 1 - 1 - C64-C65 Ledvica z ledvicnim mehom Kidney with renal pelvis M Ž 101 71 0 0 2 2 40 22 59 47 C67 Secni mehur Bladder M Ž 179 63 0 0 0 1 69 7 110 55 C70-C72 Centralni in avtonomni živcni sistem Central and autonomic nervous system M Ž 83 80 2 2 11 5 48 37 22 36 C73 Šcitnica Thyroid gland M Ž 8 11 0 0 0 0 6 3 2 8 C81 Hodgkinov limfom Hodgkin’s lymphoma M Ž 8 7 0 0 0 1 5 3 3 3 C82-C85 Ne-Hodgkinovi limfomi Non-Hodgkin’s lymphoma M Ž 110 87 0 0 0 1 45 27 65 59 C90 Difuzni plazmocitom in maligne neoplazme plazmatk Multiple myeloma and malignant plasma cell neoplasms M Ž 53 57 0 0 2 0 21 12 30 45 C91-C95 Levkemije Leukaemias M Ž 103 86 1 1 4 2 36 16 62 67 Preživetje Survival Tabela 8: Eno- in pet-letno cisto preživetje (s 95 % intervalom zaupanja) bolnikov po spolu, zbolelih v letih 2016–2020. Table 8: One- and five-year net survival (with 95% confidence interval) of patients diagnosed in period 2016–2020 by sex. Šifra MKB ICD code Primarna lokacija Primary site Spol Sex Eno-letno preživetje s 95 % intervalom zaupanja Pet-letno preživetje s 95 % intervalom zaupanja One-year survival with 95% confidence interval Five-year survival with 95% confidence interval C00-C96 brez C44** Vse lokacije All sites M+Ž M Ž 75,7 75,3-76,0 74,2 73,7-74,7 77,4 76,9-77,9 59,9 59,3-60,4 58,0 57,3-58,7 62,0 61,3-62,8 C00-C14 Usta in žrelo Mouth and pharynx M Ž 73,5 71,0-76,1 84,8 81,1-88,7 45,1 41,7-48,6 63,5 57,4-70,1 C15 Požiralnik Oesophagus M Ž 35,4 30,7-40,7 34,7 26,1-46,1 12,1 8,8-16,6 15,2 9,0-25,7 C16 Želodec Stomach M Ž 52,9 50,1-55,8 51,6 48,1-55,3 29,3 26,3-32,7 31,2 27,6-35,2 C18 Debelo crevo Colon M Ž 79,6 77,8-81,4 80,0 78,0-82,0 63,0 60,2-66,1 63,2 60,1-66,5 C19-C20 Rektum in rektosigmoidna zveza Rectum and rectosigmoid junction M Ž 84,1 82,1-86,1 80,2 77,5-83,1 63,4 60,0-66,9 59,3 55,3-63,7 C22 Jetra in intrahepaticni vodi Liver and intrahepatic bile ducts M Ž 36,1 33,0-39,6 29,8 25,2-35,3 11,1 8,8-13,9 11,0 7,7-15,9 C23-C24 Žolcnik in žolcevodi Gallbladder and billiary tract M Ž 37,3 33,2-42,0 28,4 24,6-32,9 13,5 10,4-17,6 10,7 7,9-14,5 C25 Trebušna slinavka Pancreas M Ž 31,5 28,8-34,5 28,8 26,0-31,8 9,3 7,4-11,6 9,1 7,3-11,4 C32 Grlo Larynx M Ž 88,0 84,8-91,4 * 66,5 60,6-73 * C33-C34 Sapnik, sapnici in pljuca Trachea, bronchus and lung M Ž 46,6 45,2-48,1 55,1 53,2-56,9 20,4 19,0-21,8 28,3 26,4-30,2 C43 Maligni melanom kože Malignant melanoma of skin M Ž 96,6 95,3-97,9 98,3 97,3-99,4 87,3 84,1-90,7 92,4 89,5-95,3 C44 Druge maligne neoplazme kože Skin, excl. melanoma M Ž ** ** ** ** C48-C49 Vezivno in mehko tkivo Connective and soft tissue M Ž 78,3 72,2-84,9 80,1 74,6-86,1 54,9 46,6-64,6 53,0 44,8-62,6 C50 Dojka Breast M Ž * 96,8 96,2-97,3 * 87,6 86,3-88,9 C53 Maternicni vrat Cervix uteri M Ž - 84,8 81,7-88,0 - 72,4 68,1-77 C54 Maternicno telo Corpus uteri M Ž - 91,7 90,3-93,1 - 79,3 76,7-82,1 C56 Jajcnik Ovary M Ž - 75,5 72,4-78,8 - 47,2 43,2-51,5 C61 Prostata Prostate M Ž 97,8 97,3-98,3 - 94,0 92,7-95,3 - C62 Modo Testis M Ž 99,1 98,3-100,0 - 97,1 95,3-99,0 - C64-C65 Ledvica z ledvicnim mehom Kidney with renal pelvis M Ž 82,2 80,0-84,4 75,0 71,6-78,5 70,8 67,5-74,3 61,5 56,6-66,9 C67 Secni mehur Bladder M Ž 77,0 74,5-79,6 65,6 61,3-70,2 55,0 51,1-59,3 49,2 43,8-55,3 C70-C72 Centralni in avtonomni živcni sistem Central and autonomic nervous system M Ž 48,2 44,0-52,8 44,7 39,8-50,2 20,2 16,8-24,3 16,7 12,9-21,5 C73 Šcitnica Thyroid gland M Ž 95,7 92,8-98,7 97,0 95,7-98,4 87,6 79,6-96,5 97,0 94,8-99,2 C81 Hodgkinov limfom Hodgkin’s lymphoma M Ž 91,9 87,2-96,8 91,3 86,4-96,4 85,0 78,3-92,2 85,8 78,8-93,5 C82-C85 Ne-Hodgkinovi limfomi Non-Hodgkin’s lymphoma M Ž 76,9 74,3-79,6 79,8 77,3-82,3 65,1 61,4-69,0 68,0 64,4-71,9 C90 Difuzni plazmocitom in maligne neoplazme plazmatk Multiple myeloma and malignant plasma cell neoplasms M Ž 81,6 77,6-85,7 79,3 74,9-84,0 53,0 46,9-59,9 49,6 43,0-57,1 C91-C95 Levkemije Leukaemias M Ž 75,4 72,6-78,2 71,5 68,4-74,9 60,3 56,5-64,4 55,1 50,7-60,0 * Število v analizo vkljucenih bolnikov je v povprecju manjše od 15 na leto / Average number of patients included in the analysis is less than 15 annually** Preživetje bolnikov z nemelanomskim kožnim rakom se ne razlikuje v primerjavi s splošno populacijo Survival of patients with non-melanoma skin cancer does not differ in comparison with the general population Zdravljenje Treatment Tabela 9a: Število in deleži bolnikov (brez primerov, registriranih samo iz zdravniških porocil o vzroku smrti), v Sloveniji zbolelih leta 2020, ki so bili v okviru prvega zdravljenja operirani, zdravljeni s sistemskim zdravljenjem ali obsevani (številka v oklepaju se nanaša na obsevane na Onkološkem inštitutu Ljubljana - OIL). Table 9a: Number of patients (without cases registered from death certificates only) diagnosed in Slovenia in 2020, that were treated by surgery, systemic therapy or radiotherapy during their first treatment (in parenthesis the number of radiotherapies at Institute of Oncology Ljubljana - IOL is given). Šifra MKB ICD code Primarna lokacija Primary site Število novih primerov Number of new cases Število kakorkoli zdravljenih* Number of all treated* Število operiranih Number of treated by surgery Število zdravljenih s sistemsko terapijo No. of treated by systemic therapy Število obsevanih Number of treated by radiotherapy Število Number %** Število Number %** Število Number %** Število (od tega OIL) Number (IOL only) %** C00-C96 Vse lokacije / All sites 15062 12206 81,0 9365 62,2 4439 29,5 3138 (2691) 20,8 C00-C14 Usta in žrelo Mouth and pharynx 326 290 89,0 157 48,2 19 5,8 218 (217) 66,9 C15 Požiralnik Oesophagus 94 49 52,1 13 - 16 17,0 34 (30) 36,2 C16 Želodec Stomach 423 260 61,5 186 44,0 120 28,4 41 (25) 9,7 C18 Debelo crevo Colon 821 702 85,5 665 81,0 199 24,2 10 (7) - C19-C20 Rektum in rektosigmoidna zveza Rectum and rectosigmoid junction 478 396 82,8 312 65,3 168 35,1 173 (168) 36,2 C22 Jetra in intrahepaticni vodiLiver and intrahepatic bile ducts 234 90 38,5 35 15,0 49 20,9 7 (4) - C23-C24 Žolcnik in žolcevodi Gallbladder and billiary tract 198 85 42,9 66 33,3 40 20,2 7 (7) - C25 Trebušna slinavka Pancreas 419 188 44,9 98 23,4 128 30,5 12 (11) - C32 Grlo Larynx 91 82 90,1 47 51,6 5 - 66 (66) 72,5 C33-C34 Sapnik, sapnici in pljuca Trachea, bronchus and lung 1553 1078 69,4 420 27,0 476 30,7 480 (411) 30,9 C43 Maligni melanom kože Malignant melanoma of skin 639 635 99,4 632 98,9 41 6,4 31 (31) 4,9 C44 Druge maligne neoplazme kože Skin, excl. melanoma 3008 2960 98,4 2841 94,4 26 0,9 122 (122) 4,1 C48-C49 Vezivno in mehko tkivo Connective and soft tissue 87 79 90,8 57 65,5 20 23,0 35 (35) 40,2 C50 Dojka Breast 1455 1399 96,2 1223 84,1 1331 91,5 976 (720) 67,1 C53 Maternicni vrat Cervix uteri 133 121 91,0 96 72,2 14 - 72 (66) 54,1 C54 Maternicno telo Corpus uteri 373 347 93,0 332 89,0 69 18,5 131 (121) 35,1 C56 Jajcnik Ovary 151 119 78,8 107 70,9 94 62,3 1 (0) - C61 Prostata Prostate 1452 1078 74,2 726 50,0 399 27,5 174 (148) 12,0 C62 Modo Testis 112 112 100 112 100,0 67 59,8 0 (0) - C64-C65 Ledvica z ledvicnim mehom Kidney with renal pelvis 415 325 78,3 282 68,0 49 11,8 19 (17) 4,6 C67 Secni mehur Bladder 384 349 90,9 342 89,1 63 16,4 24 (20) 6,3 C70-C72 Centralni in avtonomni živcni sistem Central and autonomic nervous system 184 150 81,5 140 76,1 80 43,5 110 (106) 59,8 C73 Šcitnica Thyroid gland 175 167 95,4 162 92,6 162 92,6 102 (101) 58,3 C81 Hodgkinov limfom Hodgkin’s lymphoma 47 43 91,5 2 - 41 87,2 10 (10) - C82-C85 Ne-Hodgkinovi limfomi Non-Hodgkin’s lymphoma Difuzni plazmocitom in maligne 460 340 73,9 38 8,3 269 58,5 121 (118) 26,3 C90 neoplazme plazmatkMultiple myeloma and malignant plasma cell neoplasms 155 134 86,5 2 - 129 83,2 18 (12) 11,6 C91-C95 Levkemije Leukaemias 365 181 49,6 1 - 174 47,7 12 (12) - *Število bolnikov zdravljenih s specificnim onkološkim zdravljenjem v okviru prvega zdravljenja ne glede na nacin zdravljenja (vkljucno z drugimi zdravljenji, ki ne spadajo med operacijo, sistemsko terapijo ali obsevanje) Number of all treated patients with specific oncological treatment regardless of the means of treatment (including other treatments not included into surgery, systemic therapy or radiotherapy) ** Odstotki niso racunani, ce je število zdravljenih manjše od 15 Percentages are not calculated for less than 15 cases Tabela 9b: Število bolnikov (brez primerov, registriranih samo iz zdravniških porocil o vzroku smrti) v Sloveniji, zbolelih leta 2020, ki so bili v okviru prvega zdravljenja operirani*, po ustanovi posega. Table 9b: Number of patients (without cases registered from death certificates only) diagnosed in Slovenia in 2020, that were treated by surgery during their first treatment* by treatment institution. Šifra MKB ICD code Primarna lokacija Primary site Število novih primerovNumber of new casesŠtevilo operiranihNumber of treated by surgerySplošna bolnišnica BrežiceSplošna bolnišnica CeljeSplošna bolnišnica JeseniceSplošna bolnišnica IzolaUniverzitetni klinicni center LjubljanaOnkološki inštitut LjubljanaUniverzitetni klinicni center MariborSplošna bolnišnica Murska SobotaSplošna bolnišnica Nova GoricaSplošna bolnišnica Novo mestoSplošna bolnišnica PtujSplošna bolnišnica Slovenj GradecZasebne ordinacijePrivate clinicsOstale ustanove** Other institutions** C00-C96 Vse lokacijeAll sites 15062 9365 30 668 294 242 2313 1352 1771 319 203 437 119 426 1018 173 C00-C14 Usta in žrelo Mouth and pharynx 326 157 0 2 1 1 119 1 29 1 1 2 0 0 0 0 C15 Požiralnik Oesophagus 94 13 0 0 0 0 11 0 1 0 0 0 0 0 1 0 C16 Želodec Stomach 423 186 0 6 7 9 81 12 56 7 1 1 1 0 4 1 C18 Debelo crevo Colon 821 665 8 48 61 46 187 61 75 29 32 29 17 28 27 17 C19-C20 Rektum in rektosigmoidna zveza Rectum and rectosigmoid junction 478 312 3 12 11 29 74 77 35 7 4 11 5 17 23 4 C22 Jetra in intrahepaticni vodiLiver and intrahepatic bile ducts 234 35 0 0 0 0 20 1 13 0 0 0 1 0 0 0 C23-C24 Žolcnik in žolcevodi Gallbladder and billiary tract 198 66 1 2 2 1 38 0 16 2 0 1 1 2 0 0 C25 Trebušna slinavka Pancreas 419 98 0 0 0 5 60 1 31 0 0 0 0 0 0 1 C32 Grlo Larynx 91 47 0 3 0 0 27 0 17 0 0 0 0 0 0 0 C33-C34 Sapnik, sapnici in pljuca Trachea, bronchus and lung 1553 420 0 2 0 0 127 1 94 0 0 0 0 0 194 2 C43 Maligni melanom kože Malignant melanoma of skin 639 632 3 68 32 28 128 41 66 12 15 34 13 9 144 39 C44 Druge maligne neoplazme kože Skin, excl. melanoma 3008 2841 10 305 125 85 490 30 635 173 24 252 75 24 556 57 C48-C49 Vezivno in mehko tkivo Connective and soft tissue 87 57 1 0 0 0 12 37 5 0 0 1 1 0 0 0 C50 Dojka Breast 1455 1223 0 28 0 0 1 819 296 1 48 0 0 25 1 4 C53 Maternicni vrat Cervix uteri 133 96 2 3 1 2 60 3 11 2 0 0 2 1 0 9 C54 Maternicno telo Corpus uteri 373 332 1 16 14 8 139 49 56 9 10 11 0 4 0 15 C56 Jajcnik Ovary 151 107 1 2 2 3 49 24 13 0 4 2 1 4 0 2 C61 Prostata Prostate 1452 726 0 106 16 5 154 3 88 32 29 27 0 216 47 3 C62 Modo Testis 112 112 0 10 1 1 54 0 19 6 5 7 0 8 0 1 C64-C65 Ledvica z ledvicnim mehom Kidney with renal pelvis 415 282 0 15 1 1 90 13 55 14 13 26 0 46 3 5 C67 Secni mehur Bladder 384 342 0 26 13 15 141 0 53 15 12 26 0 36 1 4 C70-C72 Centralni in avtonomni živcni sistem Central and autonomic nervous system 184 140 0 2 0 0 87 0 51 0 0 0 0 0 0 0 C73 Šcitnica Thyroid gland 175 162 0 4 0 0 18 120 13 0 0 0 0 0 6 1 C81 Hodgkinov limfom Hodgkin’s lymphoma 47 2 0 0 0 0 2 0 0 0 0 0 0 0 0 0 C82-C85 ne-Hodgkinovi limfomi non-Hodgkin’s lymphoma Difuzni plazmocitom in maligne460 38 0 1 2 0 12 12 5 1 1 1 0 1 2 0 C90 neoplazme plazmatkMultiple myeloma and malignant plasma cell neoplasms 155 2 0 1 0 0 0 0 0 0 0 0 0 1 0 0 C91-C95 Levkemije Leukaemias 365 1 0 0 0 0 0 0 0 0 0 0 0 0 1 0 * Bolniki, ki so bili v okviru prvega zdravljenja operirani vec kot enkrat, so vkljuceni le s prvo operacijo Patients that underwent multiple surgery procedures in the course of first treatment were included with the first procedure only ** V posamezni ustanovi so operirali manj kot 30 bolnikov Less then 30 patients were treated by surgery in individual institution Tabela 9c: Število bolnikov (brez primerov registriranih samo iz zdravniških porocil o vzroku smrti) v Sloveniji, zbolelih leta 2020, ki so v okviru prvega zdravljenja prejeli sistemsko zdravljenje*, po ustanovi zdravljenja. Table 9c: Number of patients (without cases registered from death certificates only) diagnosed in Slovenia in 2020, that were treated by systemic therapy during their first treatment* by treatment institution. Šifra MKB ICD code Primarna lokacija Primary site Število novih primerovNumber of new casesŠtevilo zdravljenih s sistemsko terapijoNumber of treated systemic therapySplošna bolnišnica CeljeUniverzitetna klinika GolnikSplošna bolnišnica IzolaUniverzitetni klinicni center LjubljanaOnkološki inštitut LjubljanaUniverzitetni klinicni center MariborSplošna bolnišnica Murska SobotaSplošna bolnišnica Nova GoricaSplošna bolnišnica Novo mestoSplošna bolnišnica Slovenj GradecZasebne ordinacijePrivate clinicsOstale ustanove** Other institutions** C00-C96 Vse lokacijeAll sites 15062 4439 71 141 28 460 2548 876 38 92 55 77 22 18 C00-C14 Usta in žrelo Mouth and pharynx 326 19 0 0 0 0 18 0 0 0 1 0 0 0 C15 Požiralnik Oesophagus 94 16 0 0 0 0 10 6 0 0 0 0 0 0 C16 Želodec Stomach 423 120 0 0 0 6 60 52 0 1 0 1 0 0 C18 Debelo crevo Colon 821 199 0 0 0 1 137 54 1 2 0 4 0 0 C19-C20 Rektum in rektosigmoidna zveza Rectum and rectosigmoid junction 478 168 0 0 0 1 153 12 0 1 0 1 0 0 C22 Jetra in intrahepaticni vodiLiver and intrahepatic bile ducts 234 49 0 0 0 33 4 11 0 0 1 0 0 0 C23-C24 Žolcnik in žolcevodi Gallbladder and billiary tract 198 40 0 0 0 17 10 13 0 0 0 0 0 0 C25 Trebušna slinavka Pancreas 419 128 0 0 0 37 42 42 0 5 0 1 0 0 C32 Grlo Larynx 91 5 0 0 0 0 5 0 0 0 0 0 0 0 C33-C34 Sapnik, sapnici in pljuca Trachea, bronchus and lung 1553 476 0 131 0 0 219 124 0 0 0 0 0 0 C43 Maligni melanom kože Malignant melanoma of skin 639 41 0 0 0 0 41 0 0 0 0 0 0 0 C44 Druge maligne neoplazme kože Skin, excl. melanoma 3008 26 1 0 0 2 7 13 0 0 1 0 1 1 C48-C49 Vezivno in mehko tkivo Connective and soft tissue 87 20 0 0 0 4 16 0 0 0 0 0 0 0 C50 Dojka Breast 1455 1331 16 0 5 0 890 346 0 46 2 19 1 1 C53 Maternicni vrat Cervix uteri 133 14 0 0 0 0 11 3 0 0 0 0 0 0 C54 Maternicno telo Corpus uteri 373 69 0 0 0 0 56 13 0 0 0 0 0 0 C56 Jajcnik Ovary 151 94 0 0 0 1 74 18 0 1 0 0 0 0 C61 Prostata Prostate 1452 399 26 0 13 73 97 55 17 23 39 32 14 9 C62 Modo Testis 112 67 0 0 0 1 66 0 0 0 0 0 0 0 C64-C65 Ledvica z ledvicnim mehom Kidney with renal pelvis 415 49 0 0 0 2 33 14 0 0 0 0 0 0 C67 Secni mehur Bladder 384 63 0 0 0 3 46 8 5 0 0 1 0 0 C70-C72 Centralni in avtonomni živcni sistem Central and autonomic nervous system 184 80 0 0 0 9 71 0 0 0 0 0 0 0 C73 Šcitnica Thyroid gland 175 162 4 0 0 15 123 13 0 0 0 0 6 0 C81 Hodgkinov limfom Hodgkin’s lymphoma 47 41 0 0 0 3 38 0 0 0 0 0 0 0 C82-C85 Ne-Hodgkinovi limfomi Non-Hodgkin’s lymphoma Difuzni plazmocitom in maligne 460 269 4 0 2 20 229 6 1 1 1 2 0 1 C90 neoplazme plazmatkMultiple myeloma and malignant plasma cell neoplasms 155 129 6 0 4 67 0 20 9 6 5 8 0 4 C91-C95 Levkemije Leukaemias 365 174 10 0 3 110 8 24 3 5 4 7 0 0 * Bolniki, ki so v okviru prvega zdravljenja prejeli vec kot eno vrsto sistemskega zdravljenja, so vkljuceni le enkrat Patients that underwent multiple systemic treatments in the course of first treatment were included with the first treatment only ** V posamezni ustanovi so zdravili manj kot 10 bolnikov Less then 10 patients were treated in individual institution Breme najpogostejših rakov Cancer Fact Sheets Vsi raki / All cancer sites (C00–C96) INCIDENCA (povprecje v obdobju 2016–2020) / INCIDENCE (average during 2016–2020) Moški / Male Ženske / Female Skupaj / All Število novih primerov v enem letu / Number of new cases per year 8400 7346 15746 Tveganje raka do 75. leta starosti (%) / Risk of getting cancer before age 75 (%) 37,6 30,1 33,7 Groba incidencna stopnja na 100.000 / Crude incidence rate per 100,000 810,9 705,0 757,8 Starostno standardizirana incidencna stopnja (SSS) na 100.000 / Age-standardized incidence rate (ASR) per 100,000 396,4 318,9 350,9 Ocenjeni delež letne spremembe grobe inc. stopnje zadnjih 10 let (%) / Estimated annual change of crude incidence rate latest 10 years (%) 1,0 2,4* 1,7* Ocenjeni delež letne spremembe SSS zadnjih 10 let (%) / Estimated annual change of ASR latest 10 years (%) -1,0* 1,4* 0,1 UMRLJIVOST (povprecje v obdobju 2016–2020) / MORTALITY (average during 2016–2020) Število smrti v enem letu / Number of deaths per year 3562 2812 6374 Tveganje smrti za rakom do 75. leta starosti (%) / Risk of dying from cancer before age 75 (%) 14,9 9,3 12,0 Groba umrljivostna stopnja na 100.000 / Crude mortality rate per 100,000 343,8 269,9 306,8 Starostno standardizirana umrljivostna stopnja (SSS) na 100.000 / Age-standardized mortality rate (ASR) per 100,000 148,8 89,8 115,4 Ocenjeni delež letne spremembe grobe umr. stopnje zadnjih 10 let (%) / Estimated annual change of crude mortality rate latest 10 years (%) 0,8* 1,2* 1,0* Ocenjeni delež letne spremembe SSS zadnjih 10 let (%) / Estimated annual change of ASR latest 10 years (%) -1,7* -0,8 -1,2* PREVALENCA (na dan 31.12.2020) / PREVALENCE (on December 31, 2020) Število živih oseb z diagnozo raka ob koncu leta 2020 (prevalenca) / Persons living with cancer at the end of 2020 (prevalence) 57593 67237 124830 Število živih oseb z diagnozo raka na 100.000 (prevalencna stopnja) / Number of persons living with cancer per 100,000 at the end of 2020 5461,7 6430,2 5943,9 Število živih oseb z diagnozo raka manj kot eno leto po diagnozi / Persons living with cancer less than 1 year after diagnosis 6386 5837 12223 Število živih oseb z diagnozo raka 1–4 leta po diagnozi / Persons living with cancer 1-4 years after diagnosis 20078 19709 39787 * Statisticno znacilno / Statistically significant Incidenca Incidence Slovenija 1961–2020 Umrljivost Mortality Slovenija 1985–2020 Groba in starostno standardizirana stopnja na 100.000Groba in starostno standardizirana stopnja na 100.000 Crude and age-standardized rate per 100.00 Crude and age-standardized rate per 100.00 900 800 700 600 500 400 300 200 100 0 1961 1964 1967 1970 1973 1976 1979 1982 1985 1988 1991 1994 1997 2000 2003 2006 2009 2012 2015 2018 Leto / Year Groba stopnja MOŠKIGroba stopnja ŽENSKEStarostno standardizirana stopnja MOŠKIStarostno standardizirana stopnja ŽENSKE Crude rate MALE Crude rate FEMALE Age-standardized rate MALE Age-standardized rate FEMALE 900 800 700 600 500 400 300 200 100 0 1985 1988 1991 1994 1997 2000 2003 2006 2009 2012 2015 2018 Leto / Year Prostata / Prostate (C61) INCIDENCA (povprecje v obdobju 2016–2020) / INCIDENCE (average during 2016–2020) Moški / Male Število novih primerov v enem letu / Number of new cases per year 1648 Odstotek med vsemi raki (%) / Percentage of all cancers (%) 19,6 Mesto po pogostnosti med vsemi raki / Frequency rank among all cancers 2. Odstotek med vsemi raki razen kožnega (%) / Percentage of all cancers excl. non-melanoma skin (%) 24,5 Tveganje raka do 75. leta starosti (%) / Risk of getting cancer before age 75 (%) 9,8 Groba incidencna stopnja na 100.000 / Crude incidence rate per 100,000 159,2 Starostno standardizirana incidencna stopnja (SSS) na 100.000 / Age-standardized incidence rate (ASR) per 100,000 74,6 Ocenjeni delež letne spremembe grobe inc. stopnje zadnjih 10 let (%) / Estimated annual change of crude incidence rate latest 10 years (%) -0,6 Ocenjeni delež letne spremembe SSS zadnjih 10 let (%) / Estimated annual change of ASR latest 10 years (%) -2,8* UMRLJIVOST (povprecje v obdobju 2016–2020) / MORTALITY (average during 2016–2020) Število smrti v enem letu / Number of deaths per year 445 Odstotek med vsemi smrtmi zaradi raka (%) / Percentage of all cancer deaths (%) 12,5 Tveganje smrti za rakom do 75. leta starosti (%) / Risk of dying from cancer before age 75 (%) 1,2 Groba umrljivostna stopnja na 100.000 / Crude mortality rate per 100,000 42,9 Starostno standardizirana umrljivostna stopnja (SSS) na 100.000 / Age-standardized mortality rate (ASR) per 100,000 15,3 Ocenjeni delež letne spremembe grobe umr. stopnje zadnjih 10 let (%) / Estimated annual change of crude mortality rate latest 10 years (%) 2,2* Ocenjeni delež letne spremembe SSS zadnjih 10 let (%) / Estimated annual change of ASR latest 10 years (%) -0,9 PREVALENCA (na dan 31.12.2020) / PREVALENCE (on December 31, 2020) Število živih oseb z diagnozo raka ob koncu leta 2020 (prevalenca) / Persons living with cancer at the end of 2020 (prevalence) 16607 Število živih oseb z diagnozo raka na 100.000 (prevalencna stopnja) / Number of persons living with cancer per 100,000 at the end of 2020 1574,9 Število živih oseb z diagnozo raka manj kot eno leto po diagnozi / Persons living with cancer less than 1 year after diagnosis 1358 Število živih oseb z diagnozo raka 1–4 leta po diagnozi / Persons living with cancer 1-4 years after diagnosis 5692 * Statisticno znacilno / Statistically significant Incidenca 180 Incidence 160 Slovenija 140 1961–2020 120 100 80 60 40 20 0 1961 1964 1967 1970 1973 1976 1979 1982 1985 1988 1991 1994 1997 2000 2003 2006 2009 2012 2015 2018 Leto / Year Groba stopnja MOŠKIStarostno standardizirana stopnja MOŠKI Crude rate MALE Age-standardized rate MALE 180 160 140 120 100 80 Umrljivost 60 Mortality40 Slovenija 20 1985–2020 0 1985 1988 1991 1994 1997 2000 2003 2006 2009 2012 2015 2018 Leto / Year Groba in starostno standardizirana stopnja na 100.000Groba in starostno standardizirana stopnja na 100.000 Crude and age-standardized rate per 100.00 Crude and age-standardized rate per 100.00 Pljuca in sapnik / Lung and trachea (C33, C34) INCIDENCA (povprecje v obdobju 2016–2020) / INCIDENCE (average during 2016–2020) Moški / Male Ženske / Female Skupaj / All Število novih primerov v enem letu / Number of new cases per year 968 595 1563 Odstotek med vsemi raki (%) / Percentage of all cancers (%) 11,5 8,1 9,9 Mesto po pogostnosti med vsemi raki / Frequency rank among all cancers 3. 3. 3. Odstotek med vsemi raki razen kožnega (%) / Percentage of all cancers excl. non-melanoma skin (%) 14,4 10,5 12,6 Tveganje raka do 75. leta starosti (%) / Risk of getting cancer before age 75 (%) 5,7 3,2 4,4 Groba incidencna stopnja na 100.000 / Crude incidence rate per 100,000 93,5 57,1 75,3 Starostno standardizirana incidencna stopnja (SSS) na 100.000 / Age-standardized incidence rate (ASR) per 100,000 44,7 24,8 33,9 Ocenjeni delež letne spremembe grobe inc. stopnje zadnjih 10 let (%) / Estimated annual change of crude incidence rate latest 10 years (%) 1,3 6,3* 3,1* Ocenjeni delež letne spremembe SSS zadnjih 10 let (%) / Estimated annual change of ASR latest 10 years (%) -0,8 4,4* 1,1* UMRLJIVOST (povprecje v obdobju 2016–2020) / MORTALITY (average during 2016–2020) Število smrti v enem letu / Number of deaths per year 776 438 1214 Odstotek med vsemi smrtmi zaradi raka (%) / Percentage of all cancer deaths (%) 21,8 15,6 19,0 Tveganje smrti za rakom do 75. leta starosti (%) / Risk of dying from cancer before age 75 (%) 4,27 2,1 3,1 Groba umrljivostna stopnja na 100.000 / Crude mortality rate per 100,000 74,9 42,1 58,4 Starostno standardizirana umrljivostna stopnja (SSS) na 100.000 / Age-standardized mortality rate (ASR) per 100,000 34,4 16,3 24,6 Ocenjeni delež letne spremembe grobe umr. stopnje zadnjih 10 let (%) / Estimated annual change of crude mortality rate latest 10 years (%) -0,7 3,9* 0,9* Ocenjeni delež letne spremembe SSS zadnjih 10 let (%) / Estimated annual change of ASR latest 10 years (%) -2,9* 1,7 -1,3* PREVALENCA (na dan 31.12.2020) / PREVALENCE (on December 31, 2020) Število živih oseb z diagnozo raka ob koncu leta 2020 (prevalenca) / Persons living with cancer at the end of 2020 (prevalence) 2441 1805 4246 Število živih oseb z diagnozo raka na 100.000 (prevalencna stopnja) / Number of persons living with cancer per 100,000 at the end of 2020 231,5 172,6 202,2 Število živih oseb z diagnozo raka manj kot eno leto po diagnozi / Persons living with cancer less than 1 year after diagnosis 572 423 995 Število živih oseb z diagnozo raka 1–4 leta po diagnozi / Persons living with cancer 1-4 years after diagnosis 1008 819 1827 * Statisticno znacilno / Statistically significant 0 1961 1964 1967 1970 1973 1976 1979 1982 1985 1988 1991 1994 1997 2000 2003 2006 2009 2012 2015 2018 Leto / Year Groba in starostno standardizirana stopnja na 100.000Crude and age-standardized rate per 100.00 Incidenca Incidence Slovenija 1961–2020 120 100 80 60 40 20 Groba stopnja MOŠKIGroba stopnja ŽENSKEStarostno standardizirana stopnja MOŠKIStarostno standardizirana stopnja ŽENSKE Crude rate MALE Crude rate FEMALE Age-standardized rate MALE Age-standardized rate FEMALE Umrljivost MortalitySlovenija 1985–2020 Groba in starostno standardizirana stopnja na 100.000Crude and age-standardized rate per 100.00 120 100 80 60 40 20 0 1985 1988 1991 1994 1997 2000 2003 2006 2009 2012 2018 2015 Leto / Year Dojka / Breast (C50) INCIDENCA (povprecje v obdobju 2016–2020) / INCIDENCE (average during 2016–2020) Ženske / Female Število novih primerov v enem letu / Number of new cases per year 1481 Odstotek med vsemi raki (%) / Percentage of all cancers (%) 20,2 Mesto po pogostnosti med vsemi raki / Frequency rank among all cancers 2. Odstotek med vsemi raki razen kožnega (%) / Percentage of all cancers excl. non-melanoma skin (%) 26,1 Tveganje raka do 75. leta starosti (%) / Risk of getting cancer before age 75 (%) 8,1 Groba incidencna stopnja na 100.000 / Crude incidence rate per 100,000 142,2 Starostno standardizirana incidencna stopnja (SSS) na 100.000 / Age-standardized incidence rate (ASR) per 100,000 74,6 Ocenjeni delež letne spremembe grobe inc. stopnje zadnjih 10 let (%) / Estimated annual change of crude incidence rate latest 10 years (%) 2,6* Ocenjeni delež letne spremembe SSS zadnjih 10 let (%) / Estimated annual change of ASR latest 10 years (%) 1,8* UMRLJIVOST (povprecje v obdobju 2016–2020) / MORTALITY (average during 2016–2020) Število smrti v enem letu / Number of deaths per year 439 Odstotek med vsemi smrtmi zaradi raka (%) / Percentage of all cancer deaths (%) 15,6 Tveganje smrti za rakom do 75. leta starosti (%) / Risk of dying from cancer before age 75 (%) 1,5 Groba umrljivostna stopnja na 100.000 / Crude mortality rate per 100,000 42,2 Starostno standardizirana umrljivostna stopnja (SSS) na 100.000 / Age-standardized mortality rate (ASR) per 100,000 14,6 Ocenjeni delež letne spremembe grobe umr. stopnje zadnjih 10 let (%) / Estimated annual change of crude mortality rate latest 10 years (%) 1,8* Ocenjeni delež letne spremembe SSS zadnjih 10 let (%) / Estimated annual change of ASR latest 10 years (%) -0,1 PREVALENCA (na dan 31.12.2020) / PREVALENCE (on December 31, 2020) Število živih oseb z diagnozo raka ob koncu leta 2020 (prevalenca) / Persons living with cancer at the end of 2020 (prevalence) 19833 Število živih oseb z diagnozo raka na 100.000 (prevalencna stopnja) / Number of persons living with cancer per 100,000 at the end of 2020 1896,7 Število živih oseb z diagnozo raka manj kot eno leto po diagnozi / Persons living with cancer less than 1 year after diagnosis 1384 Število živih oseb z diagnozo raka 1–4 leta po diagnozi / Persons living with cancer 1-4 years after diagnosis 5157 * Statisticno znacilno / Statistically significant Incidenca 160 Incidence 140 Slovenija 120 1961–2020 100 80 60 40 20 0 1961 1964 1967 1970 1973 1976 1979 1982 1985 1988 1991 1994 1997 2000 2003 2006 2009 2012 2015 2018 Leto / Year Groba stopnja ŽENSKEStarostno standardizirana stopnja ŽENSKE Crude rate FEMALE Age-standardized rate FEMALE 1985–2020 0 1985 1988 1991 1994 1997 2000 2003 2006 2009 2012 2015 2018 Leto / Year Groba in starostno standardizirana stopnja na 100.000 Crude and age-standardized rate per 100.00 Umrljivost MortalitySlovenija Groba in starostno standardizirana stopnja na 100.000Crude and age-standardized rate per 100.00 120 100 80 60 40 20 160 140 Debelo crevo in danka / Colon and rectum (C18–C20) INCIDENCA (povprecje v obdobju 2016–2020) / INCIDENCE (average during 2016–2020) Moški / Male Ženske / Female Skupaj / All Število novih primerov v enem letu / Number of new cases per year 814 561 1375 Odstotek med vsemi raki (%) / Percentage of all cancers (%) 9,7 7,6 8,7 Mesto po pogostnosti med vsemi raki / Frequency rank among all cancers 4. 4. 5. Odstotek med vsemi raki razen kožnega (%) / Percentage of all cancers excl. non-melanoma skin (%) 12,1 9,9 11,1 Tveganje raka do 75. leta starosti (%) / Risk of getting cancer before age 75 (%) 4,2 2,5 3,3 Groba incidencna stopnja na 100.000 / Crude incidence rate per 100,000 78,5 53,8 66,2 Starostno standardizirana incidencna stopnja (SSS) na 100.000 / Age-standardized incidence rate (ASR) per 100,000 37,0 21,4 28,4 Ocenjeni delež letne spremembe grobe inc. stopnje zadnjih 10 let (%) / Estimated annual change of crude incidence rate latest 10 years (%) -2,5* -1,6* -2,1* Ocenjeni delež letne spremembe SSS zadnjih 10 let (%) / Estimated annual change of ASR latest 10 years (%) -4,5* -2,7* -3,8* UMRLJIVOST (povprecje v obdobju 2016–2020) / MORTALITY (average during 2016–2020) Število smrti v enem letu / Number of deaths per year 421 297 718 Odstotek med vsemi smrtmi zaradi raka (%) / Percentage of all cancer deaths (%) 11,8 10,6 11,2 Tveganje smrti za rakom do 75. leta starosti (%) / Risk of dying from cancer before age 75 (%) 1,7 0,8 1,2 Groba umrljivostna stopnja na 100.000 / Crude mortality rate per 100,000 40,6 28,5 34,5 Starostno standardizirana umrljivostna stopnja (SSS) na 100.000 / Age-standardized mortality rate (ASR) per 100,000 16,8 8,2 12,0 Ocenjeni delež letne spremembe grobe umr. stopnje zadnjih 10 let (%) / Estimated annual change of crude mortality rate latest 10 years (%) -1 -2,5* -1,6* Ocenjeni delež letne spremembe SSS zadnjih 10 let (%) / Estimated annual change of ASR latest 10 years (%) -3,8* -4,4* -3,9* PREVALENCA (na dan 31.12.2020) / PREVALENCE (on December 31, 2020) Število živih oseb z diagnozo raka ob koncu leta 2020 (prevalenca) / Persons living with cancer at the end of 2020 (prevalence) 6961 5374 12335 Število živih oseb z diagnozo raka na 100.000 (prevalencna stopnja) / Number of persons living with cancer per 100,000 at the end of 2020 660,1 513,9 587,3 Število živih oseb z diagnozo raka manj kot eno leto po diagnozi / Persons living with cancer less than 1 year after diagnosis 644 431 1075 Število živih oseb z diagnozo raka 1–4 leta po diagnozi / Persons living with cancer 1-4 years after diagnosis 2000 1395 3395 * Statisticno znacilno / Statistically significant 0 1961 1964 1967 1970 1973 1976 1979 1982 1985 1988 1991 1994 1997 2000 2003 2006 2009 2012 2015 2018 Leto / Year Groba stopnja MOŠKIGroba stopnja ŽENSKEStarostno standardizirana stopnja MOŠKIStarostno standardizirana stopnja ŽENSKE Crude rate MALE Crude rate FEMALE Age-standardized rate MALE Age-standardized rate FEMALE 1985–2020 0 1985 1988 1991 1994 1997 2000 2003 2006 2009 2012 2015 2018 Leto / Year Groba in starostno standardizirana stopnja na 100.000Crude and age-standardized rate per 100.00 Incidenca Incidence Slovenija 1961–2020 120 100 80 60 40 20 Umrljivost MortalitySlovenija Groba in starostno standardizirana stopnja na 100.000Crude and age-standardized rate per 100.00 120 100 80 60 40 20 Koža, razen melanoma / Skin, non-melanoma (C44) INCIDENCA (povprecje v obdobju 2016–2020) / INCIDENCE (average during 2016–2020) Moški / Male Ženske / Female Skupaj / All Število novih primerov v enem letu / Number of new cases per year 1662 1664 3326 Odstotek med vsemi raki (%) / Percentage of all cancers (%) 19,8 22,7 21,1 Mesto po pogostnosti med vsemi raki / Frequency rank among all cancers 1. 1. 1. Odstotek med vsemi raki razen kožnega (%) / Percentage of all cancers excl. non-melanoma skin (%) / / / Tveganje raka do 75. leta starosti (%) / Risk of getting cancer before age 75 (%) 7,6 6,6 7,1 Groba incidencna stopnja na 100.000 / Crude incidence rate per 100,000 160,4 159,7 160,4 Starostno standardizirana incidencna stopnja (SSS) na 100.000 / Age-standardized incidence rate (ASR) per 100,000 72,5 62,2 65,9 Ocenjeni delež letne spremembe grobe inc. stopnje zadnjih 10 let (%) / Estimated annual change of crude incidence rate latest 10 years (%) 4,1* 4,5* 4,3* Ocenjeni delež letne spremembe SSS zadnjih 10 let (%) / Estimated annual change of ASR latest 10 years (%) 1,6 3,6* 2,6* UMRLJIVOST (povprecje v obdobju 2016–2020) / MORTALITY (average during 2016–2020) Število smrti v enem letu / Number of deaths per year 24 27 51 Odstotek med vsemi smrtmi zaradi raka (%) / Percentage of all cancer deaths (%) 0,7 1,0 0,8 Tveganje smrti za rakom do 75. leta starosti (%) / Risk of dying from cancer before age 75 (%) 0,05 0,01 0,03 Groba umrljivostna stopnja na 100.000 / Crude mortality rate per 100,000 2,3 2,6 2,5 Starostno standardizirana umrljivostna stopnja (SSS) na 100.000 / Age-standardized mortality rate (ASR) per 100,000 0,8 0,5 0,6 Ocenjeni delež letne spremembe grobe umr. stopnje zadnjih 10 let (%) / Estimated annual change of crude mortality rate latest 10 years (%) --- Ocenjeni delež letne spremembe SSS zadnjih 10 let (%) / Estimated annual change of ASR latest 10 years (%) --- PREVALENCA (na dan 31.12.2020) / PREVALENCE (on December 31, 2020) Število živih oseb z diagnozo raka ob koncu leta 2020 (prevalenca) / Persons living with cancer at the end of 2020 (prevalence) 16857 18386 35243 Število živih oseb z diagnozo raka na 100.000 (prevalencna stopnja) / Number of persons living with cancer per 100,000 at the end of 2020 1598,6 1758,3 1678,1 Število živih oseb z diagnozo raka manj kot eno leto po diagnozi / Persons living with cancer less than 1 year after diagnosis 1521 1401 2922 Število živih oseb z diagnozo raka 1–4 leta po diagnozi / Persons living with cancer 1-4 years after diagnosis 5806 6141 11947 * Statisticno znacilno / Statistically significant 0 1961 1964 1967 1970 1973 1976 1979 1982 1985 1988 1991 1994 1997 2000 2003 2006 2009 2012 2015 2018 Leto / Year Groba in starostno standardizirana stopnja na 100.000Crude and age-standardized rate per 100.00 Incidenca Incidence Slovenija 1961–2020 120 100 80 60 40 20 200 160 140 180 Groba stopnja MOŠKIGroba stopnja ŽENSKEStarostno standardizirana stopnja MOŠKIStarostno standardizirana stopnja ŽENSKE Crude rate MALE Crude rate FEMALE Age-standardized rate MALE Age-standardized rate FEMALE 200 180 160 140 120 100 80 Umrljivost 60 Mortality40 Slovenija 20 1985–2020 0 1985 1988 1991 1994 1997 2000 2003 2006 2009 2012 2015 2018 Leto / Year Groba in starostno standardizirana stopnja na 100.000 Crude and age-standardized rate per 100.00 Kožni melanom / Malignant melanoma of skin (C43) INCIDENCA (povprecje v obdobju 2016–2020) / INCIDENCE (average during 2016–2020) Moški / Male Ženske / Female Skupaj / All Število novih primerov v enem letu / Number of new cases per year 316 294 610 Odstotek med vsemi raki (%) / Percentage of all cancers (%) 3,8 4,0 3,9 Mesto po pogostnosti med vsemi raki / Frequency rank among all cancers 6. 6. 6. Odstotek med vsemi raki razen kožnega (%) / Percentage of all cancers excl. non-melanoma skin (%) 4,7 5,2 4,9 Tveganje raka do 75. leta starosti (%) / Risk of getting cancer before age 75 (%) 1,8 1,6 1,7 Groba incidencna stopnja na 100.000 / Crude incidence rate per 100,000 30,5 28,3 29,4 Starostno standardizirana incidencna stopnja (SSS) na 100.000 / Age-standardized incidence rate (ASR) per 100,000 16,3 15,9 15,8 Ocenjeni delež letne spremembe grobe inc. stopnje zadnjih 10 let (%) / Estimated annual change of crude incidence rate latest 10 years (%) 2,2* 2,8* 2,5* Ocenjeni delež letne spremembe SSS zadnjih 10 let (%) / Estimated annual change of ASR latest 10 years (%) 0,1 1,5 0,8 UMRLJIVOST (povprecje v obdobju 2016–2020) / MORTALITY (average during 2016–2020) Število smrti v enem letu / Number of deaths per year 70 55 125 Odstotek med vsemi smrtmi zaradi raka (%) / Percentage of all cancer deaths (%) 2,0 2,0 2,0 Tveganje smrti za rakom do 75. leta starosti (%) / Risk of dying from cancer before age 75 (%) 0,4 0,2 0,3 Groba umrljivostna stopnja na 100.000 / Crude mortality rate per 100,000 6,7 5,3 6,0 Starostno standardizirana umrljivostna stopnja (SSS) na 100.000 / Age-standardized mortality rate (ASR) per 100,000 3,2 2,0 2,5 Ocenjeni delež letne spremembe grobe umr. stopnje zadnjih 10 let (%) / Estimated annual change of crude mortality rate latest 10 years (%) -0,6 0,7 0,1 Ocenjeni delež letne spremembe SSS zadnjih 10 let (%) / Estimated annual change of ASR latest 10 years (%) -3,2 -2,2 -2,8* PREVALENCA (na dan 31.12.2020) / PREVALENCE (on December 31, 2020) Število živih oseb z diagnozo raka ob koncu leta 2020 (prevalenca) / Persons living with cancer at the end of 2020 (prevalence) 3534 4230 7764 Število živih oseb z diagnozo raka na 100.000 (prevalencna stopnja) / Number of persons living with cancer per 100,000 at the end of 2020 335,1 404,5 369,7 Število živih oseb z diagnozo raka manj kot eno leto po diagnozi / Persons living with cancer less than 1 year after diagnosis 318 299 617 Število živih oseb z diagnozo raka 1–4 leta po diagnozi / Persons living with cancer 1-4 years after diagnosis 1024 1029 2053 * Statisticno znacilno / Statistically significant Incidenca 35 0 1961 1964 1967 1970 1973 1976 1979 1982 1985 1988 1991 1994 1997 2000 2003 2006 2009 2012 2015 2018 Leto / Year Groba in starostno standardizirana stopnja na 100.000Crude and age-standardized rate per 100.00 Incidence Slovenija 1961–2020 25 20 15 10 5 30 Groba stopnja MOŠKIGroba stopnja ŽENSKEStarostno standardizirana stopnja MOŠKIStarostno standardizirana stopnja ŽENSKE Crude rate MALE Crude rate FEMALE Age-standardized rate MALE Age-standardized rate FEMALE Umrljivost MortalitySlovenija 1985–2020 Groba in starostno standardizirana stopnja na 100.000Crude and age-standardized rate per 100.00 35 25 20 15 10 5 0 30 1985 1988 1991 1994 1997 2000 2003 2006 2009 2012 2018 2015 Leto / Year Glava in vrat / Head and neck (C00–C14, C30–C32) INCIDENCA (povprecje v obdobju 2016–2020) / INCIDENCE (average during 2016–2020) Moški / Male Ženske / Female Skupaj / All Število novih primerov v enem letu / Number of new cases per year 362 103 465 Odstotek med vsemi raki (%) / Percentage of all cancers (%) 4,3 1,4 3,0 Mesto po pogostnosti med vsemi raki / Frequency rank among all cancers 5. 15. 7. Odstotek med vsemi raki razen kožnega (%) / Percentage of all cancers excl. non-melanoma skin (%) 5,4 1,8 3,7 Tveganje raka do 75. leta starosti (%) / Risk of getting cancer before age 75 (%) 2,3 0,6 1,4 Groba incidencna stopnja na 100.000 / Crude incidence rate per 100,000 34,9 9,9 22,4 Starostno standardizirana incidencna stopnja (SSS) na 100.000 / Age-standardized incidence rate (ASR) per 100,000 18,7 4,9 11,6 Ocenjeni delež letne spremembe grobe inc. stopnje zadnjih 10 let (%) / Estimated annual change of crude incidence rate latest 10 years (%) -0,8 0,7 -0,4 Ocenjeni delež letne spremembe SSS zadnjih 10 let (%) / Estimated annual change of ASR latest 10 years (%) -2,4* -0,7 -2,0* UMRLJIVOST (povprecje v obdobju 2016–2020) / MORTALITY (average during 2016–2020) Število smrti v enem letu / Number of deaths per year 173 36 209 Odstotek med vsemi smrtmi zaradi raka (%) / Percentage of all cancer deaths (%) 4,8 1,3 3,3 Tveganje smrti za rakom do 75. leta starosti (%) / Risk of dying from cancer before age 75 (%) 1,05 0,17 0,6 Groba umrljivostna stopnja na 100.000 / Crude mortality rate per 100,000 16,7 3,5 10,1 Starostno standardizirana umrljivostna stopnja (SSS) na 100.000 / Age-standardized mortality rate (ASR) per 100,000 8,4 1,4 4,7 Ocenjeni delež letne spremembe grobe umr. stopnje zadnjih 10 let (%) / Estimated annual change of crude mortality rate latest 10 years (%) -1,9 -0,4 -1,5 Ocenjeni delež letne spremembe SSS zadnjih 10 let (%) / Estimated annual change of ASR latest 10 years (%) -3,8* -3,5 -3,4* PREVALENCA (na dan 31.12.2020) / PREVALENCE (on December 31, 2020) Število živih oseb z diagnozo raka ob koncu leta 2020 (prevalenca) / Persons living with cancer at the end of 2020 (prevalence) 2703 959 3662 Število živih oseb z diagnozo raka na 100.000 (prevalencna stopnja) / Number of persons living with cancer per 100,000 at the end of 2020 256,3 91,7 174,4 Število živih oseb z diagnozo raka manj kot eno leto po diagnozi / Persons living with cancer less than 1 year after diagnosis 284 84 368 Število živih oseb z diagnozo raka 1–4 leta po diagnozi / Persons living with cancer 1-4 years after diagnosis 823 276 1099 * Statisticno znacilno / Statistically significant 0 1961 1964 1967 1970 1973 1976 1979 1982 1985 1988 1991 1994 1997 2000 2003 2006 2009 2012 2015 2018 Leto / Year Groba in starostno standardizirana stopnja na 100.000Crude and age-standardized rate per 100.00 Incidenca Incidence Slovenija 1961–2020 30 25 20 15 10 5 45 40 35 Groba stopnja MOŠKIGroba stopnja ŽENSKEStarostno standardizirana stopnja MOŠKIStarostno standardizirana stopnja ŽENSKE Crude rate MALE Crude rate FEMALE Age-standardized rate MALE Age-standardized rate FEMALE Umrljivost MortalitySlovenija 1985–2020 Groba in starostno standardizirana stopnja na 100.000Crude and age-standardized rate per 100.00 30 25 20 15 10 5 0 45 40 35 1985 1988 1991 1994 1997 2000 2003 2006 2009 2012 2018 2015 Leto / Year Maternicno telo / Corpus uteri (C54) INCIDENCA (povprecje v obdobju 2016–2020) / INCIDENCE (average during 2016–2020) Ženske / Female Število novih primerov v enem letu / Number of new cases per year 367 Odstotek med vsemi raki (%) / Percentage of all cancers (%) 5,0 Mesto po pogostnosti med vsemi raki / Frequency rank among all cancers 5. Odstotek med vsemi raki razen kožnega (%) / Percentage of all cancers excl. non-melanoma skin (%) 6,5 Tveganje raka do 75. leta starosti (%) / Risk of getting cancer before age 75 (%) 2,0 Groba incidencna stopnja na 100.000 / Crude incidence rate per 100,000 35,2 Starostno standardizirana incidencna stopnja (SSS) na 100.000 / Age-standardized incidence rate (ASR) per 100,000 16,4 Ocenjeni delež letne spremembe grobe inc. stopnje zadnjih 10 let (%) / Estimated annual change of crude incidence rate latest 10 years (%) 2,1* Ocenjeni delež letne spremembe SSS zadnjih 10 let (%) / Estimated annual change of ASR latest 10 years (%) 1,2 UMRLJIVOST (povprecje v obdobju 2016–2020) / MORTALITY (average during 2016–2020) Število smrti v enem letu / Number of deaths per year 71 Odstotek med vsemi smrtmi zaradi raka (%) / Percentage of all cancer deaths (%) 2,5 Tveganje smrti za rakom do 75. leta starosti (%) / Risk of dying from cancer before age 75 (%) 0,26 Groba umrljivostna stopnja na 100.000 / Crude mortality rate per 100,000 6,8 Starostno standardizirana umrljivostna stopnja (SSS) na 100.000 / Age-standardized mortality rate (ASR) per 100,000 2,2 Ocenjeni delež letne spremembe grobe umr. stopnje zadnjih 10 let (%) / Estimated annual change of crude mortality rate latest 10 years (%) 6,0* Ocenjeni delež letne spremembe SSS zadnjih 10 let (%) / Estimated annual change of ASR latest 10 years (%) 5,8* PREVALENCA (na dan 31.12.2020) / PREVALENCE (on December 31, 2020) Število živih oseb z diagnozo raka ob koncu leta 2020 (prevalenca) / Persons living with cancer at the end of 2020 (prevalence) 5049 Število živih oseb z diagnozo raka na 100.000 (prevalencna stopnja) / Number of persons living with cancer per 100,000 at the end of 2020 482,9 Število živih oseb z diagnozo raka manj kot eno leto po diagnozi / Persons living with cancer less than 1 year after diagnosis 346 Število živih oseb z diagnozo raka 1–4 leta po diagnozi / Persons living with cancer 1-4 years after diagnosis 1142 * Statisticno znacilno / Statistically significant Incidenca 40 Incidence 35 Slovenija 30 1961–2020 25 20 15 10 5 0 1961 1964 1967 1970 1973 1976 1979 1982 1985 1988 1991 1994 1997 2000 2003 2006 2009 2012 2015 2018 Leto / Year Groba stopnja ŽENSKEStarostno standardizirana stopnja ŽENSKE Crude rate FEMALE Age-standardized rate FEMALE 40 35 30 25 20 Umrljivost 15 Mortality10 Slovenija 5 1985–2020 0 1985 1988 1991 1994 1997 2000 2003 2006 2009 2012 2015 2018 Leto / Year Groba in starostno standardizirana stopnja na 100.000Groba in starostno standardizirana stopnja na 100.000 Crude and age-standardized rate per 100.00 Crude and age-standardized rate per 100.00 Ne-Hodgkinov limfom / Non-Hodgkin’s lymphoma (C82–C85) INCIDENCA (povprecje v obdobju 2016–2020) / INCIDENCE (average during 2016–2020) Moški / Male Ženske / Female Skupaj / All Število novih primerov v enem letu / Number of new cases per year 231 223 454 Odstotek med vsemi raki (%) / Percentage of all cancers (%) 2,8 3,0 2,9 Mesto po pogostnosti med vsemi raki / Frequency rank among all cancers 10. 7. 8. Odstotek med vsemi raki razen kožnega (%) / Percentage of all cancers excl. non-melanoma skin (%) 3,4 3,9 3,7 Tveganje raka do 75. leta starosti (%) / Risk of getting cancer before age 75 (%) 1,3 1,1 1,2 Groba incidencna stopnja na 100.000 / Crude incidence rate per 100,000 22,3 21,4 21,9 Starostno standardizirana incidencna stopnja (SSS) na 100.000 / Age-standardized incidence rate (ASR) per 100,000 11,8 9,5 10,5 Ocenjeni delež letne spremembe grobe inc. stopnje zadnjih 10 let (%) / Estimated annual change of crude incidence rate latest 10 years (%) 2,6* 2,4* 2,5* Ocenjeni delež letne spremembe SSS zadnjih 10 let (%) / Estimated annual change of ASR latest 10 years (%) 0,9 1,5 1,3 UMRLJIVOST (povprecje v obdobju 2016–2020) / MORTALITY (average during 2016–2020) Število smrti v enem letu / Number of deaths per year 96 86 182 Odstotek med vsemi smrtmi zaradi raka (%) / Percentage of all cancer deaths (%) 2,7 3,1 2,9 Tveganje smrti za rakom do 75. leta starosti (%) / Risk of dying from cancer before age 75 (%) 0,4 0,3 0,3 Groba umrljivostna stopnja na 100.000 / Crude mortality rate per 100,000 9,3 8,3 8,8 Starostno standardizirana umrljivostna stopnja (SSS) na 100.000 / Age-standardized mortality rate (ASR) per 100,000 3,8 2,4 3,0 Ocenjeni delež letne spremembe grobe umr. stopnje zadnjih 10 let (%) / Estimated annual change of crude mortality rate latest 10 years (%) 6,1* 2,0 4,1* Ocenjeni delež letne spremembe SSS zadnjih 10 let (%) / Estimated annual change of ASR latest 10 years (%) 2,9 0,4 1,7 PREVALENCA (na dan 31.12.2020) / PREVALENCE (on December 31, 2020) Število živih oseb z diagnozo raka ob koncu leta 2020 (prevalenca) / Persons living with cancer at the end of 2020 (prevalence) 1888 1947 3835 Število živih oseb z diagnozo raka na 100.000 (prevalencna stopnja) / Number of persons living with cancer per 100,000 at the end of 2020 179,0 186,2 182,6 Število živih oseb z diagnozo raka manj kot eno leto po diagnozi / Persons living with cancer less than 1 year after diagnosis 186 184 370 Število živih oseb z diagnozo raka 1–4 leta po diagnozi / Persons living with cancer 1-4 years after diagnosis 581 598 1179 * Statisticno znacilno / Statistically significant 0 1961 1964 1967 1970 1973 1976 1979 1982 1985 1988 1991 1994 1997 2000 2003 2006 2009 2012 2015 2018 Leto / Year Groba in starostno standardizirana stopnja na 100.000Crude and age-standardized rate per 100.00 Incidenca Incidence Slovenija 1961–2020 30 25 20 15 10 5 Groba stopnja MOŠKIGroba stopnja ŽENSKEStarostno standardizirana stopnja MOŠKIStarostno standardizirana stopnja ŽENSKE Crude rate MALE Crude rate FEMALE Age-standardized rate MALE Age-standardized rate FEMALE Umrljivost MortalitySlovenija 1985–2020 Groba in starostno standardizirana stopnja na 100.000Crude and age-standardized rate per 100.00 30 25 20 15 10 5 0 1985 1988 1991 1994 1997 2000 2003 2006 2009 2012 2015 2018 Leto / Year Pojmovnik Definicije kazalnikov in metod so podrobneje razložene na spletnem portalu SLORA: http://www.slora.si/definicije-kazalnikov-in-metod. Incidenca Umrljivost Prevalenca Preživetje Groba stopnja Starostno standardizirana stopnja Kumulativna stopnja Kumulativno tveganje Ocena incidence Število vseh na novo ugotovljenih primerov raka v tocno doloceni populaciji v enem koledarskem letu. Število vseh umrlih za doloceno boleznijo v tocno doloceni populaciji v enem koledarskem letu. Število vseh bolnikov z doloceno boleznijo, ki so bili živi na izbrani datum (ponavadi zadnji dan v letu). Glede na cas, kdaj so zboleli, locimo: . Celotna prevalenca upošteva vse bolnike z rakom ne glede na to, kdaj so zboleli. . Delna prevalenca upošteva tiste bolnike z rakom, ki so zboleli v tocno dolocenem obdobju pred datumom izracuna. Na primer, v enoletno delno prevalenco so vkljuceni bolniki, ki so zboleli leto dni pred datumom izracuna ter so na ta datum še živi. Preživetje predstavlja delež bolnikov, ki so po izbranem obdobju od postavitve diagnoze še živi. V porocilu podajamo cisto preživetje, izracunano po metodi Pohar-Perme, ki ocenjuje preživetje bolnikov v primeru, da bi upoštevali kot vzrok smrti samo proucevanega raka (hipoteticen primer, v katerem ne umirajo zaradi drugih vzrokov smrti). Incidenca ali umrljivost, preracunani na velikost opazovane populacije. Obicajno je izražena na 100.000 prebivalcev. Starostna standardizacija nam pove, kakšna bi bila groba stopnja v opazovani populaciji, ce bi bila starostna struktura te populacije enaka kot je v standardni populaciji. Uporabljene so tri standardne populacije: svetovna (Segi 1961), evropska (Doll 1976) in slovenska standardna populacija (Popis 2002). Kumulativna incidencna ali umrljivostna stopnja je poseben primer neposredne starostne standardizacije, kjer je standardna populacija v vseh starostnih skupinah enaka in zato vrednost ni odvisna od izbora standarda. Kumulativna stopnja je približek za kumulativno tveganje. Kumulativno tveganje izražamo v odstotkih in interpretiramo kot verjetnost posameznika, da zboli za rakom v izbranem starostnem obdobju (npr. do svojega 74. leta starosti), ce ne umre prej zaradi drugih vzrokov. Ocena števila novih primerov za tekoce koledarsko leto 2020 je pripravljena z metodo po Dybi in Hakulinenu. V model so vkljuceni bolniki glede na obdobje diagnoze in starost ob diagnozi za zadnjih deset let, ko so podatki na voljo. Glossary Definitions of indicators and methods are explained in detail on web portal SLORA: http://www.slora.si/en/definicije-kazalnikov-in-metod. Incidence Mortality Prevalence Survival Crude rate Age-standardized rate Cumulative rate Cumulative risk Estimation of incidence Number of all newly diagnosed cancer cases that develop in a defined population in one calendar year. Number of all patients who died because of certain disease in a defined population in one calendar year. Prevalence is the number of all patients with specific disease that are alive on a given date (usually the last day of the year). According to the time of diagnosis we distinguish: . Lifetime prevalence is defined as the number of all persons ever diagnosed with cancer and being alive at a specific time date. . Partial prevalence is the number of only those cancer patients, who were diagnosed with cancer within a defined period of time before the date of calculation. For example, one year partial prevalence includes patients diagnosed with cancer one year before the date of calculation. In groups of patients, survival represents the proportion of patients still alive after a selected period of time from diagnosis. The net survival calculated by Pohar-Perme method is given. It estimates patients’ survival from cancer only (all other causes of death excluded). Incidence or mortality calculated per observed population, usually expressed per 100.000 population. Age-standardization tells what the crude rate would be in observed population, if its age structure were the same as in standard population. For comparison we used three standard populations: World (Segi 1961), European (Doll 1976) and Slovenian standard population (Census 2002). The cumulative incidence or mortality rate is a special form of direct age stan dardization with the same standard population size in each age group. Thus, it avoids the arbitrary choice of standard population. Cumulative rate is an approximation for the cumulative risk. Cumulative risk is expressed in percentages and interpreted as the risk an individual would have of developing the disease in question during a certain age range (e.g. up to the age of 74), if there were no other causes of death. Estimation of cancer cases in present calendar year 2020 is calculated by the Dyba and Hakulinen method. This model includes patients according to the period of diagnosis and their age at diagnosis for the last ten registered years. POROCILO RR št. 62 REPORT No. 62 Ljubljana 2023 ISSN 1318-5845